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ABSTRACT 
Rhodococcus equi is a Gram-positive soil organism that causes an aggressive 
bronchopneumonia in foals and opportunistic infections in immuno-compromised 
humans. Virulent strains possess an 80 – 90 kb plasmid that encodes an 
immunogenic surface-located virulence-associated protein VapA. The virulence of 
the organism has been largely attributed to this protein since mutants lacking vapA 
are attenuated for virulence in mice. VapA is an unusual lipoprotein and existing 
evidence suggests its biogenesis may not involve normal lipoprotein processing.  
In order to understand the structure of VapA and other virulence associated proteins, 
their genes were cloned, expressed, purified and crystallised. VapG produce high 
quality crystals that diffracted to 1.8 Å. The structure was resolved to be a closed ȕ-
barrel with a long unstructured N-terminus which is similar to both VapB and VapD 
which have also recently been characterised. 
Analysis of covalently-bound lipids extracted from membrane proteins that included 
VapA revealed their modification by mycolic acids, the characteristic branched long-
chain fatty acids that define the outer wall of this organism. In order to determine 
whether a mechanism for mycolylation of surface-exposed lipoproteins might be 
conserved across the mycolic acid containing actinobacteria, vapA was expressed in 
Corynebacterium glutamicum. Here the abundance of protein-bound mycolic acid in 
VapA-containing fractions increased with vapA overexpression. The development of 
a corynomycoloyl protein transferase assay using surface lipids from various mycolic 
acid containing bacteria with the characterised enzyme of C. glutamicum was 
attempted. Although the modification of VapA was not observed, an enzyme-lipid 
adduct seemed to form. 
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VapA production is coordinated with that of other vaps which are secreted. However 
the cell bound protein VapA is most critical for virulence. Despite its ascendency, 
VapA is not sufficient for virulence. It was considered that other Vaps might 
associate with VapA at the cell surface to exert their effect. Interactions between 
VapA and the other Vaps were monitored using surface plasmon resonance. VapE, 
VapG and VapH interacted with VapA in a concentration-dependent manner while 
VapD seem not to interact with VapA. The implications of the findings are 
discussed.  
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CHAPTER ONE 
1 Rhodococcus equi: Virulence, Pathogenesis and 
Genetics 
1.1 Rhodococcus equi: An animal and human pathogen 
Rhodococcus equi was first isolated from Swedish foals suffering from 
bronchopneumonia (Magnusson, 1923).  The organism is one of the most important 
causes of a sub-acute to a chronic suppurative bronchopneumonia, lung abscesses, 
and several extrapulmonary disorders in foals (Figure 1.1). The host range of the 
bacterium is relatively broad; it has been isolated from various animals including 
pigs, sheep, wild boars, cats and dogs (Makrai et al., 2002; Takai et al., 2003; Ribero 
et al., 2011; Rzewuska et al., 2014).  However the greatest burden of rhodococcosis 
(R. equi disease) is in foals between the ages of 1 and 6 months, with most of these 
showing clinical signs of the disease before the age of four months (Nordmann et al., 
1992; Giguere and Prescott, 1997).  If not treated, mortality rates could approach 80 
% (Elissalde et al., 1980; Cohen et al., 2005; Coulson et al., 2010), and it has been 
reported that foal deaths from pneumonia caused by R. equi account for 
approximately 3 % of foal deaths per annum (Oldfield et al., 2004). The disease is 
also a major cause of wastage in foals and costs the equine industry millions of 
dollars to treat (Muscatello, 2012). 
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Figure 1.1 Right lung from a foal with severe purulent pneumonia caused by 
R. equi. 
There is marked consolidation of the cranial portion of the lung and 
multiple abscesses are present (Vázquez-Boland et al., 2013). 
 
Rhodococcus equi is a facultative intracellular organism that is widespread in horse 
droppings and their environment, thus the organism is isolated primarily from 
clinical specimens and manure-rich environments (Letek et al., 2010).  It tolerates a 
wide pH range but its growth is optimal between pH 8.5 and 10. This alkaline pH is 
similar to that of untreated manure and this tolerance potentially provides a selective 
advantage for colonisation of the farm habitat (Letek et al., 2010). The organism has 
simple growth requirements that are easily met by organic acids found in herbivore 
manure and warm temperatures (Barton and Hughes, 1984; Hughes and Sulaiman, 
1987; Prescott, 1987).  
Two sources for transmission via aerosol inoculation are apparent; through inhalation 
of dust or the breath of companions in farms inhabited by infected horses (Mosser 
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and Hondalus, 1996; Hondalus, 1997; Letek et al., 2010).  However, much remains 
to be defined; even though the disease is widely reported across horse breeding 
farms, it remains absent in some farms while in other farms where the disease is 
reported, only few foals develop the disease (Buntain et al., 2010).  
Extrapulmonary disorders (EPDs) that have been reported in horses may be 
associated with or independent of bronchopneumonia (Reuss et al., 2009). These 
include diarrhoea, osteomyelitis, hyperthermia and immune-mediated haemolytic 
anaemia.  Interestingly, these may represent the first clinical abnormality observed or 
they may arise after treatment of the pneumonia.  In the latter instance, EPDs may be 
the ultimate cause of death or prompt for euthanasia (Reuss et al., 2009).  Metastatic 
spread of the organism from the lungs or gastrointestinal tract could be responsible 
for the reported observed EPDs (Vazquez-Boland et al., 2013). 
The administration of rifampin was initially considered to be the treatment of choice 
for Rhodococcus equi infections based on in vitro susceptibility data, 
pharmacokinetic studies and retrospective studies (Giguere et al., 2011). Treatment 
involving a combination of antibiotics (macrolides and rifampin) has proved to be 
effective against antibiotic-resistant strains which have been isolated from horse-
breeding farms (Giguere et al. 2012, Burton et al., 2013). However, therapy 
involving antibiotics with streptolysin-O (as adjuvant) has been shown to be superior 
to treatment involving antibiotics alone (Horohov et al., 2011, Gurel et al., 2013). 
Though a veterinary pathogen, the organism has emerged as an opportunistic human 
pathogen as it causes significant morbidity in human patients that are 
immunocompromised and are exposed to livestock and a dry soil environment 
(Yamshchikov et al., 2010).  Thus HIV-infected patients, individuals receiving organ 
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transplants and cancer patients are highly susceptible to R. equi infections (Prescott, 
1991; Perez et al., 2002). In these immunocompromised patients, the clinical 
manifestations are diverse but about 80 % have pulmonary involvement (Meeuse et 
al., 2007). However, Rhodococcus equi infections have been reported recently in 
immunocompetent individuals where it manifested as granulomatous mastitis, 
polymicrobial infections, brain abscesses and abdominal infections (Dias et al., 2013; 
Nath et al., 2013; Velazquez Benito et al., 2013). 
1.2 Morphology and Taxonomy of Rhodococcus equi 
Rhodococcus equi is a non-motile, non-spore forming globally-distributed Gram-
positive soil organism. It is a coccobacillus especially on solid media (Figure 1.2), 
but is also pleomorphic with long rods or filaments, rudimentary beading and 
mycelial branching in liquid media (Yamshchikov et al., 2010). The organism cannot 
oxidise carbohydrates and alcohols thus cannot utilise sugars as sources of carbon – a 
property that differentiates it from many Corynebacterineae such as R. jostii, R. 
erythropolis and R. opacus (Letek et al., 2010). It is catalase, urease, lipase and 
phosphatase positive, but DNAse, elastase, and lecithinase negative (Prescott, 1991; 
Bidaud et al., 2012). Rhodococcus equi grows on non-selective media to a pink– red, 
irregular, 
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Figure 1.2 Ultrastructural morphology of Rhodococcus equi in transmission 
epectron microscopy 
Virulent, plasmid-positive R. equi 103+ of a late exponential phase 
culture were fixed, stained with ruthenium red and prepared for 
transmission electron microscopy. The image shows a thick layer of 
polysaccharide capsule material that is surrounding the complex cell 
wall and stained by the cationic dye (von Bargen and Hass, 2009). 
Scale bar = 500 nm. 
 
mucoid and round colony which may vary from 2 mm – 4 mm diameter after 48 
hours of incubation (Figure 1.3). It is weakly acid-fast in Ziehl-Neelsen stain; though 
this may depend on the age of the culture, the growth medium and the staining 
technique (Barton and Hughes, 1980; Kaura and Mutimer, 1987). 
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Figure 1.3 Coalescent, mucoid, pink-tinged Rhodococcus equi colonies on 
chocolate agar plate. 
From Yamshchikov et al. (2010) 
 
The taxon has a confused history. Rhodococcus (red-pigmented coccus) belongs to 
the phylogenetic group referred to as nocardioform actinomycetes that includes 
Corynebacterium, Nocardia, and the Mycobacterium genera, which are characterised 
by their high genomic GC content (Goodfellow, 1987; Mosser and Hondalus, 1996). 
The name ‘Rhodococcus’ was first used by Zopf in 1891 but was redefined in 1977 
as a genus that resembles but did not belong to the Nocardia, Corynebacterium, and 
Mycobacterium genera (Goodfellow and Alderson, 1977). However, Magnusson 
proposed the name Corynebacterium equi for isolates obtained from Swedish foals 
having pyogranulomatous pneumonia in 1923 (Takai, 1997). 
Chapter One Rhodococcus equi: Virulence, Pathogenesis and Genetics 
7 
 
The organisms that were initially grouped under the Rhodococcus genus were further 
divided into two genera (as a result of the heterogeneity of the organisms) namely 
Gordona and Rhodococcus. Gordona comprised of Rhodococcus bronchialis, 
Rhodococcus rubropectinus and Rhodococcus terrae, while all other species were 
grouped under Rhodococcus.  However, Rhodococcus equi is the only species found 
in the soil with significant pathogenic potential on horses and other animals 
including humans (Prescott, 1991; McNeil and Brown, 1994; Mosser and Hondalus, 
1996).  Recently, Rhodococcus equi has been considered to be a new genus with 
Prescottella equi as the proposed name of the type strain. The rationale for this 
reclassification is that R. equi isolated from various sources exhibit minor differences 
based on phenotypic and genotypic features (Jones et al., 2013 a, b).  Furthermore 
the strains are relatively distantly-related to other rhodococci and Norcardia spp 
(Sangal et al., 2014) (Figure 1.4).  The classification of Rhodococcus equi presently 
is: 
Phylum: Actinobacteria 
Class:  Actinobacteria 
Subclass:  Actinobacteridae 
Order:  Actinomycetales 
Suborder: Corynebacterineae 
Family: Nocardiaceae 
Genus:  Rhodococcus 
Species: equi 
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Figure 1.4 Phylogenetic tree from 400 universal proteins showing the genomic 
relationship of Rhodococcus equi to representatives of closely 
related taxa. 
Scale bar shows normalized fraction of total branch lengths (Sangal et 
al., 2014). 
 
1.3 Genome and Virulence Associated Proteins 
The genome of R. equi 103S consists of a circular chromosome of 5,043,170 bp with 
4,525 predicted genes and a circular virulence plasmid of about 80 – 90 kb with an 
overall GC content of about 68.76 % (Letek et al., 2010) (Figure 1.5). Though the 
mechanisms of virulence of R. equi are not completely understood, there is evidence 
that it largely depends on the circular virulence plasmid (Meijer and Prescott, 2004) 
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since strains that are avirulent in horses lack the plasmid (Takai et al., 2000).  
Sequence analysis shows that this virulence plasmid has 69 open reading frames 
which span along four regions though only three regions encode proteins with known 
functions (Figure 1.5). One of the functional regions is involved in plasmid 
replication and another in conjugation (Meijer and Prescott, 2004: von Bargen and 
Hass, 2009).  The third region of the plasmid (27.5 kb in size) is the pathogenicity 
island which is characterised by a lower GC content than the rest of the plasmid 
(Merjer and Prescott, 2004). 
This pathogenicity island (PAI) (Figures 1.6) is made up of 26 putative ORFs and 
contains a gene family that encodes a family of virulence-associated proteins (Vaps) 
namely VapA, C, D, E, F, G and H (Figure 1.7) (Meijer and Prescott, 2004). Other 
Vaps namely VapF, pseudo-VapE (VapX) and VapI are frame-shift mutants and 
thought to be non-functional (von Bargen and Hass, 2009). The Vap genes vapA, 
vapC, vapD, vapE, vapF, vapG and vapH are found over a span of 19,000 base pairs 
(Meijer and Prescott, 2004).  vapA, vapC, vapD are clustered in close proximity to 
each other while vapE and vapF are immediately adjacent to each other.  However, 
vapG and vapH are present as individual genes with vapG found in the negative 
strand (Takai et al., 2000). vapI, (ORF13) located just downstream of vapA, 
interrupts the cluster of vapA, vapC, vapD (Polidori and Hass, 2006). Apart from the 
vap locus, other genes which encode proteins with known functions are orf3 
(encoding a SAM-dependent methyl transferase); lsr2 (encoding a homologue of the 
mycobacterial nucleoid associated protein); vcgB (encoding a protein conserved in 
pathogenic mycobacteria); scm2 (encoding a chorismate mutase); and the virR 
operon (Vázquez-Boland et al., 2013). The remainder of the non-vap genes encode 
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products of unknown functions (Ren and Prescott, 2003; Vázquez-Boland et al., 
2013). 
 
Figure 1.5 The R. equi genome. 
Circular diagram of (A) Rhodococcus equi 103S chromosome and (B) 
virulence plasmid (not represented at scale). Outer two rings (in 
chromosome), coding sequences in the forward and reverse strand. 
Inner rings in the chromosome, orthologue plots from 13 actinobacterial 
genomes: R. jostii RHA1, Nocardia farcinica IFM10152, 
Mycobacterium smegmatis MC2155, Streptomyces coelicolor A3(2), 
Mycobacterium tuberculosis H37Rv, Arthrobacter sp. FB24, 
Corynebacterium glutamicum ATCC 13032, Thermobifida fusca YX, 
Frankia sp. CcI3, Corynebacterium diphtheriae NCTC 13129, 
Propionibacterium acnes KPA171202, Bifidobacterium longum 
NCC2705 and Tropheryma whipplei TW08 27. Horizontally acquired 
(HGT) islands are shown in red joined by a red circle; note they tend to 
coincide with void areas in the orthologue plots, indicating they are not 
part of the vertically evolving actinobacterial core genome. Inner plots: 
G + C% (gray) and G + C skew (violet/yellow, origin of replication is 
clearly detectable). In the plasmid (B), the vap PAI is represented as a 
black line (Adapted from Vázquez-Boland et al., 2013). 
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Figure 1.6 Structure of virulence plasmid pVAPA1037 of R. equi 103S strain. 
The circular map shows the position of the pathogenicity island (PAI) 
(dark green bar) and the positions of the open reading frames.  The 
linear map provides detail of the PAI with genes having known or 
suspected function named.  Functional vap genes are coloured in red, 
the resolvases that limit the PAI in orange, and pseudogenes in 
turquoise. Very small ORFs or features are illustrated as blue bars. 
 
 
vapA encodes a protein of 180 amino acids, vapC 174, vapD 164, vapE 189, vapF 
150, vapG 172, vapH encodes a protein of 187 amino acids. The virulence of the 
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organism is largely attributed to the pathogenicity island because VapA (a 15 – 17 
kDa antigen) is thought to mediate intracellular growth of the organism in 
macrophages and disease development via the arrest of phagosome maturation. It has 
been reported that deletion of vapA attenuates R. equi virulence to almost the same 
degree as that of the deletion of the entire vap locus (Jain et al., 2003). Active 
immunisation of attenuated Salmonella expressing VapA confers long-lasting 
protection against experimental rhodoccocosis (Cardoso et al., 2013). 
Rhodococcus equi isolated from the submaxillary lymph nodes of infected pigs 
contains one of five plasmids of 79 to 100 kb that encode an 18 - 20 kDa variant of 
VapA known as VapB (Takai et al., 1996). These isolates exhibit intermediate 
virulence in mice when compared to the VapA-producing strains. VapA and VapB 
share 78 % homology (Figure 1.7) and they are allelic variants of one locus that has 
divergently evolved in two different plasmids. The similarity of VapA and VapB 
raises the possibility that they could have analogous functions in different strains of 
R. equi (Bryne et al., 2001). They are thus mutually exclusive and also exhibit 
significant immunological cross reactivity hence the two types of virulence plasmid 
could have evolved from a single episome (Figure 1.8) (Byrne et al., 2001; Oldfield 
et al., 2004; Letek et al., 2008).  VapB is made up of 197 amino acids.  Other vaps 
present in the pathogenicity island of the VapB producing strains are vapJ which 
encodes a protein of 183 amino acids, and vapK which encodes a protein of 202 
amino acids (Letek et al., 2008).  
Chapter One Rhodococcus equi: Virulence, Pathogenesis and Genetics 
13 
 
 
Figure 1.7 Comparison of the amino acid sequences of VapA and VapB. 
Sequences were aligned using the Clustal 2.1 sequence alignment 
program.  These share 78 % homology.  Arrow shows potential 
cleavage site for signal peptidase for both proteins. 
 
 
Figure 1.8 Model of the evolutionary dynamics of the vap multigene family. 
On a schematic representation of the vap PAIs from pVAPB1593 (vapB 
type plasmid) and pVAPA1037 (vapA type plasmid), vap genes (in 
black) presumably derived from vertical evolution of a pre-existing 
common ancestral determinant are connected by straight arrows, and 
those probably originated by gene duplication in the specific plasmid 
are connected by curved arrows (see the text for details). The 
connection between vapM and the vapX pseudogene was deduced from 
a phylogenetic tree constructed with the 28-residue VapX product 
aligned with the corresponding protein fragments from other members 
of the Vap family (not shown). Asterisks indicate degenerate vap genes; 
note in pVAPA1037 that one gene in each of the duplicated vapIE and 
vapCF tandems is undergoing decay; pVAPB1593 is the vapB type 
plasmid; pVAPA1037 is the vapA type plasmid (Adapted from Letek et 
al., 2008). 
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1.4 Pathogenesis and pathology of Rhodococcus equi infections 
A key virulence determinant is the possession of the virulence plasmid described in 
detail in Section 1.3.  Several strains of Rhodococcus equi have been identified based 
on plasmid diversity but the organism can be grouped into vapA-expressing strains, 
vapB-expressing strains and those that neither express vapA nor vapB i.e. that 
possess no virulence plasmid (Meijer and Prescott, 2004; Poolkhet et al., 2010).  
The vapA-containing strains cause rhodococcosis in young horses where the most 
common manifestation is a chronic suppurative bronchopneumonia with extensive 
abscessation (Figure 1.2) and associated suppurative lymphadenitis (Phumoonna et 
al., 2006). In vitro experiments suggest that the infectivity of Rhodococcus equi is 
limited to the monocyte-macrophage lineage (Mosser and Hondalus, 1996) thus 
alveolar macrophages could be the main targets of the organism. The early stages of 
the infection resemble those of other lung infections thus may pose difficulties in 
early diagnosis coupled with the slow spread of the lung infection (the organism 
being a slow grower itself) (Giguere and Prescott, 1997).  In fact, R. equi infections 
have been misdiagnosed as mycobacterial and diphtherial infections (Salifu et al., 
2013). Early lesions are characterised by cellular influx into the alveolar spaces 
(which normally consists of macrophages and giant cells with fewer neutrophils) 
where the bacteria inhabit the phagocytic cells (Hondalus, 1997). Their ability to 
replicate in macrophages may result in necrosis followed by the destruction of the 
lung parenchyma at the advanced stages of the disease (Hondalus, 1997). This may 
result from the destruction of the cell via lysosomal degranulation after intracellular 
multiplication of the organism (Yager, 1987). Though the exact mechanism 
underlying the survival of the organism is unknown, inadequate acidification of the 
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phagosome may be responsible for the inability of the phagocytes to degrade the 
bacteria (Zink et al., 1987; Toyooka et al., 2005). Sometimes, the infection manifests 
as intestinal pneumonia and, in such cases, the clinical signs could be fever, anorexia, 
diarrhoea and weight losses which may be severe thus difficult to treat (Zink et al., 
1986; Baldwin et al., 1992). The vapB-containing R. equi mostly cause disease in 
pigs and cattle which manifests as chronic pyogranulomatous adenitis (de Vagas et 
al., 2013). These strains also cause human rhodococcal lung infection which 
resembles pulmonary tuberculosis and is thought to have a high mortality (Poolkhet 
et al., 2010; Vázquez-Boland et al., 2010).  In general, the vapB-bearing strains are 
less virulent than the vapA-containing strains (Meijer and Prescott, 2004). 
1.5  Rhodococcus equi cell envelope 
The basis of the pathogenicity of R. equi relies on its ability to multiply inside the 
macrophage where it eventually causes degranulation of the lysosome and 
subsequently leads to cell death (Prescott, 1991). The organism has a complex cell 
envelope which enables it to survive under very harsh conditions such as low pH and 
oxidative stress; the latter being a major mechanism used by macrophages to combat 
foreign bodies (Benoit et al., 2000; Benoit et al., 2002). 
The rhodococcal cell envelope is dominated by mycolic acids.  These branched long-
chain fatty acids are covalently linked to a peptidoglycan-arabinogalactan complex 
and thus form the basis for an anchored outer permeability barrier. Other components 
not covalently attached to the core are glycolipids, polysaccharides, lipoglycans, 
lipoproteins and channel-forming porins (Sutcliffe et al., 2010). A model of the 
rhodococcal cell envelope is shown in figure 1.9.  This is heavily based upon the 
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Minnikin model of the cell wall of mycobacteria (Minnikin, 1982) and developments 
thereof. 
 
Figure 1.9 Model for the organisation of the rhodococcal cell envelope. 
This figure represents an adaptation of the published model by Sutcliffe 
et al. (2010). It illustrates that mycolic acids form the basis of an outer 
lipid permeability barrier.  Individual envelope components are 
identified beneath the model.  Not shown are the outermost layers 
composed of the cell envelope polysaccharides and/or capsules that are 
known to be present in many rhodococci.  The model emphasises the 
possibility that lipoproteins which occupy the outer permeability barrier 
might be mycoloylated.  
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1.5.1 Mycolic acids 
Mycolic acids are high molecular weight α-alkyl, ȕ-hydroxy fatty acids. They vary in 
size and complexity and are found exclusively in the cell envelopes of different 
genera of the mycolata (all mycolic acid-containing Actinobacteria) (Sutcliffe, 1998). 
In Corynebacterium, mycolic acids can contain from 22-36 carbon atoms; 34-38 
carbon atoms in Dietzia; 46-66 in Nocardia while those of Mycobacterium range 
between 60 and 90 carbon atoms; Rhodococcus can produce mycolic acids in the 
range of 28-54 carbon atoms (Sutcliffe et al., 2010; Marrakchi et al., 2014). In R. 
equi, the mycolic acids are covalently-bonded to the cell wall arabinogalactan and 
are also esterified to carbohydrate groups to form glycolipids (Sutcliffe, 1998; Hsu et 
al., 2011).  For the most part however, they are esterified to the terminal arabinose 
units of the peptidoglycan-linked polysaccharide complex, i.e. arabinogalactan (Lee 
et al., 1997). These long-chain lipids are the primary mediators of the hydrophobic 
character of the cell envelope and form a closely packed, impermeable monolayer 
(Tahlan et al., 2012).  The mycolic acids of R. equi have no functional groups in their 
meromycolate chains other than the possibility of one or more double bonds 
(Verschoor et al., 2012). The structures of some representative mycolic acids within 
the mycolata are shown in figure 1.10. 
The biosynthesis of mycolic acids has been a subject of intense investigation but 
considering their exclusive presence in organisms grouped in the Corynebacterineae 
suborder, the enzymatic steps involved in their biosynthesis may only be common to 
this group of organisms (Portevin et al., 2004). The reactions that constitute mycolic 
acid biosynthesis (also known as the mycolic acid pathway) consist of over 200  
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Figure 1.10 Structures of representative mycolic acids from Corynebacterium, 
Rhodococcus and Mycobacterium species. 
Structures illustrate their differing complexity. Mycobacterium 
tuberculosis methoxymycolate is an example of the most complex 
mycolic acids. The less complex M. smegmatis mycolates encompass 
either double or single unsaturations whilst retaining the longer chain 
length. Rhodococcus sp. mycolates are of an intermediate size. They 
present an aliphatic 2-alkyl chain varying from 12 to 16 carbons, whilst 
the 3- hydroxyl meromycolate typically contains 18–40 carbons (i.e. x, 
y and z total 18–40) (Sutcliffe et al., 2010). 
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different reactions and up to 200 metabolites mediated through a sequence of 
proteins (Raman et al., 2005). The reactions of the mycolic acid biosynthesis are 
grouped under the following major pathways (a) production of malonyl-CoA, (b) 
fatty acid synthase-I (FAS-I pathway), (c) fatty acid synthase-II (FAS-II pathway) 
(d) the condensation of FAS-I and FAS-II products (Raman et al., 2005). Acetyl-
CoA (produced from other pathways) is carboxylated to malonyl-CoA in a reaction 
catalysed by acetyl-CoA carboxylase. FAS-I then catalyses the elongation of 
malonyl-CoA to short-chain acyl-CoAs such as C16, C20, or C24 CoAs that could 
serve as the α-alkyl branch (R2) (Gao et al., 2003; Bhatt et al., 2007; Grzegorzewicz 
et al., 2012). For the meromycolate backbone (R1), products of the FAS-I are further 
elongated in reactions catalysed by FAS-II. This elongation likely ceases when the 
chain attains the length required for the meromycolate chain modification or 
condensation (Marrakchi et al., 2014). In mycobacteria, this chain is further 
functionalised with cis or trans double bonds, cis or trans cyclopropane rings and/or 
polar functional groups such as methyl ethers, ketones, esters or epoxides 
(Grzegorzewicz et al., 2012). The elongation reactions are catalysed by a series of ȕ-
ketoacyl-ACP synthases which are components of the fatty acyl synthase pathways.  
The R1 and R2 chains are finally condensed in a series of reactions catalysed by 
polyketide synthase (a subunit of the FAS-II complex) to yield the mycolic acids 
(Portevin et al., 2004). 
In addition to being a probable virulence factor of the organism, mycolic acids also 
contribute to resistance to antibiotics and offer a considerable hydrophobic cell 
surface property. This feature is a major determinant of the organism’s physiology 
(Bendinger et al., 1993; Jarlier and Nikaido, 1994; Lee et al., 1997). 
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1.5.2 Lipoarabinomannans and Glycolipids 
Lipoarabinomannans (LAMs) are lipoglycans that are almost ubiquitous in mycolic 
acid-containing Actinobacteria. They are amphipathic molecules presenting a 
tripartite structure which is made up of a mannosyl-phosphatidyl-myo-inositol (MPI) 
lipid anchor that embeds in the outer leaflet of the plasma membrane, a 
polysaccharide backbone composed of D-mannan and D-arabinose (or D-arabinan) 
and terminal oligosaccharide caps (Chatterjee and Khoo, 1998; Vercellone et al., 
1998). LAM and its related macroamphiphile precursors, lipomannan (LM) and 
phosphatidyl-myo-inositol mannosides (PIMs), are often found together in the cell 
walls of the mycolata (Besra and Brennan, 1997; Nigou et al., 2003). 
In addition to the LAMs, many glycolipids are bound to the cell walls of members of 
the mycolata (Sutcliffe et al., 2010).  In Mycobacterium tuberculosis, some important 
surface-exposed antigenic glycolipids have been reported.  They include the phenolic 
glycolipids, diacyltrehaloses, and lipooligosaccharides (Munoz et al., 1997).  Some 
of the glycolipids that are surface exposed in the cell wall contain mycolyl residues 
and thus are termed mycolyl glycolipids (Figure 1.11). Trehalose 6, 6'-dimycolate 
(TDM), which was first isolated as a ‘cord factor’ from highly virulent 
Mycobacterium tuberculosis, has been recognised as one of the virulence factors 
inhibiting the formation of the phagolysosome in infected macrophages (Kai et al., 
2007). TDM is also found in many Actinomycetales including Rhodococcus, 
Nocardia and Corynebacterium. Other glycolipids isolated from members of 
Rhodococcus include trehalose 6-monomycolate, glucose 6-monomycolate, mannose 
6-monomycolate and fructose 6-monomycolate (Ueda et al., 2001).  
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Figure 1.11 Glycolipids derived from Rhodococcus. 
The number of carbon atoms, i.e. n could be 16, 18 or 20. (Modified 
from Ueda et al., 2001). 
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1.5.3 Channel-forming porins 
In Rhodococcus and other related mycolata, the presence of the asymmetric outer 
mycolic acid layer serves as a permeability barrier surrounding the peptidoglycan 
layer (Riess and Benz, 2000). Therefore this group of organisms must contain 
features in their cell wall that could allow hydrophilic substances to move in/out of 
what is termed the pseudoperiplasm (Sutcliffe et al., 2010). These so-called porins 
produce large and water-filled channels that are permeable to small hydrophilic 
substances and waste products but are not permeable to larger and more lipophilic 
compounds such as antibiotics and inhibitors (Nikaido, 1994). The presence of 
cation-selective pore-forming proteins has been reported in many mycolata such as 
Corynebacterium glutamicum, Mycobacterium bovis, M. tuberculosis and 
Rhodococcus erythropolis (Lichtinger et al., 2000).  Mycobacterium bovis also 
contains an anion-selective channel in the cell wall (Lichtinger et al., 1999), thus the 
mycolata contain porins of different specificities. Two porins in the cell wall of R. 
equi have been described by Riess et al. (2003). These porins are organic solvent-
extractable proteins with complementary selectivity for anions and cations. The 
cation-selective channel denoted PorAReq is a voltage-gated channel with an apparent 
molecular weight of 67 kDa and a pore diameter of 1.8 - 2.0 nm while the anion 
selective channel PorBReq is not voltage-gated and also has a pore diameter of about 
2.0 nm but this protein has an apparent molecular weight of only 11 kDa; clearly 
there are fundamental differences regarding the protein architecture of these channels 
(Riess et al., 2003). The properties of these pore-forming proteins are similar to those 
found in the cell walls of other closely-related mycolic acid containing Actinomyces 
(as described by Riess et al. 2003) as shown in Table 1.1. 
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Table 1.1 Comparison of the cell wall channel properties of R. equi and other 
related Mycolata 
(Modified from Riess et al., 2003. *From Mafakhari et al., 2014) 
Species Porin G(nS)1 Selectivity2 
Point charges at 
channel mouth 
Channel 
diameter 
(nm) 
Rhodococcus equi 
PorAReq 4.00 9.0 -1.5 2.0 
PorBReq 0.30 0.16 +1.5 1.4 
Rhodococcus erythropolis PorA 6.00 11.80 -2.7 2.0 
Rhodococcus corynebacteroides PorA 5.50 3.80 -2.7 2.2 
Corynebacterium glutamicum PorA 5.50 8.10 -2.0 2.2 
Nocardia farcinica NfpA 3.0 8.2 -1.3 1.4 
Dietzia maris* PorA 5.75 20.7 -2.4 2.1 
1
G, Single channel conductance (in nanoSiemens, nS) in 1 M KCl. 2 Pcation/Panion measured in KCl.  
 
In C. glutamicum, the possession of the cation-selective channel PorA (due to the 
presence of negatively-charged groups localised at the channel mouth) is solely 
responsible for the cell wall permeability to hydrophilic substances (Lichtinger et al., 
1998). Since R. equi is a relative of C. glutamicum, PorAReq and PorBReq may also 
perform roles similar to those of C. glutamicum. 
1.6 Other virulence factors 
1.6.1 Plasmid-encoded factors 
The virulence of R. equi is largely attributed to vapA and its transcription is 
predominantly under the regulation of proteins encoded by the genes virR and virS, 
which are part of the virR operon (Byrne et al., 2007) (Figure 1.6). Thus the 
expression of vapA is significantly reduced and virulence of R. equi is attenuated if 
there is mutation of either virR or virS (Giguere et al., 2011; MacArthur et al., 2011).  
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Another gene, icgA is also a component of the virR operon (Figure 1.6) that encodes 
a major facilitator superfamily transport protein. Though deletion of icgA did not 
affect the transcription of vapA, it elicited an enhanced growth phenotype in 
macrophages and a significant reduction of the viability of the organism in 
macrophages (Wang et al., 2014). 
1.6.2 Chromosome-encoded factors 
Rhodococcus equi chromosome encodes two important enzymes of the aromatic 
amino acid biosynthesis pathway; chorismate mutase and anthranilate synthase 
(REQ23860 and REQ23850 respectively). The encoding genes are strongly co-
induced with the vap genes (Letek et al., 2010). The amino acids tyrosine, 
phenylalanine and tryptophan appear to be present at limited concentrations inside 
the hypoxic macrophage intracellular environment, thus R. equi relies on de novo 
supply of the aromatic acids. Thus full proliferation and intracellular fitness of the 
bacterium could be compromised following independent mutations of REQ23860 
and REQ23850 (Letek et al., 2010). 
Other factors are important in the modification and exploitation of host lipids. The 
exoenzymes cholesterol oxidase and phospholipase C could also be important 
virulence factors (Hondalus, 1997).  The 54 kDa secreted protein, cholesterol oxidase 
catalyses the oxidation of cholesterol to 4-cholesten-3-one and is thought to be 
responsible for the destabilisation of the host cell membrane thus may play a role in 
tissue damage associated with R. equi infections (Linder and Bernheimer, 1997).  
There are four phospholipase C proteins encoded in the genome of R. equi (Vera-
Cabrera et al., 2013). The activity of cholesterol oxidase is enhanced by 
phospholipase C and provides access to the target thus the combined action of 
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cholesterol oxidase and phospholipase C may confer membranolytic activity of R. 
equi. These two enzymes have been termed ‘equi factors’ (Prescott, 1991). The target 
of cholesterol oxidase may be the sterol layer of the lysosomal or cellular membranes 
of the macrophage and thus it may contribute to the macrophage degeneration 
observed in vitro on challenge with R. equi (Hondalus, 1997). Rhodococcus equi 
catabolises cholesterol to products used as substrates for other important biochemical 
pathways.  Mutations in some key enzymes of this pathway of cholesterol catabolism 
(also called the steroid catabolic pathway) in R. equi displayed attenuated phenotypes 
and reduced proliferation in an in vitro macrophage infection assay (van der Geize et 
al., 2011). Rhodococcus equi may use this pathway to utilise macrophage membrane 
sterols possibly due to the extra demand for carbon in the hostile environment. In 
addition to cholesterol oxidase and phospholipase, Rhodococcus equi contains an 
abundant array of other secreted lipases which can degrade host cells for fatty acid 
oxidation (Alvarez et al., 2013; Villalba et al., 2013) (Figure 1.12). 
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Figure 1.12 Relative proportions of diverse lipolytic enzymes occurring in 
Rhodococcus equi 
(Adapted from Villalba et al., 2013) 
 
The nitrate reductase encoded by narG for could also be a possible virulence factor. 
Though being an aerobe, R. equi is also facultative since it is suited for anaerobic 
respiration via denitrification reducing nitrates to nitrites (Letek et al., 2010). This 
may suggest that the organism could use nitrate as a terminal electron acceptor in its 
respiratory chain in the hypoxic macrophage vacuolar compartment. Mutation in 
narG was also found to be significantly attenuated in a mouse challenge study 
(Giguere et al., 2011). 
1.6.3 Environmental factors 
Temperature and pH are important determinants of the virulence of Rhodococcus 
equi. The expression of the vap PAI genes is transcriptional regulated by temperature 
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and pH with strong upregulation at 37°C pH 6.5 and downregulation at 30°C pH 8.0 
(Vázquez-Boland et al., 2013). Other environmental stresses that regulate the 
expression of genes within the pathogenicity island are oxidative stress, magnesium 
and iron (Meijer and Prescott, 2004). The ability of the organism to acquire ferric 
iron from the host is directly related to virulence (Letek et al., 2010). 
1.7 Immunological aspects of Rhodococcus equi infections 
The ability to replicate inside the macrophage is a major determinant of the virulence 
of R. equi (Hondalus and Mosser, 1994). Macrophages may be the prime hosts of the 
organism since in vitro experiments show that the virulence of the organism is 
limited to cells that express the complement receptor Mac-1 (CD11b and CD18).  
These receptors are exclusive to the macrophage superfamily (Hondalus et al., 1993).  
The intracellular growth of the organism has been considered toxic because it 
inhibits the formation of the phagolysosome either as a consequence of intracellular 
growth or as a mechanism for survival (Hondalus and Mosser, 1994). Usually, a 
phagosome is created when a phagocyte engulfs a non-self substance including a 
bacterium via receptor-mediated endocytosis. This phagosome then matures to a 
phagolysosome via an early phagosome and a late phagosome stage by interacting 
with the lysosome (von Bargen and Haas, 2009). Destruction of the foreign body is 
then achieved by the combination of low pH (4.0 – 5.0), hydrolytic enzymes, and the 
production of reactive oxygen and nitrogen species (von Bargen and Haas, 2009).  
According to Fernandez-Mora et al. (2005), the majority (ca. 90 %) of the vacuoles 
containing R. equi are arrested at a late endosome stage en route to the lysosome thus 
preventing the maturation of the phagosome (Figure 1.13). 
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However, Toyooka et al. (2005) argued that when virulent R. equi are internalised in 
the macrophage, maturation of the phagosome proceeds initially just like other 
phagosomes containing harmless microorganisms, but they are tolerant to the 
bactericidal substances in the phagolysosomal environment. Rhodococcus equi does 
so by secreting substances that hinder the acidification of the phagolysosome thus the 
optimum pH required for the activity of the phagosolysosome is not attained 
(Toyooka et al., 2005). Hence the organism continues to multiply in the compartment 
and eventually causes cell necrosis (Figure 1.14).  
When macrophages are activated (maybe by engulfed microorganisms), cytokines, 
chemokines and other pro-inflammatory mediators are expressed and this could lead 
to generation of an oxidative burst - a process whereby reactive oxygen and nitrogen 
species (ROS and RNS) are released, which destroy the microorganisms. Lysozyme, 
a cell wall degrading enzyme, is an important component of the innate immune 
system.  It has been reported that R. equi is moderately resistant to lysozyme (Hebert 
et al., 2014). This is to be expected as the enzyme would not readily access its 
peptidoglycan substrate which lies beneath the mycolic acid layer. 
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Figure 1.13 A model for R. equi infectivity in macrophages. 
Clathrin-coated vesicles (CCV) feed extracellular liquid into the 
endocytic system. Phagosomes are formed at the plasma membrane and 
normally interact serially with early sorting endosomes (SE), late 
endosomes (LE) and lysosomes (Lys), but not with early recycling 
endosomes (RE) through which plasma membrane receptors can be 
recycled from the SE back to the surface. Some 10% of the ingested R. 
equi are transported along the degradative pathway to a 
(phago)lysosomal compartment and likely degraded, whereas the 
majority (some 90%) are directed to an unusual compartment whose 
composition is between the SE and the LE. The Golgi compartment 
communicates through vesicular trafficking with the SE/LE system but 
not with RCVs. Typical compartmental markers are indicated 
(Modified from Fernandez-Mora et al., 2005). 
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Figure 1.14 Alternative model for R. equi infection in macrophages. 
After engulfing R. equi, phagosomes containing virulent or avirulent R. 
equi fuse with lysosomes. Thereafter, avirulent R. equi lacking a 
plasmid cannot survive an acidic compartment in the phagolysosomes. 
Virulent R. equi harbouring an 85 kb plasmid suppresses the 
acidification. Thus they survive and replicate in the phagolysosomes 
(Adapted from Toyooka et al., 2005) 
 
Nitric oxide (NO) is an important reactive nitrogen species that is synthesised from 
arginine in a reaction catalysed by inducible nitric oxide synthase (iNOS). Interferon 
gamma (IFN-Ȗ) is a primary signal for the transcription of iNOS though there are 
other secondary signals such as tumour necrosis factor alpha (Darrah et al., 2000). 
When R. equi strains enter the alveolar macrophage of susceptible foals, there is an 
initial decrease in the transcription of IFN-Ȗ mRNA (Hines et al., 2003). This 
suggests that R. equi may produce factors that suppress the production of IFN-Ȗ. 
Interferon gamma activates macrophages and upregulates phagolysosomal fusion (as 
part of the Th1 response) thus the cytokine plays a central role in host susceptibility 
to R. equi with regards to phagocytosis (Kanaly et al., 1995). 
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Experiments in mouse models involving adoptive transfer and neutralising antibodies 
have shown that challenge with R. equi results in the development of Th2 responses, 
characterised by production of interleukin-4 (IL-4) rather than IFN-Ȗ. Such mice 
develop characteristic pulmonary lesions probably because of the dearth of IFN-Ȗ 
(Patton et al., 2005). Macrophages could be activated to produce other reactive 
species such as hydrogen peroxide, but R. equi is highly resistant to hydrogen 
peroxide stress (Meijer and Prescott, 2004). In fact, hydrogen peroxide triggers the 
induction of vap genes of the organism especially vapA and vapG (Benoit et al., 
2002; Meijer and Prescott, 2004). 
Though the exact mechanism of protective immune response in adult horses is 
unknown, there is evidence that pulmonary clearance of R. equi is as a result of a 
Th1 response where virulent strains are cleared with an increase in CD4+ and CD8+ 
T-lymphocytes (Hines et al., 2001). Experiments have also shown that 
T-lymphocytes, obtained from lungs of adult horses following immune clearance, 
proliferate in culture in response to R. equi antigens with the production of IFN-Ȗ but 
not interleukin-4 (Lopez et al., 2002). 
Antibody-mediated responses also play a significant role in protective immunity. In 
foals, colostrum-derived maternal antibody declines to its lowest level by 8 weeks of 
age, after which time they start to produce antibodies to the organism. Foals with low 
levels of maternal antibody are particularly susceptible to R. equi infections 
(Prescott, 1991). Immunoglobulin G (IgG) plays an important role in opsonisation 
and phagocytosis of virulent R. equi while mucosal IgA (from infected foals) is 
highly reactive to a specific B-cell epitope on VapA (Muscatello, 2012). The 
apparent absence of IgA from the nasal mucosa (during the first 4 weeks of life) and 
Chapter One Rhodococcus equi: Virulence, Pathogenesis and Genetics 
32 
 
the low circulating antibody titres (usually between 1 and 3 months) may increase the 
susceptibility of foals to R. equi infection (Muscatello 2012). Adult horses are 
generally resistant to R. equi infection since most of them have measurable antibody 
titres to the organism thus are said to be hyperimmune. This indicates the inverse 
relationship between antibody levels and disease prevalence and severity (Hietala et 
al., 1985). Results with passive immunisation of hyperimmune sera to foals exposed 
to R. equi protected them from disease (Mosser and Hondalus, 1996). In addition to 
humoral immunity, cell-mediated immunity could also be transferred by mare’s 
colostrum to foals (Porto et al., 2014). 
1.8 Mechanism of lipoprotein processing 
Lipoproteins in monoderm Gram-positive bacteria are cell envelope proteins that are 
anchored onto the outer leaflet of the plasma membrane (Hutchings et al., 2009).  
They contain lipids covalently attached to an N-terminal cysteine residue and this 
acylated N-terminal cysteine motif is believed to anchor the proteins to the plasma 
membrane via hydrophobic interactions of the acyl groups (Kovacs-Simon et al., 
2011).  Hence, the insertion of the lipid group provides a mechanism for localising 
proteins to bacterial cell membranes (Sutcliffe et al., 2010). In Gram positive 
bacteria (including R. equi), lipoproteins perform diverse functions such as antibody 
resistance, substrate binding, signalling, conjugation and secretory functions 
(Sutcliffe and Russel, 1995).  These proteins (especially of intracellular pathogens 
like R. equi) are also primary targets of the host immune response thus they may be 
key molecules to induce immune protection, and consequently, key targets for 
vaccine development (Barbey et al., 2009).  The preprolipoproteins (especially those 
of the membrane-anchored lipoproteins) contain an N-terminal signal peptide (or 
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signal sequence) that is involved in the targeting of proteins towards organelles or in 
their secretion which require the translocation of such proteins across membranes 
(Creuzenet et al., 1997). The signal sequence is the part that is recognised by the 
receptors of the translocation machinery, serves as a topological determinant for the 
prolipoprotein in the membrane and as a signal to inhibit the folding of nascent 
chains. This avoids the activation of potentially harmful secretory enzymes inside the 
cell and concurrently retaining translocation competence (Van Roosmalen et al., 
2004). A signal peptide is usually 14 – 25 amino acids long and consists of three 
distinct domains: the amino (N-), hydrophobic (H-), and the carboxylic-terminal (C-) 
regions (Figure 1.15). The H-region is the longest region of the signal peptide and 
consists of 10 – 15 amino acids. This region tends to organise into an α-helical 
conformation when in contact with a membrane lipid phase because of the presence 
of hydrophobic residues (Van Wely et al., 2001). At the N-terminal side of the H-
region, there is a stretch of positively-charged amino acids which is the N-region of 
the signal peptide. This region determines the orientation of the signal peptide due to 
its relatively high positively-charged polar nature (Van Roosmalen et al., 2004).  The 
C-region contains the cleavage site (lipobox) for the signal peptidase (Lsp) and is 
hydrophilic in nature (Van Wiley et al., 2001). 
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Figure 1.15 Structure of a typical bacterial signal peptide. 
It consists of a positively charged N-terminus (N-region), a central 
hydrophobic region (H-region), and a polar C-terminal region (C-
region). Helix-breaking proline or glycine residues are often found in 
the middle of the H-region and between the H- and C-regions at the −6 
position relative to the cleavage site. The Lsp recognition sequence 
consists of small aliphatic residues at positions −1 and −γ, relative to 
the cleavage site. The most common residue at these positions is Ala 
(Adapted from Van Roosmalen et al., 2004). 
 
This conserved motif directs the protein to the lipoprotein biogenesis machinery after 
transport (Hutchings et al., 2009). The signal peptide is then cleaved in a reaction 
catalysed by lipoprotein signal peptidase II (LspII) (for Gram positive bacteria) 
leaving the lipid-modified cysteine as the N-terminus of the mature lipoprotein 
(Sutcliffe and Harrington, 2002) (Figure 1.16). In many bacteria, the ligation of the 
diacylglycerol to the cysteine moiety within the lipobox by the prolipoprotein 
diacylglyceroltransferase (lgt) is a pre-requisite for the activity of Lsp (Sander et al., 
2004; Denham et al., 2009). Structural studies reveal that in some bacteria, the 
diacylglycerol is linked to the N-terminal cysteine via a thioether bond and this lipid 
group serves to orientate the protein by anchoring it to the inner leaflet of the 
membrane (Sutcliffe and Harrington, 2002). The diacylglycerol group of the 
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lipoproteins are derived from the membrane phospholipids which may not only 
provide anchorage of the lipoprotein to the membrane but also other functional roles 
since the lipoproteins are surface exposed (Kovacs-Simon et al., 2011). 
 
 
Figure 1.16 Lipoprotein biosynthesis in Gram-positive bacteria. 
Lipid modification of prolipoproteins (by thioether linkage of 
diglyceride to the lipobox cysteine) is followed by signal peptide 
cleavage, generating the mature lipid-anchored lipoprotein. The signal 
sequence shown is just a representation of a classical signal peptide 
(Adapted from Sutcliffe and Harrington, 2002). 
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Apart from VapF, VapI, and VapX, the full length proteins of the Vap family exhibit 
significant homology in their C-terminal regions (Figure 1.17). Even though there are 
significant differences in the amino termini of the proteins of the Vap family (VapA, 
-B, -C, -D,-E, -G, -H, -J, -K), they all possess a predicted signal peptide with an N-
terminal, hydrophobic, and a C-terminal regions with a potential cleavage sites for 
signal peptidase (Byrne et al., 2001; Takai et al., 2000). This clearly shows that they 
possess features of secretory proteins. VapA has long been recognised as a lipidated 
protein but the lack of the characteristic cysteine residue employed in lipoprotein 
biogenesis suggests that this protein might possess an unusual Lgt-independent lipid 
modification. 
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Figure 1.17 Sequence alignment of the Vap proteins from the vapB plasmid 
pVAPB1593 and the vapA plasmid pVAPA1037 
Alignment was done using ClustalW 2.1 multiple alignment programme 
formatted using ESPript3.0 (Gouet et al., 2003). Apart from VapF and 
VapI, the proteins exhibit significant homology in their C-terminal 
regions. 
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1.9 Aim of the study 
The virulence of R. equi is largely attributed to its virulence plasmid, which bears a 
pathogenicity island that encodes VapA (a 15 – 17 kDa immunodominant surface-
expressed protein). Even though the exact mechanism of virulence is not known, 
VapA is thought to mediate the intracellular growth of the organism in macrophages 
and disease development via the arrest of phagosome maturation (Polidori and Haas, 
2006; Barbey et al., 2009; Letek et al., 2010). 
VapA is susceptible to trypsin digestion and can be labelled with a biotin-containing 
bifunctional agent which suggests that it is a surface-anchored protein.  Biotin esters 
do not penetrate the cell membrane thus have been used as biotinylation reagents for 
membrane proteins (Smither et al., 2007). Its metabolic labelling with [3H] palmitate 
shows that it is a lipid-modified protein, a key property for cell wall anchorage 
(Meijer and Prescott, 2004). In addition, VapA has a predicted signal sequence, a 
positively charged amino acid region and a hydrophobic region with potential 
cleavage site for signal peptidase at the C-region (Bryne et al., 2001). These 
properties show that VapA is a lipoprotein that maybe non-covalently attached to the 
rhodococcal cell envelope. Even though VapA is an exported secretory protein, 
nucleotide sequence analysis studies also show that preproVapA has no lipobox and 
the mature VapA lacks the typical acylated N-terminal cysteine motif (Tan et al., 
1995) which implies that Rhodococcus equi may possess a different mechanism to 
lipidate its proteins especially VapA i.e. independent of prolipoprotein diacylglycerol 
transferase (Lgt) (Meijer and Prescott, 2004). Reports have it that VapA is an 
acylated protein and it has been suggested that lipid modification of VapA may likely 
occur at a site close to the N-terminus of the mature protein (Tan et al., 1995). Thus 
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one of the focuses of the study will be the investigation of the post-translational 
lipidation status of VapA. 
In Corynebacterium (a related genus of Rhodococcus), channel forming porins (e.g 
CgPorA in Corynebacterium glutamicum) are modified by O-linked mycolic acids 
and this post-translational mycoloylation enhances their pore-forming abilities (Huc 
et al., 2010). Since lipoproteins and channel forming porins are non-covalently 
attached to the wall, one objective of this research is to establish whether VapA has 
mycolyl residues analogous to CgPorA in Corynebacterium glutamicum since in 
some cases the mycolic acid layer serves as a potential anchoring point for 
lipoproteins (Kovacs-Simon et al., 2011). The aim was to investigate this hypothesis 
via chemical analysis of purified material and heterologous expression of cloned 
vapA in C. glutamicum to establish whether the unusual modification of the protein 
can be generated in an organism of a related genus. Corynebacterium glutamicum 
could represent a suitable model for functional studies of expression of rhodococcal 
genes related to cell wall function because it possesses the simplest cell wall 
structure of the mycolata and hence is functionally and structurally close to R. equi. 
It represents a good model organism as it is a fast grower and does not form clumps 
and heterologous expression of antigens of related bacteria had already proved to be 
effective (Puech et al., 2001). 
Expression of vapA in either an isogenic plasmidless derivative or a vap PAI deletion 
mutant showed that VapA alone, in the absence of other vap PAI products, is not 
sufficient to restore the capacity of R. equi to proliferate in macrophages or mouse 
organs and to colonise the lungs of experimentally infected foals (Vazquez-Boland et 
al., 2010; Vazquez-Boland et al., 2013). Hence the Vap proteins could interact to 
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sustain complete virulence of the organism in the host. Potential interaction of Vaps 
was to be investigated using biophysical techniques including surface plasmon 
resonance and analytical ultracentrifugation.  
In the absence of mechanistic insight, a structural study of the virulence associated 
proteins using X-ray crystallography was also planned. Vap genes were to be cloned 
and expressed in E. coli. The proteins would be purified to commence the production 
of crystals for X-ray diffraction studies, which might deliver structural information 
that might inform subsequent functional studies. 
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 CHAPTER TWO 
2 Materials and methods 
2.1 Chemicals and Reagents 
All chemicals and reagents were of analytical grade hence were used without further 
purification. Solutions and buffers were prepared using Milli-Q (18 mΩ.cm-1) water 
and stored at room temperature unless otherwise stated. All primers for PCR were 
supplied by Eurofins Genomics, those used for sequencing were synthesised and 
used at GATC Biotech. 
2.2 Media 
Media were prepared using distilled water, sterilised by autoclaving and stored at 
room temperature except for solid media that were stored at 4°C.  
2.2.1 Liquid media (Broth)  
Liquid media (Broth) used in the study include Luria-Bertani (LB), Terrific Broth, 
and Brain Heart Infusion (BHI). Recipes for each are given in appendix A. 
2.2.2 Solid media 
Solid media used were LB agar and BHI agar. Recipes are given in appendix A. 
2.2.3 Selective media (Media containing antibiotic) 
Antibiotics used for the preparation of selective media are ampicillin and kanamycin. 
Preparations of selective media are given in appendix A. 
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2.3 Bacterial strains and plasmids 
Bacterial strains used include Rhodococcus equi 103+ (I. C. Sutcliffe collection), 
Rhodococcus equi ΔkasA (Sydor et al., 2013), Corynebacterium glutamicum ATCC 
13032 (ATCC), E. coli Top 10 (Invitrogen) and E. coli BL21 (DE3) (Invitrogen). E. 
coli Top 10 was used as host for cloning while E. coli BL21 (DE3) was used for 
recombinant gene expression. Bacterial strains were stored in 20 % glycerol (sterile) 
and maintained at -80°C while plasmids were stored at -20°C. The plasmids used 
include pET23a (Novagen), pET28a (Novagen), E. coli-C. glutamicum shuttle vector 
pEKEx2 (Eikmanns et al., 1991) and the cosmid p10.1 (Raul Miranda-Casoluengo, 
University College Dublin). The relevant features of pET23a, pET28a, and pEKEx2 
are briefly described in appendix B.  
2.4 Production of chemically competent cells 
Chemically competent cells were prepared according to the method of Sambrook and 
Russell (2001) with some modifications. Briefly, 5 mL of LB broth was inoculated 
with a single colony of E. coli Top10 cells and grown overnight at 37°C with shaking 
at 200 rpm as a starter culture. One millilitre of the starter culture was transferred to 
50 mL of LB broth and grown at 37°C with shaking at 200 rpm until an OD600 of 
0.35 – 0.4 was obtained. Cells were recovered by centrifuging 25 mL of the culture 
at 2880 x g for 10 min at 4°C. The supernatant was discarded and the pellet re-
suspended in 15 mL of ice-cold universal solvent (0.08 M MgCl2 solution containing 
0.02 M CaCl2 and autoclaved), held on ice for 60 min and recovered by 
centrifugation as before. The supernatant was discarded and the pellet re-suspended 
in 1 mL of cold CaCl2 (0.1 M). The cells (50 µL portion) were used directly for 
transformation or re-suspended in glycerol (15 % - 20 % final concentration) and 
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dispensed as 50 µL aliquots in sterile 1.5 mL microcentrifuge tubes which were flash 
frozen in liquid N2 and stored at -80°C.  
2.5 Plasmid maps 
The maps of the plasmids (where applicable) were constructed using PlasMapper 
which is a web-based plasmid map drawing tool developed by Dong et al. (2004). 
The plasmid sequence was fed into programme which generated the map.  
2.6 Estimation of Protein and DNA concentrations 
The concentration of DNA and purified proteins were quantified using a NanoDrop 
1000 Spectrophotometer following the manufacturer’s protocol. The estimation for 
other protein solutions (where applicable) was made via the Bradford reagent using 
bovine serum albumin (BSA) as the standard. A standard curve (Appendix C) was 
generated with different concentrations of BSA (0.1 mg/mL – 1.0 mg/mL) and the 
concentration of the protein solution (treated identically to the standards) was 
determined with reference to the standard curve. Briefly, 0.1 mL of either standard or 
sample was delivered in a cuvette. Bradford reagent (3 mL) was added to the protein 
solution, mixed using a pipette and held at room temperature for 10 min before 
measuring absorbance at 595 nm.  
2.7 DNA methods 
2.7.1 Extraction of Corynebacterium glutamicum genomic DNA 
A single colony of Corynebacterium glutamicum ATCC 13032 was picked from a 
culture plate and grown in 25 mL of BHI broth at 30°C to OD600 of 0.6 to 0.8. The 
cells were recovered by centrifuging culture at 2880 x g for 30 mins at 20°C and re-
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suspended in 450 µL of GTE-RNase buffer (Appendix D) and transferred into a 1.5 
mL microcentrifuge tube. Fifty microlitres of lysozyme (10 mg/mL) was added to the 
mixture and incubated overnight at 30°C. The next day, 100 µL of sodium dodecyl 
sulphate (10 % w/v), 20 µL of proteinase K (15 mg/mL) were added, mixed gently 
and held at 55°C for 3 hrs. The mixture was allowed to cool and 10 µL of RNase A 
(10 mg/mL) was added, mixed and incubated for 30 min at 37°C. Two hundred 
microlitres of NaCl (5 M), 1 mL of chloroform: isoamyl alcohol (24:1) were added, 
mixed and centrifuged at 13,000 rpm (using a bench top centrifuge) for 10 min. The 
upper aqueous layer was collected and delivered into a new microcentrifuge tube and 
mixed with 1 mL of chloroform: isoamyl alcohol (24:1) and centrifuged. The 
aqueous layer was recovered and mixed with 0.7 volume of ice-cold isopropanol 
(about 0.7 mL) by inversion, and centrifuged at 4°C, 27,000 x g for 30 min. The 
supernatant was removed and the pellet was washed with 0.7 mL of ice-cold ethanol 
(70 %) and centrifuged at 4°C, 27,000 x g for 30 min. The ethanol was removed with 
a pipette and the pellet was allowed to dry at room temperature on the bench. The 
pellet was finally re-suspended in 20 µL of elution buffer from QIAprep spin mini-
prep kit (Qiagen). 
2.7.2 Extraction of plasmid DNA 
Plasmid DNA was extracted using a QIAprep spin mini-prep kit (Qiagen) following 
the manufacturers’ protocol. Recombinant plasmids were sent for sequence analysis 
thereafter. 
Chapter Two Materials and methods 
45 
 
2.7.3 Electrophoretic analysis of DNA 
The gel casting tray was prepared by boiling 0.3 g of dry agarose powder in 30 mL 
of Gel buffer (Tris-Acetic acid-EDTA or TAE buffer, appendix D). A comb was 
inserted into the electrophoresis tray and the molten agarose solution poured in a 
casting chamber and allowed to set. The casting chamber was placed in the 
electrophoresis chamber and covered with TAE buffer up to the maximum mark in 
the tank. The comb was removed and sample (1 µL) was loaded on each well after 
mixing with 1 µL of DNA loading buffer (Appendix D). The gel was run at a 
constant current of 120 mA for 25 min. The gel was placed in a stain box containing 
ethidium bromide solution (0.5 µg/mL) for 10 min and visualised under UV light and 
an image captured using a Bio-Rad Gel Doc system with Quantity One software. 
2.7.4 Oligonucleotide primers for gene cloning 
The sequences that code for the virulence associated proteins A, C, D, E, G, H and 
corynomycolyl transferase (Cmt) were amplified via PCR. Since the proteins contain 
predicted signal peptides, oligonucleotide primers were designed for the 
amplification of the genes in such a way to avoid the regions which code for the 
putative signal peptides (for cloning expression in E. coli) as validated by SignalP 
(Appendix E). Primers (for ligation and restriction digestion) were designed to have 
restriction enzyme sites at the 5′ and γ′ ends and addition number of bases at each 
end to allow for efficient binding and cleavage. The genes were amplified using 
oligonucleotide primers (as shown in table 2.1) for insertion of the ORFs into either 
pET23a or pET28a (in frame for expression in E. coli) or pEKEx2 (in frame for 
expression in C. glutamicum). 
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Table 2.1 Oligonucleotides used for the study. 
OLIGO NAME SEQUENCE (5′- γ′) Restriction 
endonuclease 
pET23/28-VapAup  GATCGATCCATATGACCGTTCTTGATTCCGGTAGCAGCAGTGCGGTGCG NdeI 
pET23-VapAfull GATCGATCCATATGAAGACTCTTCACAAGACGGTTTCTAAGGCG NdeI 
pET23-VapAlo TATAAATAGCGGCCGCGGCGTTGTGCCAGCTACCAGAGCCG NotI 
pET28-VapAlo TATAAATAGCGGCCGCCTAGGCGTTGTGCCAGCTACCAGAGCCG NotI 
   
pET23/28-
VapCup 
GATCGATCCATATGAATGTAGTCGCTCCGTCGGCGTGG NdeI 
pET23-VapClo AATTTATAGCGGCCGCCACCAAATGCCATCGCCCATTCC NotI 
pET28-VapClo AATTTATAGCGGCCGCTCACACCAAATGCCATCGCCCATTCC NotI 
   
pET23/28VapDup GTAGGAACCATATGCAGGAGCTAGCTGGCACCAAGAC NdeI 
pET23-VapDlo GTAGGAACGAATTCCTCCCACCCGCCAGTG EcoRI 
pET28-VapDlo GTAGGAACGAATTCCTACTCCCACCCGCCAGTG EcoRI 
   
pET23/28-
VapEup 
GTACGATCCATATGCGGGAAATTGGCGCCCAG NdeI 
pET28-VapElo GTACGATCGAATTCCTATCGCCAGGCGCCAGTG  EcoRI 
   
pET23/28-
VapGup 
GACGATCCATATGGAAACTTCAATGGTATCCACTACAGCAGCATCG NdeI 
pET-28VapGlo GACGATCGAATTCCTATTGCCACCCTCCGGTTCC EcoRI 
   
pET-
23/28VapHup 
GACGATCCATATGGCCCCGCCACCATTACCAGATG NdeI 
pET28-VapHlo GACGATCGAATTCCTACGCTACATCGCCTATCCAGGTTCCCGTAC EcoRI 
   
pET23/28-Cmtup AATCAATTCATATGGCCGAAGTAACCCCAGCAGACG NdeI 
pET23-Cmtlo AATCAATCGCGGCCGCGGCCTCTAGCTCAAACGC NotI 
pET28-Cmtlo AATCAATCGCGGCCGCCTAGGCCTCTAGCTCAAACG NotI 
   
pEKEx2VapAup GATCGATCGGTACCAAGGAGATATAGATATGAAGACTCTTCACAAGACGG KpnI 
pEKEx2-VapAlo GATCGATCGAATTCCTAGGCGTTGTGCCAGCTAC EcoRI 
pEKEx2-
VapAHislo 
GATCGATCGAATTCCAACTCAGCTTCCTTTCGGGCTTTG EcoRI 
All oligonucleotides were designed to introduce recognition sites for restriction endonucleases 
upstream and downstream of the target sequence (recognition sites are underlined, and restriction 
endonucleases are in brackets) to facilitate cloning into vectors. Highlighted in bold (but not 
underlined) is the ribosomal binding site. 
 
PCR reactions used Vent DNA polymerase (New England Biolabs) which has a high 
proof reading ability. The cosmid p10.1 was used as a template for the amplification 
of vapA, vapC, and vapD (for cloning into either pET23a or pET28a) as it contains 
coding sequences for the respective Vap proteins. For the amplification of vapE, 
vapG, and vapH, relcalcitrant genes (which codes for the VapE, VapG and VapH) 
were sourced from Eurofins MWG Operon while for cmt, C. glutamicum genomic 
DNA was used as the template.  For each oligonucleotide pair, reaction mixture (50 
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µL final volume) was made up of Thermopol buffer (1 time strength), 
deoxynucleotide triphosphates mix (80 µM each), oligonucleotide primer (20 pg/µL 
each), 1 – 5 µg of template DNA and 20 units of Vent DNA polymerase. The thermal 
cycling conditions are shown in table 2.2. 
Table 2.2 Thermocycler program for PCR 
Phase 
Initial 
denaturation 
Amplification 
Polishing 
Denaturation Annealing Extension 
T°C 95 95 55 72 72 
Time 
(mins) 
3 0.5 0.5 
1 / kb 
plasmid  
10 
Cycles 
(n) 
1 35 1 
* For ORFs less than 500 bp, extension time was set at 30 seconds 
 
2.7.5 Gel purification of amplified products 
Where appropriate, samples containing PCR products were pooled together and 
loaded on a broad well in an agarose gel. After running the gel, it was stained in 
freshly prepared ethidium bromide solution (0.5 µg/mL) and visualised using the 
prep UV setting of a trans-illuminator. The band corresponding to DNA size of 
interest was excised from the gel and DNA purified using either QIAquick gel 
extraction kit or NzyTech Gelpure kit following the manufacturers’ protocols. A 
sample was analysed for purity using agarose gel electrophoresis. 
2.7.6 Cloning of amplified DNA in pET23a and pET28a 
The genes were cloned into either the NotI/NdeI or Nde1/EcoRI cloning sites of both 
pET23a and pET28a vectors. Purified PCR products (DNA inserts) for vapA, vapC 
and cmt were separately digested with NdeI and NotI restriction enzymes to generate 
cohesive ends in NE Buffer 3 which supports maximal activity for digestion using 
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those two enzymes. While purified PCR products of vapD, vapE, vapG, and vapH 
were digested separately with NdeI and EcoR1 in NE buffer 4 as it supports 
maximum activity for the enzyme pair. The vectors were also digested with either 
NotI/NdeI or NdeI/EcoRI. The mixture for restriction digestion is shown in table 2.3. 
Table 2.3 Restriction enzymes digest mixture 
Item Volume (µL) 
Plasmid or PCR product 40 
NE Buffer (10 x strength) 10 
BSA (100 x strength) 1 
Restriction enzyme 1 5 
Restriction enzyme 2 5 
Sterile Milli Q water 39 
 
Each digestion mixture was incubated at 37°C for 3 hrs. Plasmids (now linearised) 
and DNA insert were gel purified thereafter. Each insert was ligated to linearised 
plasmid in a reaction whose constituents were 1 µL of gel-purified linearised plasmid 
DNA solution, 11.5 µL of insert DNA solution (vap or cmt), 1.5 µL of T4 DNA 
ligase buffer (10 x strength) and 1 µL of T4 DNA ligase (400,000 U/mL). Each 
mixture was incubated at 16°C overnight and used to transform chemically 
competent E. coli Top10. 
2.7.7 Cloning of amplified DNA into pEKEx2 
In this case, a second gene amplification was performed using pET23-vapAfull as the 
template with the primer pairs pEKEx2-vapAup/pEKEx2-vapAlo and pEKEx2-
vapAup/pEKEx2-vapAhislo as shown in table 2.1. After amplification of the targets, 
the products were gel purified, restriction digested with KpnI and EcoRI and ligated 
to pEKEx2 (which was also restriction digested with KpnI and EcoRI, and gel 
purified).  
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2.7.8 Transformation of chemically competent E. coli  
Fifteen microlitres of suspected ligated DNA was added to a 50 µL aliquot of freshly 
thawed glycerol stock of chemically competent E. coli Top10 and incubated on ice 
for 20 min. It was heat shocked at 42°C in a water bath for 2 min and transferred 
immediately to ice for another 2 min for recovery. LB broth (200 µL) was added to 
the solution and incubated for 45 min at 37°C.  A 200 µL sample of the suspension 
(containing transformed cells) was spread on LB agar (supplemented with 100 
µg/mL ampicillin for cloning into pET23a or 25 µg/mL kanamycin for cloning into 
pET28a/pEKEx2) and incubated at 37°C overnight. Single colonies (transformants) 
were selected and inoculated into 5 mL of LB broth (with either ampicillin or 
kanamycin) and incubated overnight at 37°C with shaking at 150 rpm. The broth was 
used for plasmid extraction. 
2.7.9 Electroporation of pEKEx2-derived plasmids into Corynebacterium 
glutamicum 
Electroporation of pEKEx2-vapA and pEKEx2-vapAhistag into C. glutamicum was 
performed according to the method of Van der Rest et al. (1999) with modifications.  
Ten millilitres of LB broth (containing 2 % glucose sterile filtered) was inoculated 
with a colony of C. glutamicum from a fresh plate as a starter culture overnight at 
30°C with shaking at 150 rpm. One hundred millilitres of special medium (for 
growing electro-competent cells, appendix A) was inoculated with 5 mL of the 
overnight culture and grown to an OD600 of about 1 at 18°C and 150 rpm. The 
culture was chilled on ice and pelleted by centrifuging at 2880 x g for 10 min at 4°C. 
The pellet was re-suspended and washed three times with 20 mL ice-cold Tris-
Glycerol buffer (1 mM Tris-HCl buffer, pH 7.5; 10 % v/v glycerol) by centrifuging 
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at 2880 x g for 10 min at 4°C. The pellet was re-suspended in 1 mL ice-cold 10 % 
glycerol (v/v) and stored as aliquots in 200 µL volumes in pre-chilled 1.5 mL 
microcentrifuge tubes and stored at -80ºC (cells now electro-competent). Electro-
competent cells (150 µL) and 2 µL of plasmid DNA (recombinant) were transferred 
to a pre-chilled electroporation cuvette (0.2 cm gap),  topped gently with 0.8 mL of 
ice-cold 10 % glycerol and electroporated (using a Gene Pulser System from Bio-
Rad) with a single pulse with parameters set at 25 µF, 2500 V, and 600 Ω. Solution 
was transferred immediately into 4 ml of pre-warmed (at 46ºC) BHI medium 
containing 2 % sorbitol (BHIS) and heat shocked by incubating for 6 min at 46°C in 
a water bath, and immediately for 1 hr at 30°C for recovery. Two hundred microlitres 
of the mixture was subsequently plated on BHIS agar (containing 25 µg/mL 
kanamycin) and incubated at 30°C overnight. 
2.7.10 Site-directed mutagenesis 
The plasmid pEKEx2-vapA was amplified using primers that were designed to bear 
point mutations in vapA. The oligonucleotides used for site-directed mutagenesis are 
shown in Table 2.5. 
PCR reactions used pEKEx2-vapA as the template, primers (table 2.4), Vent DNA 
polymerase, thermopol reaction buffer, dNTPs, and distilled water with volumes and 
concentrations as described in section 2.7.4. However the thermocycler programme 
is shown in table 2.4. 
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Table 2.4 Thermocycler program for site-directed mutagenesis 
Phase 
Initial 
denaturation 
Amplification 
Polishing 
Denaturation Annealing Extension 
T°C 95 95 55 68 68 
Time 
(mins) 
3 0.5 1 
1 minute/kb 
plasmid 
length 
30-60 
minutes 
Cycles 
(n) 
1                                   12 1 
 
After the reaction, the tube was later placed on ice and 1 µL of the restriction enzyme 
DpnI (20,000 U/mL) was added to the mixture, gently mixed by pipetting and 
incubated for 1 hr at 37°C to digest parental DNA. One microlitre of the solution was 
later used to transform chemically competent E. coli Top 10 cells. A single 
transformant was grown in 5 mL LB broth (containing kanamycin), plasmid 
extracted and sent for sequence analysis. The pEKEx2-vapAmutant was later used to 
transform electro-competent C. glutamicum. 
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Table 2.5 Oligonucleotides used for site-directed mutagenesis. 
The mutant sites are highlighted in bold. Where the targets are not 
continues (in more than once codon), the codons in the antisense 
sequence (per primer pair) are underlined 
OLIGO NAME SEQUENCE (5′- γ′) 
VapAST/ABlock1up GGCTGCGCTAATGCGGCCGTTCTTGATTCCG 
VapAST/ABlock1lo CGGAATCAAGAACGGCCGCATTAGCGCAGCC 
  
VapAST/ABlock2up GCTAATGCGACCGTTCTTGATGCCGGTAGCAGCAGTGCGATTCTC 
VapAST/ABlock2lo GAGAATCGCACTGCTGCTACCGGCATCAAGAACGGTCGCATTAGC 
  
VapAST/ABlock3up CCGTTCTTGATTCCGGTGCCGCCGCTGCGATTCTCAATAGTGGG 
VapAST/ABlock3lo CCCACTATTGAGAATCGCAGCGGCGGCACCGGAATCAAGAACGG 
  
VapAST/ABlock4up GCAGTGCGATTCTCAATGCTGGGGCAGGCGCTGGCATTGTCGGTTCTGGG 
VapAST/ABlock4lo CCCAGAACCGACAATGCCAGCGCCTGCCCCAGCATTGAGAATCGCACTGC 
  
VapAST/ABlock5up GGCATTGTCGGTGCTGGGGCCTATGACAGCTCG 
VapAST/ABlock5lo CGAGCTGTCATAGGCCCCAGCACCGACAATGCC 
  
VapAST/ABlock6up CTGGGAGCTATGACGCCGCGGCGGCTGCGTTAAACCTTCAG 
VapAST/ABlock6lo CTGAAGGTTTAACGCAGCCGCCGCGGCGTCATAGCTCCCAG 
  
VapAST/ABlock7up GAACGGTCGAGCAGCCGATGCCGCCGGGCAAGAG 
VapAST/ABlock7lo CTCTTGCCCGGCGGCATCGGCTGCTCGACCGTTC 
  
VapAST/ABlock8up CACGGAGACGTCATCGCCGCGGTCGTCTACCAG 
VapAST/ABlock8lo CTGGTAGACGACCGCGGCGATGACGTCTCCGTG 
  
VapAST/ABlock9up GATGCAGGGGGACTCGCGCTTCCTGGGGCCGGC 
VapAST/ABlock9lo GCCGGCCCCAGGAAGCGCGAGTCCCCCTGCATC 
  
VapAST/ABlock10up GTTCTGGGGGGCTCTCTTCGCAAATGACCTTCAG 
VapAST/ABlock10lo CTGAAGGTCATTTGCGAAGAGAGCCCCCCAGAAC 
  
VapAST/ABlock11up CTCTACAAAGACGCCGTCGCGTTCCAGTACAAC 
VapAST/ABlock11lo GTTGTACTGGAACGCGACGGCGTCTTTGTAGAG 
  
VapAST/ABlock12up CAACTTCTTCGATGCCGCAGGTGCCTTCCTCGGCCATATC 
VapAST/ABlock12lo GATATGGCCGAGGAAGGCACCTGCGGCATCGAAGAAGTTG 
  
VapAST/ABlock13up CTCGGCCATATCCAGGCCGGTGGAGTTAGTACTGTG 
VapAST/ABlock13lo CACAGTACTAACTCCACCGGCCTGGATATGGCCGAG 
  
VapAST/ABlock14up CAGTCCGGTGGAGTTGCTGCTGTGGTGGGCGTCGGCGTC 
VapAST/ABlock14lo GACGCCGACGCCCACCACAGCAGCAACTCCACCGGACTG 
  
VapAST/ABlock15up GGCGTCGGCGGCGGCGCTGGTGCCTGGCACAACGCCTAG 
VapAST/ABlock15lo CTAGGCGTTGTGCCAGGCACCAGCGCCGCCGCCGACGCC 
 
Chapter Two Materials and methods 
53 
 
2.8   Protein Methods 
2.8.1 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)  
A discontinuous electrophoresis gel system (Laemmli, 1970) was used with a 12 % 
resolving gel in a mini-gel format (Miniprotean® II, Bio-Rad). The formulation of 
the buffers required (resolving gel buffer, stacking gel buffer, sample loading buffer, 
and SDS running buffer) and staining solutions are detailed in appendix D. The 
resolving gel was mixed as detailed in Table 2.6 and was poured immediately after 
preparation into the gel casting cassette, overlaid with water and allowed to set for 
about 20 min. The water was removed and the stacking gel (Table 2.7) was poured 
immediately after preparation into the casting cassette on top of the resolving gel, the 
comb was inserted and allowed to set. The gel sandwich was clamped and placed 
inside the chamber, which was filled with SDS running buffer. Each protein sample 
(including standards) was mixed with loading buffer in a volumetric ratio of 5:1, and 
held at 95°C for 3 min and allowed to cool. The comb was removed and 10 µL of 
protein sample was loaded. Gels were electrophoresed for 50 min at a constant 
voltage of 200 V. The gel was removed, immersed in Coomassie blue stain for 15 
min, rinsed with water and soaked in de-stain overnight. Gels images were captured 
(after washing the gel in water) using a Gel Doc system with Bio-Rad Quantity One 
software. 
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Table 2.6 SDS-PAGE resolving gel recipes 
Ingredient Volume (mL) 
Resolving gel buffer (1.5 M Tris.HCl, pH 8.8, 4% SDS) 2.50 mL 
40% Acrylamide:Bisacrylamide, (37.5: 1) 3.00 mL 
Distilled water 4.50 mL 
*Ammonium per sulphate (10 %) 0.05 µL 
TEMED 0.01 µL 
TEMED is N,N,N',N'-Tetramethylethylenediamine. *Ammonium persulphate was freshly prepared 
before use and added last. 
 
 
Table 2.7 SDS-PAGE Stacking gel recipes 
Ingredient Volume (mL) 
Stacking gel buffer (0.5 M Tris.HCl, pH 6.8, 4 % SDS) 1.00 
40% Acrylamide:Bisacrylamide (37.5: 1) 0.50 
Distilled water 2.50 
*Ammonium per sulphate (10 %) 0.03 
TEMED 0.01 µL 
TEMED is N,N,N',N'-Tetramethylethylenediamine. *Ammonium persulphate was freshly prepared 
before use and added last 
 
2.8.2 Non-denaturing (Native) polyacrylamide gel electrophoresis (Native-
PAGE) 
This was also used with a 12 % resolving gel in a mini-gel format (Miniprotean® II, 
Biorad) as reported in SDS-PAGE but the stacking gel buffer, resolving gel buffer, 
running buffer and the sample loading buffer did not contain sodium 
dodecylsulphate. The protein and sample buffer were mixed and immediately loaded 
onto the gel without boiling. Staining and de-staining were done as reported for SDS-
PAGE. 
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2.8.3 Urea polyacrylamide gel electrophoresis (Urea-PAGE) 
A 12 % resolving gel in a mini-gel format (Miniprotean® II, Bio-Rad) was also used 
but the resolving and stacking gels were supplemented with urea to a final 
concentration of 1 %. Thus the recipes for Urea-PAGE are given in tables 2.8 and 
2.9. Samples were mixed with loading buffer (0.2 M Tris.HCl, pH 6.8, containing 75 
% glycerol, 3% bromophenol blue) and loading unto the wells without boiling. 
Running buffer was the same as the Native-PAGE. 
Table 2.8 Urea-PAGE resolving rel casting recipes 
Ingredient Volume (mL) 
Resolving gel buffer (2.0 M Tris.HCl, pH 8.8) 3.000 
40%Acrylamide (Acrylamide:Bisacrylamide, 37.5: 1) 4.500 
Distilled water 5.505 
0.5 M EDTA (pH 8.0) 0.015 
8 M Urea 1.875 
*Ammonium per sulphate (10 %) 0.075 
TEMED 0.030 
TEMED is N,N,N',N'-Tetramethylethylenediamine. *Ammonium persulphate was freshly prepared 
before use and added last 
 
 
Table 2.9 Urea-PAGE stacking gel casting recipes 
Ingredient Volume (mL) 
Stacking gel buffer (0.5 M Tris.HCl, pH 6.8) 1.000 
40%Acrylamide (Acrylamide:Bisacrylamide, 37.5: 1) 0.300 
Distilled water 2.100 
0.5 M EDTA (pH 8.0) 0.010 
8 M Urea 0.500 
*Ammonium per sulphate (10 %) 0.075 
TEMED 0.015 
TEMED is N,N,N',N'-Tetramethylethylenediamine. *Ammonium persulphate was freshly prepared 
before use and added last 
 
2.8.4 Optimisation of gene expression 
Gene expression was performed after inserting recombinant plasmids into an 
expression host. This was achieved by transforming chemically competent E. coli 
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BL21 (DE3) with each of the recombinant plasmids. After transformation, mixtures 
were plated on LB agar (supplemented with ampicillin) and incubated at 37°C 
overnight. Antibody-resistant colonies (transformants) were selected and grown in 5 
mL LB broth (supplemented with ampicillin) overnight at 37°C with shaking at 200 
rpm and 1 mL portions were sub-cultured in 50 mL LB broth (supplemented with 
ampicillin). The 50 mL culture was grown at 37°C and 150 rpm to an OD600 of 0.5 – 
0.7. Isopropyl ȕ-D-thiogalactopyranoside (IPTG) was added to the cultures at 
different concentrations and incubated at different times before harvesting as shown 
in table 2.10. 
Table 2.10 Conditions for gene expression 
Flask IPTG (mM) Temperature (°C) Time 
1 0 37 4 hrs 
2 0.1 37 4 hrs 
3 0.5 37 4 hrs 
4 1.0 37 4 hrs 
5 1.0 16 Overnight 
 
2.8.5 Large scale gene expression 
In this case, single antibody resistant colonies (transformants) were selected and 
grown in 10 mL LB broth (supplemented with either ampicillin or kanamycin) 
overnight at 37°C with shaking at 200 rpm. This overnight preculture was used to 
inoculate one litre of terrific broth (containing appropriate antibiotic) and grown to 
an OD600 of 0.5 – 0.7 at 180 rpm, 37°C. Protein expression was induced by the 
addition of IPTG and incubated at the temperature that gave maximum protein 
expression following optimisation.  
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2.8.6 Production of lysates 
After induction, the cells were harvested by centrifuging at 2880 x g for 10 min at 
4°C. Pelleted cells were re-suspended to 10 mL/g in 0.02 M Tris.HCl (pH 7.4, 
containing 0.5 M NaCl, 0.03 M Imidazole) and lysed by exposing re-suspended cells 
(in 5 mL aliquots) to 6 cycles of 10 s sonication/ 10 s cooling with amplitude setting 
at 10 µ using Soniprep 150. Lysate was clarified by centrifuging at 27,000 x g for 30 
min at 4°C. 
2.8.7 Protein purification 
Recombinant protein was purified from the clarified lysate via a two-step process – 
Affinity chromatography followed by ion-exchange. 
.2.8.7.1 Affinity chromatography 
The clarified lysate was subjected to Immobilised Metal Affinity Chromatography 
(IMAC) as the first step in the purification of the recombinant proteins. A Sepharose 
chelating fast flow resin column (Pharmacia Biotech) fixed to an automated AKTA 
purifier Fast Protein Liquid Chromatography (FPLC) system (Amersham Pharmacia) 
was used for IMAC. The Sepharose chelating fast flow resin was charged with Ni2+ 
by passing 0.1 M NiSO4 through the column at a flow rate of 5 mL/min (for 6 min) 
under the control of the FPLC pump. The column was equilibrated with 200 mL of 
0.02 M Tris.HCl (pH 7.4) containing 0.03 M Imidazole, 0.5 M NaCl (otherwise 
known as equilibration buffer) at a flow rate of 5 mL/min (for 20 min). The sample 
(i.e. clarified lysate) was loaded onto the column at a flow rate of 2 mL/min and 
washed with the equilibration buffer at a flow rate of 4 ml/min for 25 min. Elution of 
bound protein was effected via an imidazole linear gradient (From 0.03 M – 0.5 M) 
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with 0.02 M Tris.HCl (containing 0.5 M Imidazole, 0.5 M NaCl, pH 7.4) (otherwise 
known as elution buffer) using equilibration buffer as the diluent at a flow rate of 4 
mL/min. Eluate was collected in 4 mL fractions. The composition of each fraction 
was analysed on SDS-PAGE to identify those containing protein of interest.  
.2.8.7.2 Anion exchange chromatography 
After SDS-PAGE of fractions following IMAC, fractions suspected to contain the 
protein of interest were pooled together and concentrated to about 0.5 mL by 
centrifuging at 2880 x g, 4ºC using a 10 kDa Vivaspin 20 Centrifugal Concentrator 
(Sartorius Stedim Biotech, France). This process was repeated three times with 20 
mL of ice-cold 0.02 M Tris.HCl (pH 8.0) to remove imidazole and NaCl. After the 
final concentration the sample was diluted to a final volume of 20 mL in the same 
buffer and subjected to anion exchange chromatography. In this case, a 5 mL bed 
volume HiTrap Q HP (Hitrap ion exchange column, GE Healthcare) was attached to 
the FPLC system instead of the Sepharose chelating fast flow resin column. The 
column was equilibrated with 0.02 M Tris.HCl (pH 8.0) at a flow rate of 5 mL/min, 
sample applied at a flow rate of 2 mL/min and eluted with 0.02 M Tris.HCl, 1 M 
NaCl (pH 8.0) at a flow rate of 4 mL/min in a linear gradient using 0.02 M Tris.HCl 
(pH 8.0) as the diluent. Each fraction was analysed by SDS-PAGE. 
2.8.8 Western Blotting 
After SDS-PAGE, gels were removed from electrophoresis plates and soaked in 
transfer buffer (Appendix D) for 15 min. Nitrocellulose membranes and pieces of 
blotting paper (cut a little larger than the size of the gel) were also soaked separately 
in transfer buffer for 15 min. The base plate of the Transblot (Semi dry) apparatus 
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was cleaned and dampened with transfer buffer. Two soaked blotting papers were 
placed on the base plate followed by the nitrocellulose membrane and the gel. Two 
other soaked blotting papers were finally placed on the gel ensuring that no air 
bubbles were caught beneath the layers. The upper plate of the blotting apparatus 
was also cleaned and dampened with transfer buffer and the instrument was finally 
assembled. A current of 0.6 A was applied across the instrument for a single blot, 10 
V for 90 min. Afterwards, the apparatus was dissembled and the nitrocellulose 
membrane was removed and stained with Ponceau S for 10 min to locate sample 
bands and standards. The membrane was washed with water after marking the 
standard bands with a pencil. The membrane was incubated in blocking solution 
(Appendix D) overnight at room temperature with gentle shaking. Membrane was 
then washed with phosphate-buffered saline-Tween 20 [(PBST) (Appendix D)] once 
and incubated with primary antibody (Table 2.11) for 90 min. The membrane was 
washed three times with PBST and incubated with secondary antibody (Table 2.12). 
The membrane was washed three times with PBST and developed with 5-bromo-4-
chloro-3-indolyl-phosphate/nitro blue tetrazolium (BCIP/NBT conjugate). After 
colour development, the membrane was washed with water, dried and image 
visualised and captured using a Bio-Rad Gel Doc system with Quantity One 
software. 
Table 2.11 Primary antibodies used for Western blotting 
Primary/ labelling antibody Dilution* Analyte proteins 
Monoclonal Anti-VapA 
MAb10G5 
1/ 10,000 VapA 
Hyperimmune Horse Serum 1/ 2,000 Immunoreactive R. equi proteins 
Monoclonal Polyhistidine 1/ 3,000 Hexahistidine tagged proteins 
* Diluted in blocking buffer 
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Table 2.12 Secondary antibodies used for Western blotting 
Secondary antibody conjugate 
(alkaline phosphatase) 
Dilution* Primary antibody detected 
Anti-mouse IgG 1/20,000 Monoclonal Anti-VapA 
Anti-horse IgG 1/20,000 Hyperimmune Horse Serum 
Anti-mouse IgG  1/20,000 Monoclonal Polyhistidine 
* Diluted in blocking buffer 
 
2.8.9 Protein Crystallisation, data collection, structure solution and refinement 
After anion exchange chromatography, fractions containing purified proteins were 
pooled and buffer exchanged into 0.01 M Tris.HCl, 0.01 M NaCl, pH 7.5) and 
concentrated. Concentrated protein solution was subsequently centrifuged at 13,000 
x g, for 5 min at 4ºC to removed particulates and undissolved substances. 
Crystallisation was performed according to the hanging drop vapour diffusion 
method. Crystal screens were performed in 24-multi well plates. Crystallisation 
conditions were Crystal Screen 1, Crystal Screen 2, PEG/Ion Screen, SaltRx 
(Hampton research), and Clear Strategy Screen 1 and Clear Strategy Screen 2 
(Molecular Dimensions). Each mother liquor (500 µL) was delivered to a well and 
drops of 1 µL containing protein (30 mg/mL) were mixed with either 1 µL or 2 µL of 
the liquor drawn from the well. A drop was also constituted which contained 2 µl of 
protein and 1 µL of mother liquor. Drops were mixed on a siliconised coverslip 
(which has been polished with a silk scarf). The rim of each well (containing various 
mother liquors) was gently topped with high vacuum grease (Dow Corning) and the 
coverslip (containing the drops) was inverted and sealed above the well. In order to 
obtain crystals of good quality, the conditions in which promising crystals or 
precipitates developed were optimised by varying the concentration of salt, 
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precipitant or by adjusting the pH of the buffer. Crystals (after development) were 
harvested by transferring to a cryoprotectant (mother liquor (in which the crystal 
grew) containing 30 % glycerol) using a rayon fibre loop and stored in liquid 
nitrogen. Xray diffraction data were collected at 100 K at the Diamond Light Source 
experimental stations 102. Data were integrated using XDS (Kabsch, 2010) and 
scaled/merged with Aimless (Winn et al., 2011). Structure was solved by molecular 
replacement with the program MOLREP (Vagin and Teplykov, 2010) using a family 
related structure. The resulting model was refined using maximum likelihood 
methods implemented in REFMAC5 (Murshudov et al., 2011) with 5 % of the total 
data excluded from the refinement for the purpose of R free calculations. This 
procedure was interspersed with manual corrections to the model using COOT 
(Emsley et al., 2010) in conjunction with 2Fo-Fc and Fo-Fc electron density maps. 
2.8.10 Phase separation of Rhodococcus equi membrane proteins 
This was done via Triton X-114 phase partitioning as described by Tan et al. (1995) 
with modifications. Rhodococcus equi 103+ and Rhodococcus equiΔKasA were 
grown at 37°C to mid-stationary phase in 50 mL LB broth (about 60 hr) with 
constant shaking at 150 rpm. Cells were harvested by centrifugation and washed with 
2 mL of 0.01 M Tris. HCl (pH 7.4) containing 0.15 M NaCl (otherwise known as 
Tris buffered saline, (TBS)). Washed cells were re-suspended in 2 % Triton X-114 in 
TBS with phenylmethylsulfonylflouride (PMSF) (1 mM final concentration) and 
shaking overnight at 4°C and 150 rpm (About 30 mg - 50 mg of wet cells per mL of 
2 % TX-114). Insoluble material was removed by centrifugation at 27,000 x g at 4°C 
for 15 min. The supernatant was warmed to 37°C for 10 min for phase partitioning 
and centrifuged at 25,155 x g at 25°C for 15 min. The upper aqueous phase was 
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removed and Triton X-114 was added to a final concentration of 2 % (v/v) and re-
extracted. One millilitre of TBS was added to the lower detergent phase, mixed and 
phase partitioned again. The aqueous phases and detergents phases were pooled 
separately and proteins precipitated by 10 volumes acetone overnight at -20°C. The 
proteins were pelleted by centrifugation at 27,000 x g for 30 min at 4°C. The 
supernatant was removed, the pellet dried in a speed-vac, and subsequently re-
suspended in 100 mL of Tris.HCl (0.01 M, pH 7.4). 
2.8.11 Detection and identification of VapA from integral protein extract 
The detergent and aqueous phase extracts were later subjected to dot blotting (for the 
wild type) in order to detect the presence of VapA. Protein identification was done 
by mass spectrometry after in-gel trypsin digestion. 
.2.8.11.1 Dot Blotting 
Grids were drawn with a pencil on a nitrocellulose membrane to indicate the regions 
to spot. Two microlitres of either the detergent phase extract or the aqueous phase 
extracts were dotted on the centre of each grid and allowed to dry under room 
temperature. The membrane was soaked in blocking solution (Appendix D) for 60 
min at room temperature with gentle shaking. The membrane was washed once and 
incubated with Monoclonal anti-VapA, i.e. Mab 10G5 (1:10,000 dilution in blocking 
solution)], washed and later incubated with anti-mouse IgG, alkaline phosphatase 
conjugate (1:20,000 dilution in blocking solution). Membrane was washed and 
developed as in western blotting. Hexahistidine tagged VapA (expressed in E. coli 
BL 21 (DE3)) was used as a positive control. 
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.2.8.11.2 Liquid chromatography/Tandem mass spectrometry (LC-MS/MS) 
Ten microlitres of the detergent phase extract was subjected to SDS-PAGE, stained 
by Coomassie blue and destained overnight. Thereafter, the gel was subjected to in-
gel trypsin digestion before mass spectrometry. Briefly, the gel was placed on a 
cleaned white board and protein spots (already stained corresponding to the 
molecular size of interest) were excised using a scalp blade and transferred into clean 
1 mL siliconised low retention microcentrifuge tubes. Two hundred microlitres of 
ammonium bicarbonate (100 mM) and 120 µL of acetonitrile (ACN) were added to 
each tube and the colloidal Coomassie blue stain was removed by votex for 30 min. 
The liquid was discarded and the wash repeated thrice. The gel slices were 
dehydrated by the addition of 50 µL of ACN and incubated at room temperature for 
5 min. The liquid was discarded and further dehydrated twice. The gel slices were 
dried in a vacuum concentrator for 15 min, and incubated on ice with 25 µL of 20 
µg/mL trypsin solution (Appendix D) for 30 min. Each gel slice was covered with 30 
µL of 50 µM ammonium bicarbonate and incubated overnight at 37°C. The reaction 
was stopped by the addition of 30 µL of 50 % (v/v) ACN/ 5 % trifluoroacetic acid 
(TFA) and shaken for 30 min. The liquid (containing digested peptides) was 
recovered and transferred into a 1 mL microcentrifuge tube. Further digested 
peptides were recovered by shaking the gel for 30 min with 60 µL of 83 % (v/v) 
ACN/ 0.2 % TFA. The extract was pooled with the previous liquid containing the 
digested peptides and freeze-dried. Dried samples were re-suspended in 30 µL of 5 
% ACN and 8 µL were subjected to liquid chromatography/ Tandem mass 
spectrometry (LC-MS/MS)  using a HPLC Ultimate 3000 system (Dionex) coupled 
to an HCT Ultra mass spectrometer (Bruker Daltonics). Raw chromatographic data 
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were processed and matched to non-redundant peptides in the NCBI protein database 
using Mascot. 
2.8.12 Expression and analysis of pEKEx2-derived plasmids in Corynebacterium  
glutamicum 
A single transformant (from section 2.7.9) was selected and grown in 10 mL of LB-2 
% glucose (containing kanamycin) overnight with shaking at 150 rpm at 30°C. 
Culture was inoculated in 50 mL LB-2 % glucose at a 1:100 dilution and grown 
(under same conditions) to an optical density of 1 (at 600 nm).  Cells were subjected 
to IPTG induction (1 mM) and grown for either 4 hrs or 24 hrs with shaking at 150 
rpm at 30°C. Each culture (50 mL) was centrifuged at 2880 x g for 10 min at 4ºC. 
The pellet was sonicated and clarified [otherwise called clarified lysate (CLY)] while 
the external culture medium was recovered and further clarified by centrifuged at 
27,000 x g for 15 min at 4°C and sterile filtered. Trichloroacetic acid (TCA) was 
added to the clarified external culture to a final concentration of 10 % (w/v), mixed 
by gentle shaken and incubated at 4°C overnight. Precipitated proteins were 
harvested by centrifugation (27,000 x g, 4°C, and 30 min), re-suspended and washed 
three times in cold methanol. Washed samples were later dried using a speed vac for 
15 min and re-suspended in 0.02 M Tris.HCl (pH 7.4) containing 0.5 M NaCl 
(solution containing proteins otherwise called broth supernatant proteins, BSP). Both 
CLY and BSP were subjected to SDS-PAGE and western blot using monoclonal anti 
VapA (Mab 10G5) as primary antibody and anti-mouse IgG (alkaline phosphatase 
conjugate) as secondary antibody. Protein identification was determined via mass 
spectrometry as described in section 2.8.11.2. 
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2.8.13 Subcellular compartmentalisation of VapA in Corynebacterium 
glutamicum 
Transformants (after electroporation of pEKEx2-derived plasmids into C. 
glutamicum) were grown in 2 L LB-2 % glucose (containing kanamycin) at 30°C 
with shaking at 200 rpm. Isopropyl ȕ-D-1-thiogalactopyranoside (1 mM) was added 
after the culture grew to OD600 of 1 and incubated at 30°C with shaking at 150 rpm. 
After overnight incubation, cells were pelleted by centrifuging at 2880 x g, 4°C for 
10 min. Cells were re-suspended in Tris buffer, lysed by sonication, and clarified (as 
described). The supernatant was removed and the debris was re-suspended in 12.5 
mM Tris.HCl pH 6.8 containing 2 % SDS (otherwise known as SDS-Tris buffer) or 
12.5 mM Tris. HCl pH 6.8 containing 6 M urea (otherwise known as Urea-Tris 
buffer), and stirred overnight at 4°C and centrifuged at 27,000 x g for 30 min at 4°C 
for clarification. The clarified lysate (CLY) and the external culture medium (after 
further clarification by centrifuging at 27,000 x g and ultrafiltration (0.2 µm)) were 
subjected to high speed centrifugation at 100,000 x g for 2 hrs at 4°C. The pellets 
were also re-suspended in either SDS-Tris buffer or Urea-Tris buffer and extracted as 
in the debris. Each fraction was subjected to Western Blotting using Monoclonal 
Anti VapA (Mab 10G5) as the primary antibody. 
2.8.14 Improved protocol for compartmentalisation of VapA in Corynebacterium 
glutamicum 
The subcellular localisation of VapA in C. glutamicum was further fine-tuned. The 
debris after clarification of the lysate was subjected to Percoll density gradient 
centrifugation. A 60 % Percoll (v/v) solution was prepared in phosphate-buffered 
saline (as the relaxation buffer). The debris was re-suspended in Percoll solution (in 
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relaxation buffer) and centrifuged at 27,000 x g for 1 hr. The buoyant fraction was 
withdrawn and diluted with PBS and centrifuged at 27,000 x g for 1 hr. This was 
repeated until a fine pellet was obtained (which was washed free of Percoll). The 
pellet (cell wall material) was re-suspended in SDS-Tris buffer and stirred overnight 
and extracted as described. The protein contents of this cell wall fraction, the 
membrane fraction and the culture supernatant were standardised and subjected to 
SDS-PAGE and western blot. 
2.8.15 Analytical Ultracentrifugation 
Sedimentation velocity experiment was performed using a Beckman Optima XL-A 
analytical ultracentrifuge equipped with absorbance optics. Protein samples were 
dialysed overnight into 20 mM Tris.HCl (pH 7.9), 50 mM NaCl and loaded (with or 
without metals) into cells with 2-channel Epon centre pieces and quartz windows. 
Data were recorded at 40,000 rpm, 20°C overnight and a total of 200 absorption 
scans (280 nm) were recorded for each sample. Data analysed was done using the 
SEDFIT software fitting a single frictional coefficient.  
2.8.16 Interaction of Virulence Associated Proteins 
The interaction of Rhodococcus equi virulence associated proteins was done via 
Surface Plasmon Resonance using a BIAcore X100 at 25°C. The surface of a CM5 
censor chip (Carboxymethylated dextran covalently attached to a gold surface) was 
activated with a 1:1 mixture of 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide 
(EDC) and N-hydroxysuccinimide (NHS) at a flow rate of 5 µl/min for 1 min. VapA, 
dialysed in 10 mM acetate buffer (pH 3.5), 5 mM NaCl overnight, was diluted to 42 
µg/mL and immobilised on the activated sensor chip at 5 µl/min for 1 min. When 
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sufficient VapA was immobilised, reactive groups remaining on the activated CM5 
surface were blocked with 1 M ethanolamine-HCl pH 8.5 at a flow rate of 5 µl/min 
for 1 min. Other Vaps (different concentrations in 10 mM HEPES, pH 7.4, 
containing 150 mM NaCl, EDTA 3 mM, T20 0.005%), were passed over the VapA-
coated and control coated cells at a flow rate of 30 µl/min for 3 min. After every 
cycle, the chip was regenerated by passing through 10 mM glycine.HCl (pH 2.0) for 
1 min at a flow rate of 30 µL/min. 
2.8.17 Modelling of Virulence Associated Proteins 
Where applicable the 3D structures of R. equi virulence associated proteins were 
modelled using Modeller 9.13 (Sali, 1995). The reliability of the structures was 
validated by COOT (Emsley et al., 2010) and ProSA-web (Wiederstein and Sippl, 
2007) using the pdb files generated by the homology modelling. 
2.9 Lipid Analysis 
2.9.1 Extraction and analysis of lipids from phase separated complexes 
.2.9.1.1 Biphasic extraction of free lipids 
Stock containing phase–separated proteins (from section 2.8.10) were re-suspended 
in ice-cold trichloroacetic acid (final concentration of 10 % TCA) and incubated on 
ice for 3 hrs. These samples were centrifuged at 27,000 x g for 30 min at 4°C and 
lyophilised overnight after discarding the supernatant. The residue was re-suspended 
in 2 mL methanol:0.3 % NaCl (100:10 v/v) and transferred to a 12 mL clear screw 
capped borosilicate glass tube. Two millilitres of petroleum ether (High boiling 
point) was added and mixed thoroughly using a rotator for 30 min. The solution was 
then centrifuged at 720 x g for 5 min at 4°C. The upper phase (lipid extract) was 
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removed into a separate tube and the lower phase washed again. The lower phase 
(delipidated) was lyophilised overnight while the non-aqueous lipid phase was dried 
using a heating block. 
.2.9.1.2 Thin layer chromatography 
The residue (after drying of the upper non-aqueous phase) was re-suspended in 200 
μL of chloroform:methanol (β:1) and 10 μL was spotted on a pre-coated TLC-sheet 
(AlugramR SIL G/UV254). It was developed in chloroform:methanol:water (60:16:2) 
mobile phase. After development, bands were revealed by charring using a heat gun 
after staining with 5 % ethanolic molybdophosphoric acid. 
.2.9.1.3 Extraction and analysis of protein-bound lipids 
The residue after lyophilisation of the delipidated extract was re-suspended in 1 mL 
of 5 % aqueous tetrabutylammonium hydroxide and heated overnight at 100°C using 
a heating block and allowed to cool. Distilled water (2 mL), dichloromethane (4 mL), 
and iodomethane (β50 μL) were added and mixed for 1 hr using a rotator. The 
solution was centrifuged for 5 mins at 720 x g at room temperature and the upper 
phase discarded. The solution was washed by the addition of 4 mL distilled water, 
mixed for 30 min and centrifuged for 5 min at 720 x g. The upper phase was 
discarded and the solution washed twice using 4 mL of distilled water. The solution 
was dried overnight using a heating block and re-suspended in 4 mL of diethyl ether, 
mixed and centrifuged for 5 min under room temperature at 720 x g. The supernatant 
was transferred to a clean tube and dried at 50°C. The final residue was dissolved in 
100 μL of dichloromethane and subjected to thin layer chromatography using 
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petroleum ether: acetone (95:5) development and visualised by charring after 
staining in 5 % ethanolic phosphomolybdic acid. 
2.9.2 Analysis of protein-bound lipids from Corynebacterium glutamicum 
transformants 
Proteins were precipitated from the CLY and the BSP (obtained from section 2.8.12) 
using trichloroacetic acid. Samples were delipidated, protein-bound lipids extracted 
and subjected to TLC analysis as described previously. 
2.9.3 Extraction of cell wall associated lipids 
Cell wall associated lipids were extracted from whole cells (both from 
Corynebacterium glutamicum and Rhodococcus equi) according to the method of 
Kacem et al. (2004) with some modifications. Cells were grown in BHI broth 
overnight and harvested via centrifugation. The lipids were first extracted from wet 
cells (100 mg) with chloroform: methanol (1:1) overnight using a rotator at room 
temperature. It was centrifuged and the bacterial residue was re-extracted three times 
using chloroform:methanol (2:1). The lower organic phases were all pooled and 
evaporated to dryness in a heating block at 50°C. The crude extract was biphasically-
partitioned using a mixture of chloroform:methanol:water (8:4:2) and the lower 
organic phase recovered and dried. Residue was finally re-suspended in β00 μL of 
chloroform:methanol (β:1) and 10 μL was subjected to thin layer chromatography 
developed in chloroform:methanol:water (60:16:2) and bands visualised by charring 
after staining in 5 % ethanolic phosphomolybdic acid. The rest was dried and stored 
at room temperature for further use. 
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2.9.4 Matrix-assisted laser desorption/ ionisation-time of flight mass 
spectrometry (MALDI-TOF MS) 
Protein-bound lipids (derivatised as methyl esters) both from Rhodococcus equi 103S 
and Rhodococcus equiΔkasA (following Triton X-114 phase separation) were dried 
by evaporation at 50°C using a heating block. Dried samples were re-suspended in a 
1:1 mixture of acetonitrile (ACN) and α-Cyano-4-hydroxycinnamic acid (HCCA, 
which served as the absorbing matrix) preparation. Each sample (1.5 µL) was loaded 
on a target plate and subjected to MALDI-TOF mass spectrometry using an Ultraflex 
II TOF-TOF (Bruker Daltonics). Where the sample was too viscous, it was diluted 
with ACN and 1 µL of the solution was mixed with HCCA and loaded on the target 
plate. 
2.10 Other methods 
2.10.1 Mycoloyltransferase assay 
Cell wall associated lipids (from Corynebacterium glutamicum and Rhodococcus 
equi) were dried in a heating block and re-suspended in 0.02 M Tris. HCl pH 7.5, 
0.01 M Dithiothreitol and sonicated. Recombinant VapA and corynomycolyl 
transferase (Cmt1) were dialysed against 2 x 2 litres of 0.01 M Tris.HCl pH 7.5 
(containing 0.01 M NaCl) for 24 hrs. Ten microliters of VapA (at 1 mg/mL) was 
mixed with 5µL of each lipid preparation. The reaction was initiated by the addition 
of 10 µL of corynomycolyl transferase (at 1 mg/mL) and incubated for 45 min. 
Thereafter, reaction mixtures were subjected to Urea-PAGE and visualised by 
Coomassie blue staining as reported. The Cmt1 assay was also performed using a 
radioactive substrate. In this case, 14C-labelled free lipids extracted from 
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Mycobacterium bovis BCG were used for the assay.  After assay, reaction mixtures 
were subjected to Urea-PAGE. Gels were dried and exposed and autoradiograms 
were produced by 12 hrs exposure to Kodak BioMax MR film to reveal 14C labelled 
lipids (bound to proteins). 
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 CHAPTER THREE 
3 Cloning, purification and initial characterisation of Vap 
proteins 
3.1 Introduction 
The Vap proteins of R. equi display significant sequence similarity (especially at 
their carboxyl regions) and very few homologues have been found in any other 
organism (Letek et al., 2008).  Apart from VapF, they also possess predicted signal 
sequences of secreted proteins; with well-defined N-terminal, hydrophobic, and C-
terminal regions and potential signal peptidase cleavage sites (Takai et al., 2000; 
Byrne et al., 2001) (Figure 1.17).  VapA is retained at the cell surface and apparently 
undergoes an unusual lipid modification. At the outset of this study, neither the 
mechanism via which Vaps enhance virulence nor their molecular structures were 
defined. This chapter describes the cloning, expression, purification of the Vap 
proteins carried out in order to facilitate the studies in subsequent chapters that focus 
on their structural characterisation and the exploration of potential homologous and 
heterologous interactions of Vaps.  VapF was not considered here since its gene has a 
5’ truncation and two frame-shift mutations at the γ’ end; expression would result in 
non-secreted and a presumed non-functional protein (Takai et al., 2000: Letek et al., 
2008). 
The coding sequences for the mature secreted proteins of vapACDEGH were cloned 
in order to produce high yield soluble protein. The cloning vectors pET23a or 
pET28a were used as they represent high copy number plasmids with strong T7 
promoters. These plasmids facilitate hexahistidine tagging at the C-terminus (for 
pET23a) or the N-terminus (for pET28a) of the recombinant protein product which 
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can be exploited for purification via metal chelate affinity chromatography in a 
single step and immuno-detection with anti-polyhistidine. 
3.2 Amplification of Vap genes 
All the sequence data for ORFs that code for the Vaps under consideration were 
obtained from the National Centre for Biotechnology Information (NCBI) database 
(http://www.ncbi.nlm.nih.gov, accession codes in Table 3.1) and the amino acid 
sequences were analysed for the presence of signal peptide using the SignalP server 
(http://www.cbs.dtu.dk/services/SignalP) (Nielsen et al., 1997; Petersen et al., 2011) 
using default settings for Gram-positive bacteria. The possession of the predicted 
signal sequence in the protein may direct the proteins for secretion when the genes 
are expressed in E. coli thus could significantly limit protein yield and function. 
Hence primers were designed in order to amplify the regions that code for the 
putative mature protein for cloning into pET23a and pET28a vectors. The sizes of 
the genes and the sequences that encode the mature proteins are shown in table 3.1. 
Table 3.1 Summary of vap family properties 
vap gene 
(Accession code) 
Length / bp 
Mature 
N -terminus gene amplicon 
A  (NP_002576.1) 570 477 T32 
C  (AF116907.2) 525 438 N30 
D  (AF118814.1) 495 405 Q31 
E  (AF116907.2) 621 483 R47 
G  (AF116907.2) 519 441 E27 
H  (AF116907.2) 564 471 A32 
 
Primer pairs were designed such that each oligonucleotide had a minimum of 26 
bases and a maximum of 32 bases in length and the difference between their 
individual melting temperatures was limited to a maximum of 2ºC. For the 
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amplification of vapA and vapC, the restriction sites for NdeI and NotI were added to 
the forward and reverse primers respectively.  For the amplification of the other vaps, 
the sites for NdeI and EcoRI were added to the forward and reverse primers 
respectively. 
The regions which encode the Vap proteins were amplified via polymerase chain 
reaction using Vent DNA polymerase as described (Section 2.7.4) and analysed via 
agarose gel electrophoresis (Figure 3.1).  Initial attempts that used R. equi total DNA 
as a template were without success. Various protocols were deployed that analysed 
the use of Mg2+ and DMSO as additives and the variation of primer annealing 
temperatures through a gradient PCR approach.  After rigorous testing, the quality of 
the DNA was validated in its successful use as a template for chromosomal genes 
used in other studies in this laboratory (REQ28150 and REQ09720, data not shown).  
At this stage, two possibilities were considered; firstly that the strain in use had been 
cured of its virulence plasmid and secondly that the plasmid did not extract well in 
the protocol used to purify the genomic DNA.  The former scenario was excluded as 
VapA could be detected in extracts of these cells using the monoclonal antibody 
MabG105 (see figure 6.1) and VapA peptides could be detected in Triton X-114 
extracts (see section 6.2.1). The second scenario seemed plausible. In order to 
ameliorate plasmid loss in extraction, attempts were made to amplify the vap genes 
using a small sample of freshly-cultured biomass as a crude DNA source, this too 
proved unsuccessful. 
In order to make timely progress, a pragmatic solution was sought.  Cosmid p10.1, 
which carries vapA, vapD and vapC was used as a template and other vap sequences 
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were synthesised using a service at Eurofins MWG. These were cloned in pET23a 
consistent with our original cloning strategy. 
These alternative templates delivered high quality amplicons (Figure 3.1) with single 
bands albeit with some primer dimer evident. The migration of observed DNA bands 
was consistent with the expected amplicon sizes (Table 3.1); bands were excised 
from the gel and their DNA was purified from the agarose as discussed in section 
2.7.3. 
 
Figure 3.1 Preparation of coding sequences for C-terminally hexahistidine-
tagged recombinant vapA, vapC and vapD by PCR amplification. 
Cosmid p10.1 was used as the DNA template.  Lane H carries a DNA 
size standard (Hyperladder I). 
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Figure 3.2 PCR amplification of vapE, vapG and vapH from validated pET23 
clones to form pET28 variants. 
Lane H, size standard (Hyperladder I) 
 
3.3 Cloning of amplified products to vector and analysis 
The purified amplicons were prepared for cloning by restriction digestion, and were 
ligated with the similarly-treated pET vectors (section 2.7.6).  The ligation mixtures 
were used to transform competent E. coli Top 10 and transformants were selected in 
solid culture with appropriate antibiotics.  Plasmid DNA was extracted from selected 
transformants after small-scale broth culture and were screened via restriction 
profiling (with the enzymes used for cloning) analysed by agarose gel electrophoresis 
(figures 3.3 and 3.4).  
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Figure 3.3 Screening for recombinant plasmids pET28-vapA, pET28- vapC, 
and pET28-vapD. 
Plasmid DNA recovered from transformants was digested using 
restriction enzymes used in cloning (vapA& vapC, NdeI and NotI; vapD 
NdeI and EcoRI). Lane H carries a DNA size standard (Hyperladder I). 
 
 
Figure 3.4 Screening for recombinant plasmids pET28-vapE, pET28-vapG, 
and pET28-vapH. 
Plasmid DNA recovered from transformants was digested using 
restriction enzymes used in cloning, NdeI and EcoRI. Lane H carries a 
DNA size standard (Hyperladder I). 
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The banding patterns generated in this screening were compatible with expectations.  
The fluorescing band that migrates between the 5000 and 6000 bp markers is 
consistent with pET 28a, a high copy number plasmid of 5369 bp in length. DNA 
from supposed vap clones all generated bands that migrated consistent with 
expectations as defined in Table 3.1, which strongly implied that the vaps were all 
effectively cloned in the expression vector. Nucleotide sequencing confirmed the 
identity of the fragment, that it was intact and that the predicted gene product bore no 
mutations. 
3.4 Recombinant protein production and purification 
The recombinant plasmids were used to transform E. coli BL21 (DE3).  
Heterologous protein overproduction in E. coli depends on a number of factors 
especially temperature which has pronounced effect on protein folding and stability 
(Weickert et al., 1996). In order to determine the optimum condition for the 
production of soluble recombinant protein, cultures were grown to mid-log phase and 
induced with 1mM IPTG after cooling to an induction temperature between 16°C 
and 37°C. Electrophoretic analysis of clarified lysates (data not shown) prepared 
from the recombinant cells showed that synthesis of most of these recombinant 
proteins was induced under all conditions but was more pronounced when the 
recombinant gene expression was induced using 1mM IPTG induction with 
incubation at 16°C overnight.  This practice was adopted as standard for large scale 
production of Vaps in E. coli.  High yields of VapC were never achieved.  In order to 
make progress in functional and structural studies, experiments proceeded without 
this protein. 
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The process was scaled up to 2 L cultures in terrific broth. Cells were harvested, 
lysed in 0.02 M Tris.HCl; 0.5 M NaCl; 0.03 M Imidazole, pH 7.4.  Lysates were 
clarified (as described in section 2.8.6) and subjected to affinity chromatography.  
Fractions were eluted (monitored at 280 nm) in a linear gradient of imidazole 
concentration terminating at either 0.5 M or 1 M Imidazole as appropriate.  Fractions 
were subjected to SDS-PAGE to analyse the homogeneity of those that contained 
recombinant protein. Peak fractions were pooled, concentrated and adjusted to pH 
8.2. The solution was finally subjected to anion exchange chromatography using 0.02 
M Tris.HCl (pH 8.2) as equilibration buffer and 0.02 M Tris.HCl (containing 1 M 
NaCl, pH 8.2) as elution buffer.  Elution was monitored at 280 nm and peak fractions 
were subjected to SDS-PAGE. The SDS–PAGE gel images for VapA and VapG at 
each stage of purification are shown in figures 3.5 - 3.8. The images for VapD, VapE 
and VapH are shown in appendix F. 
 
Figure 3.5 SDS-PAGE of recombinant VapA after immobilised metal affinity 
chromatography of clarifed lysate. 
Successive fractions approaching peak elution as indicated by A280nm 
were loaded. ‘M’ indicates molecular weight markers (14.β kDa, α-
Lactalbumin from bovine milk; 20.1 kDa, Trypsin Inhibitor from 
soybean). 
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Figure 3.6 SDS-PAGE of recombinant VapA following anion exchange 
chromatography. 
Successive fractions approaching peak elution as indicated by A280nm 
were loaded. ‘M’ indicates molecular weight markers (14.β kDa, α-
Lactalbumin from bovine milk; 20.1 kDa, Trypsin Inhibitor from 
soybean). 
 
 
Figure 3.7 SDS-PAGE of recombinant VapG after immobilised metal affinity 
chromatography of clarified lysate. 
Successive fractions approaching peak elution as indicated by A280nm 
were loaded. ‘M’ indicates molecular weight markers (14.β kDa, α-
Lactalbumin from bovine milk; 20.1 kDa, Trypsin Inhibitor from 
soybean). 
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Figure 3.8 SDS-PAGE of recombinant VapG following anion exchange 
chromatography. 
Successive fractions approaching peak elution as indicated by A280nm 
were loaded. ‘M’ indicates molecular weight markers (14.β kDa, α-
Lactalbumin from bovine milk; 20.1 kDa, Trypsin Inhibitor from 
soybean).   
 
During anion exchange chromatography, the protein eluted as a symmetrical peak 
and the purity of the proteins were revealed following SDS-PAGE.  Despite some 
minor degradation, proteins were highly purified.  Peak fractions were pooled and 
concentrated for further analysis. 
3.5 Detection of Recombinant protein 
Following affinity chromatography, a sample from a peak fraction for each protein 
was subjected to Western Blot on nitrocellulose. Blotted proteins were probed using 
various detection systems based on convalescent horse serum, monoclonal anti-
polyhistidine and monoclonal anti-VapA (Mab10G5) with complementary secondary 
antibody conjugates (see section 2.8.8 and Figures 3.9 - 3.14). 
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Figure 3.9 Immunodetection of recombinant VapA, VapC and VapD using 
convalescent horse serum. 
Binding of antibodies from polyclonal convalescent serum to 
recombinant Vaps was monitored using anti-horse alkaline phosphatase 
conjugate.  Migration of size standards was monitored using Ponceau S 
and is indicated at the left margin (14.β kDa, α-Lactalbumin from 
bovine milk; 20.1 kDa, Trypsin Inhibitor from soybean) 
 
 
Figure 3.10  Immunodetection of recombinant VapA, VapE, VapG and VapH 
using convalescent horse serum. 
Binding of antibodies from polyclonal convalescent serum to 
recombinant Vaps was monitored using anti-horse alkaline phosphatase 
conjugate.  Migration of size standards was monitored using Ponceau S 
and is indicated at the left margin (14.β kDa, α-Lactalbumin from 
bovine milk; 20.1 kDa, Trypsin Inhibitor from soybean) 
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Figure 3.11 Immunodetection of recombinant VapA, VapC and VapD using 
monoclonal antipolyhistidine. 
Binding to recombinant Vaps was monitored using goat-anti-mouse 
alkaline phosphatase conjugate.  Migration of size standards was 
monitored using Ponceau S and is indicated at the left margin (14.2 
kDa, α-Lactalbumin from bovine milk; 20.1 kDa, Trypsin Inhibitor 
from soybean) 
 
 
Figure 3.12 Immunodetection of recombinant VapE, VapG and VapH using 
monoclonal antipolyhistidine. 
Binding to recombinant Vaps was monitored using goat-anti-mouse 
alkaline phosphatase conjugate.  Migration of size standards was 
monitored using Ponceau S and is indicated at the left margin (14.2 
kDa, α-Lactalbumin from bovine milk; 20.1 kDa, Trypsin Inhibitor 
from soybean). 
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Figure 3.13 Immunodetection of recombinant VapA, VapC and VapD using 
monoclonal anti-VapA (Mab10 G5). 
Binding to recombinant Vaps was monitored using goat-anti-mouse 
alkaline phosphatase conjugate.  Migration of size standards was 
monitored using Ponceau S and is indicated at the left margin (14.2 
kDa, α-Lactalbumin from bovine milk; 20.1 kDa, Trypsin Inhibitor 
from soybean). 
 
 
Figure 3.14 Immunodetection of recombinant VapA, VapE, VapG and VapH 
using monoclonal antiVapA (Mab10 G5). 
Binding to recombinant Vaps was monitored using goat-anti-mouse 
alkaline phosphatase conjugate. Migration of size standards was 
monitored using Ponceau S and is indicated at the left margin (14.2 
kDa, α-Lactalbumin from bovine milk; 20.1 kDa, Trypsin Inhibitor 
from soybean).  
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The banding profiles revealed that all of the recombinant proteins were detected with 
the hyperimmune horse serum, which strongly suggests the presence of antibodies to 
each Vap in the convalescent adult horse. This indicates that the native proteins 
exhibit significant immunogenicity in rhodococcal infection. All proteins reacted 
significantly with monoclonal anti-polyhistidine, which confirmed that the proteins 
were hexahistidine tagged.  However, only VapA reacted with Mab 10G5, validating 
its use as a detection method for VapA elsewhere in this study. Though these 
proteins exhibit some degree of homology (especially in the C-terminal region, 
Figure 1.17), it seems they do not exhibit cross reactivity. In all cases, the banding 
pattern was consistent with the expected molecular sizes of the proteins. 
In summary VapA, VapD, VapE, VapG, and VapH were produced at high yield and 
were purified to near homogeneity with a two-step chromatography protocol. 
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 CHAPTER FOUR 
4 Vap Structural models: crystallography and homology 
modelling approaches 
4.1 Protein crystallisation 
Each purified protein was exchanged to 0.01M Tris.HCl pH 7.5, 0.01 M NaCl, 
concentrated to 30 mg/mL and screened for the production of crystals using the 
vapour diffusion method as described in section 2.8.9. Only VapG produced 
promising precipitates in three conditions of the PEG/ION screen which were 
condition 8 (0.2 M potassium chloride, 20 % PEG 3350), condition 14 (0.2 M 
lithium nitrate, 20 % PEG 3350) and condition 15 (0.2 M potassium thiocyanate, 20 
% PEG 3350).  These conditions were optimised by varying either the concentration 
of the salt or PEG or both and screening performed with the protein.  Good crystals 
developed between four and eleven days (Figure 4.1). 
4.2 Structure solution and refinement for VapG 
Structural analyses of crystals produced at Northumbria were undertaken in 
collaboration with the Wilkinson Group based at University of York. Preliminary 
diffraction of X-rays with these crystals identified that VapG crystallised in 0.2 M 
potassium chloride, 22 % PEG 3350 produced high quality data. Crystals were 
transported to the Diamond Light Source, the UK’s national synchrotron facility for 
analysis on Beamline I02, a high throughput and highly automated beamline for 
optimised MAD and SAD experiments (wavelength 0.5Å - 2.5Å). The crystal 
exhibited a tetragonal space group with unit dimensions a = 44.55, b = 44.55, and c = 
259.67 Å (Table 4.1). 
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Figure 4.1 Crystals of VapG grown using the hanging drop vapour diffusion 
method. 
Crystals developed in A; 0.2 M potassium chloride, 22 % PEG 3350 
after four days, B; 0.3 M potassium chloride, 22 % PEG 3350 after 11 
days; C; 0.2 M lithium nitrate, 22 % PEG 3350 after 6 days and D; 0.2 
M lithium nitrate, 20 % PEG 3350 after 6 days. 
 
The structure of VapG was solved by molecular replacement (as described in 
sections 2.8.9) using the newly solved coordinates of VapD (PDB code 4CSB, 
Whittingham et al., 2014) as the starting model since the proteins share a 55 % 
sequence identity (Figure 4.2). Refinement statistics and structural information are 
listed in Table 4.1.  
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Figure 4.2 Amino acid similarity between VapD and VapG 
Identity matrix was performed using the Clustal Omega 1.2.1 multiple 
sequence alignment program without the predicted signal sequences of 
the proteins.  The proteins share 55 % identity.  The nature of the 
aminoacyl side-chains are indicted by residue colour; hydrophobic 
(red), polar (green), acidic (blue) and basic (pink). Conserved amino 
acid identity is indicated beneath the aligned sequences by a star, 
similarities are indicated by colons and full stops. 
 
The refined model of VapG consisted of two crystallographically independent 
protein molecules (molecules 1 and β) which are almost identical (rms Δ = 0.45 Å 
calculated on all Cα atoms) (Figure 4.3). During refinement, elongated peaks of 
positive difference electron density appeared in two independent locations in the 
asymmetric unit.  These peaks, although, generally lacking detail, had the appearance 
of additional protein chains or peptides bound between the protein molecules: in one 
location three histidine side chains were successfully built and refined; in the other a 
lysine-leucine pair were similarly identified and included in the model. Both 
elements likely derive from the artificial C-terminus 
(PNSSSVDKLAAALEHHHHHH) used for protein tagging. Difference electron 
density in the vicinity of these side chains was less easy to interpret and so was 
modelled with connecting alanine side chains only. 
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Table 4.1 Crystallisation conditions, data collection and refinement statistics 
Data Collection  and Processing Statistics 
 
Diamond beamline / wavelength (Å) I02 / 0.9795 
P41212 cell dimension (Å) a, b = 44.55, c = 259.67 
Resolution limits (Å) 31.50 – 1.80 (1.85 – 1.80)a 
No. unique reflections 24979 
Completeness (%) 98.1 (83.4) 
Multiplicity 11.4 (7.2) 
Rmerge* 0.043 (0.674) 
I/σI 31.4 (2.6) 
Refinement Statistics 
 
Rcryst/Rfree 0.2009/0.2362 
r.m.s. Δ bond length (1-2) (Å) 0.021 (0.019) 
r.m.s Δ angles (°) 1.893 (1.925) 
r.m.s Δ chiral volumes (Å3) 0.126 (0.200) 
Average B (Å2): Protein/waters and K+ ion 31.55/38.02 
Ramachandran outliers (%) 0 
aHighest resolution shell statistics given in parentheses. bAverage geometric restraints given in 
parentheses. *Rmerge = Ʃ|I - <I>| / ƩI 
 
The only notable difference between molecules 1 and 2 of the asymmetric unit 
electron density maps was a strong metal ion peak located at the centre of a cluster of 
main chain and side chains oxygen donors from residues Asn107 – Asn114 of 
molecule 1 (Figure 4.7). No such coordination was seen in molecule 2. The 
coordination distances ranged from 2.7 Å to 3.1 Å, which is consistent with a 
potassium ion (Harding, 2002).  Although other metal ion candidates (calcium and 
magnesium) were tested in refinement, only potassium refined well. Furthermore, X-
ray absorption analysis of another single crystal revealed no other metal ions present 
apart from potassium. 
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In both molecules, the N-terminal residues (Met1-Ala41) are apparently disordered.  
It is unlikely that the N-terminus is degraded (and therefore absent) since the crystals 
of VapG grew over a period of days rather than weeks or months. This finding is 
consistent with those of others (VapD in Whittingham et al., 2014; VapB in Geerds 
et al., 2014) suggesting the notion that in all R. equi Vap proteins, this part of the 
protein forms random coil.  By contrast, the C-termini of both protein molecules are 
well ordered, even extending into the C-terminal His6 affinity tag.  
 
Figure 4.3 Structure of VapG showing two molecules in the asymmetric unit 
Both structures are similar (rmsΔ = 0.45 Å) apart from that molecule 1 
has a potassium binding site (The potassium ion is indicated by an 
arrow in molecule 1). Also modelled in the structure are the peptides 
KLAA (as a fragment in molecule 1), and HHH (as a fragment in 
molecule 2). Figure was created using CCP4mg (McNicholas et al., 
2011) 
 
The protein fold of VapG consists of a compact, 8-stranded ȕ-barrel, which is 
elliptical in cross section with a single helix (Figure 4.3). The ȕ-strand ordering in 
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the barrel is non-consecutive (ȕ1- ȕβ- ȕγ- ȕ8- ȕ5- ȕ6- ȕ7- ȕ4) which requires a strand 
crossover at both ends, hence the barrel adopts a closed form. At one end of the 
barrel (subsequently termed the top), the turns between strands are very short, 
providing a smooth, rounded surface, while at the other end (bottom), there are 
longer inter-strand regions which protrude in the form of a 9-residue α-helix (ȕ4- ȕ5) 
and two flanking loops (between ȕβ- ȕγ and ȕ6- ȕ7) (Figure 4.4).  
 
Figure 4.4 Structures of the main core of VapG (molecule 1). 
Secondary structure elements are labelled.  The colour scheme indicates 
progression through the protein structure from the N-terminus (blue) to 
C-terminus (red). Figure was created using CCP4mg (McNicholas et 
al., 2011).  
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The core of the protein consists almost entirely of hydrophobic side chains from 
alternate residues of the ȕ-strands which are densely packed, allowing no space for 
internal water molecules. There is a non-uniform distribution of polar and 
hydrophobic residues in the surface of VapG (Figures 4.5-4.6). At the top (referring 
to the orientation in figure 4.4), there is a preponderance of hydrophobic residues 
while at the bottom, the loops are longer and protrude from the barrel in the form of 
an α-helix. This region is comparatively richer in charged and polar side chains 
(Figure 4.6). 
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Figure 4.5 Electrostatic surface rendering of VapG (molecule 1) (A) 
Positive and negative electrostatic potentials are shown in blue and red 
respectively.  The apparent ribbon tracing are shown in green. The non-
uniform distribution of the polar and apolar residues is evident. Figure 
was created using CCP4mg (McNicholas et al., 2011) 
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Figure 4.6 Electrostatic surface rendering of VapG (molecule 1) (B) 
Positive and negative electrostatic potentials are shown in blue and red 
respectively.  The apparent ribbon tracing are shown in green. Figure 
was created using CCP4mg (McNicholas et al., 2011) 
 
The tight potassium coordination sphere of molecule 1 consists of six oxygen 
molecules. Two are contributed by the side chains of Asn107 and Asn114; three 
from the main-chain carbonyl oxygen atoms of Asn107, Val109, Tyr112 and the 
final ligand is a water molecule (Figure 4.7), which in turn H-bonds with the main 
chain amide of Tyr112. 
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Figure 4.7 Metal coordination sphere of molecule 1. 
Residues 107 – 114 which are involved in coordination with potassium 
(in grey) shown in cylinders. The water molecule (labelled) is 
represented by a red sphere. The residues are also shown in ribbon 
tracing (coloured in ice-blue) to reveal secondary elements. Figure was 
created using CCP4mg (McNicholas et al., 2011) 
 
In summary, the VapG structure is similar to the VapD fold (Whittingham et al., 
2014) and the VapB fold (Geerds et al., 2014) (Figure 4.8). The only unique features 
of VapG are the presence of two molecules in the asymmetric unit and the possession 
of a coordinating sphere involving potassium. As this crystal was formed in a 
potassium-containing liquor, it is entirely possible that the metal binding is 
artefactual but was critical, nonetheless, in promoting crystallogenesis. It is 
interesting to note that poor crystals were also formed in liquors containing Li, 
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another group I metal but not with Na. These crystals did not produce high resolution 
data sets on diffraction so it is impossible to ascertain whether Li was bound in a 
similar fashion. Four of the coordinating groups where contributed by main-chain 
atoms or associated water, ultimately mutagenesis of Asn107 and Asn114 might 
inform our understanding of this metal binding and whether it has any significance to 
VapG function, presumably through seeking to measure a quantifiable contribution 
to virulence. 
 
Figure 4.8  Structures of VapB and VapD colour ramped from the N-terminus 
(blue) to the C-terminus (red). 
Structures were created using CCP4mg ((McNicholas et al., 2011) from 
the co-ordinates deposited in the Protein Data Bank as 4CV7 (VapB, 
Geerds et al., 2014) and 4CSB (VapD, Whittingham et al., 2014). Two 
Co2+ molecules are represented as spheres in VapB while three 
molecules of ȕ-octylglycoside are represented as cylinders in VapD 
 
The association of VapA with the mycolate layer that defines R. equi as a diderm is 
interesting.  Several outer membrane proteins of Gram negative bacteria are also ȕ-
barrels (Wimley, 2003).  In these organisms, this topology defines their localisation 
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and (probably) their function. These are often pore-forming proteins with 
consecutive ȕ-strands forming a water-filled barrel in porins that facilitates 
transmembrane diffusion of various soluble materials (Pauptit et al., 1991). Others 
have a plugged barrel in which a central globular domain occludes the central pore.  
This plug domain can afford a high-affinity binding site and direct the active 
transport route for key micronutrients like ferri-siderophores and cobalamin 
(Ferguson et al., 1998; Ratledge and Dover, 2000). Thus it might be tempting to 
speculate that VapG (and other vaps) may be directly associated with the mycolate 
layer of Rhodococcus equi. However, among the virulence associated proteins of 
Rhodococcus equi 103S, to date only VapA has been suggested to be tethered to the 
cell surface (Takai et al., 2000; Byrne et al., 2008). 
VapG carries a few solvent-exposed polar residues at a predominantly apolar surface, 
a feature it shares with others defined (Geerds et al., 2014; Whittingham et al., 2014) 
or modelled structures for R. equi Vaps (section 4.3). This polarity and its orientation 
are likely to have functional significance in the export or function of the secreted 
Vaps. The insight that these models have recently provided has delivered a blueprint 
for mutagenesis studies. This could eventually educate our understanding of Vap 
function when analysed in studies of R. equi virulence. 
4.3 Homology modelling of other Vap Structures 
4.3.1 Introduction 
Despite the rapid increase in the number of known protein sequences, only about 
one-hundredth of these sequences have been characterised at high resolution using 
experimental structure determination methods (Webb and Sali, 2014).  To bridge this 
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gap, comparative modelling remains the only method that can reliably predict the 3D 
structure of a protein with an accuracy that is comparable to that of a low-resolution 
experimentally determined structure (Moreira et al., 2013). 
At the outset of this study, the Rhodococcus equi Vap family proteins were quite 
unique since there primary sequences were related to very few proteins in databases, 
presenting a challenge in building a structure using known models. However, 
recently the 3D structures of VapB and VapD have been resolved to a high resolution 
and deposited in the protein data bank with accession numbers 4CV7 and 4CSB 
respectively thus were considered as templates (depending on sequence similarity) 
for the modelling of the other Vaps. The proteins were modelled using Modeller, 
which is a python-based program developed by Sali (1995). 
4.3.2 Structure modelling using Modeller 
The steps involved in protein modelling using modeller have been described by 
Webb and Sali (2014). The process of model building consists of four main steps 
(Figure 4.9): (1) fold assignment that identifies overall similarity between the target 
sequence and at least one known template; (2) alignment of the target sequence and 
the template; (3) building a model based in the alignment of the chosen template and 
where applicable (4) predicting the accuracy of the model. 
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Figure 4.9: Flow chart illustrating the steps in protein modelling using 
modeller (adapted from Webb and Sali, 2014). 
 
After installing the program, python scripts were written using the query sequence 
i.e. the amino acid sequence of the protein to be modelled, and the template i.e. the 
pdb file of the template available at the protein data bank.  The scripts were run on 
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the program which led to the generation of the structure in pdb formats which are 
viewed after uploading on protein structure viewing programs. 
4.3.3 Modelling of Vap proteins 
Each of the amino acid sequence of the mature proteins (i.e. VapA, VapC, VapE, and 
VapH) were subjected to a blast search against the database of experimentally 
determined protein structures in the protein data bank to select the template for each 
protein. The search identified VapB and VapD with detectable similarity and the 
identity matrix is shown in table 4.2. 
Table 4.2 Identity matrix between query sequences and template. 
Statistics generated using BlastP. 
  
Potential Templates 
 
  
VapB (Accession number 4CV7)  
VapD (Accession number 
4CSB) 
 
  
Score 
Query 
Cover 
E 
value 
Identity 
 
Score 
Query 
cover 
E 
value 
Identity 
 
M
od
el
s 
VapA 169 68% 8e-54 87%  110 67% 1e-30 55%  
VapC 103 74% 3e-28 56%  92.4 73% 6e-24 50%  
VapE 96.7 71% 2e-25 52%  89.7 60% 1e-22 48%  
VapH 87.8 67% 4e-22 51%  77.4 66 4e-18 44%  
 
In all cases, comparison with VapB produced more favourable scores for the queries 
than VapD, thus the 3D structure for VapB was used as a template for structural 
modelling of these proteins.  The final modelled structures of the queries using VapB 
as a template are shown below in Figures 4.10-4.13. 
The proteins contain a predicted cleavable signal sequence validated by SignalP 
(Appendix E) thus only the mature protein sequences were used in the modelling.  
Chapter Four Vap structure 
101 
 
 
Figure 4.10 Model of VapA in cartoon mode 
The model was created using CCP4mg (McNicholas et al., 2011) 
showing structure in A.  Colour ramped from the N-terminus (blue) to 
the C-terminus (red). B.  Coloured according to secondary structure 
elements (red, α-helices; blue, ȕ-strands; others, loops). 
 
 
Figure 4.11 Model of VapC in cartoon mode 
The model was created using CCP4mg (McNicholas et al., 2011) 
showing structure in A.  Colour ramped from the N-terminus (blue) to 
the C-terminus (red). B.  Coloured according to secondary structure 
elements (red, α-helices; blue, ȕ-strands; others, loops). 
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Figure 4.12 Model of VapE in cartoon mode 
The model was created using CCP4mg (McNicholas et al., 2011) 
showing structure in A.  Colour ramped from the N-terminus (blue) to 
the C-terminus (red). B.  Coloured according to secondary structure 
elements (red, α-helices; blue, ȕ-strands; others, loops). 
 
 
Figure 4.13 Model of VapH in cartoon mode 
The model was created using CCP4mg (McNicholas et al., 2011) 
showing structure in A.  Colour ramped from the N-terminus (blue) to 
the C-terminus (red). B. Coloured according to secondary structure 
elements (red, α-helices; blue, ȕ-strands; others, loops). 
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The models conform well to the VapB fold (4CV7, Geerds et al., 2014), and are 
inherently similar to the structures of VapD (4CSB, Whittingham, 2014) and VapG 
(this chapter). Each model represents a compact 8-stranded ȕ-barrel ordered as ȕ1- 
ȕβ- ȕγ- ȕ8- ȕ5- ȕ6- ȕ7- ȕ4 and an α-helix between ȕ4 and ȕ5 in the straight chain.  
The amino acids which make up each strand and helix are shown in table 4.3. These 
models superimposed well on the template structure, root means squared devations 
were low and ranged from 0.14Å to 0.38Å (Table 4.3). 
Table 4.3 Structural elements of VAPs produced via modelling 
 Template  Models  
Structural 
element 
VapB 
 
VapA VapC VapE VapH  
ȕ1 Q88-A99  Q52-A63 E39-A50 K50-F61 Q48-A59  
ȕβ V101-G109  V65-G73 F52-V60 F63-I71 V61-V69  
ȕγ M113-G121  K77-G85 M64-G72 K81-G89 E73-G81  
ȕ4 G126-T136  G90-T100 G77-T87 G94-T104 G86-T96  
α1 L139-D145  L103-D109 L90-E96 L107-E113 I99-R105  
ȕ5 V147-A153  V111-A117 A98-A104 V115-A121 E107-A113  
ȕ6 L158-D164  L122-D128 L109-D115 L126-A132 L118-D124  
ȕ7 G168-G176  S132-G140 A119-G127 G136-G144 A128-G136  
ȕ8 G183-H192  G147-H156 G134-H143 G151-R160 G143-I152  
        
RMSΔ   0.14 0.38 0.24 0.25  
Numbering of residues starts with 1 as the N-terminus of mature protein. The structure of the 
modelling template VapB is included for comparison.  Average root mean squared deviations (RMSΔ) 
were calculated using PDBeFold (http://www.ebi.ac.uk/msd-srv/ssm/) 
 
4.3.4 Model Evaluation 
Since the models were produced theoretically, the quality of each model was 
evaluated based on stereochemical and geometrical restraints using COOT (Emsley 
et al., 2010) and ProSA-Web (Wiederstein and Sippl, 2007).  COOT was used for the 
generation of Ramachandran plots (to assess backbone dihedral angle constraints) 
(Figure 4.14) while ProSA-Web was used for the generation of the quality score of 
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Figure 4.14 Ramachandran plots for the models for VapA VapC, VapE and 
VapH. 
Plots were generated by COOT (Emsley et al., 2010).  The regions are 
coloured coded to indicate combinations of dihedral angles considered 
as preferred (pink), allowed (yellow) and outliers (grey).  
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Table 4.4 Summary of Ramachandran statistics and ProSA Z-scores for the 
Vap models. 
Model Prefered Region (%) Allowed Region (%) Outliers Pro Z-score* 
VapA 97.44 1.92 0.64 -4.4 
VapC 96.50 2.10 1.40 -4.35 
VapE 98.10 1.27 0.63 -4.88 
VapH 95.45 3.90 0.65 -3.35 
Plots for the Z-scores (including VapB) using ProSA-web are in appendix G. 
 
each model against the scores of protein structures obtained from X-ray analysis and 
NMR spectroscopy (Table 4.4). 
As shown in table 4.4, the Ramachandran statistics reveal that the residues which 
have psi/phi angles in the most favoured regions range from 95.45 % (in VapH) to 
98.1 % (in VapE) while 1.27 % (in VapE) to 3.90 % (in VapH) of the residues fall in 
the allowed regions. The residues that fall in the disallowed regions range from 0.63 
% (in VapE) to 1.40 % (in VapC). The Z-score when the pdb file for VapB was 
analysed via ProSA-web was -4.34 while the Z-score for the models range from 
-4.88 to -3.35. This shows that the Z-score for the modelled proteins are very similar 
to the experimentally-determined structures of proteins of similar size and this 
suggests further reliability to these 3D-models (Appendix G).  
4.3.5 Model orientation and surfaces 
The apparent strong conservation of the fold within this protein family indicated by 
this modelling study suggests that and either (i) these proteins are very similar and 
there is great functional redundancy encoded within each PAI, (ii) any functional 
resolution is defined in the unstructured N-terminal regions, (iii) surface chemistry in 
the structured core dictates function or (iv) combinations of (ii) and (iii) are 
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responsible for individual contributions to virulence. Using these models, (iii) could 
be considered.  Figure 4.15 illustrates the electrostatic surface rendering for each of 
the four models. It is clear that the general trends observed earlier for the crystal 
structure of VapG are evident here. The ‘top’ of the molecules have a more 
hydrophobic nature; polar residues are distributed across the bottoms and the lower 
half of the barrel walls. Beyond these general principles however, it is clear that the 
patterns of charge distribution exhibited by the individual proteins are distinctive and 
could represent the structural basis for a range of specific interactions that promote 
virulence. These molecular interactions might include those that could be categorised 
via the origin of the partners as Vap:Vap, Vap:other bacterial or Vap:host. These 
models, along with the three experimentally-derived Vap structures, provide a 
blueprint for site-directed mutagenesis studies to dissect the structure: function 
relationships of these interesting ȕ-barrel domains. 
4.4 The unstructured N-terminus 
One crucial feature of each of the 3D crystal structures defined to date is the absence 
of structure in the N-terminal regions of VapB, VapD and VapG. This region 
represents about 30 % of each molecule and could be important functionally to this 
class of proteins since it is structurally conserved. Although these regions 
(intrinsically disordered or unstructured regions as they are sometimes called) do not 
form well-defined structures in their native states under crystallisation conditions, 
they are likely free to rapidly sample many alternate configurations and could form 
stable 3D- structures upon binding to specific molecular targets (Huang and Sarai, 
2012). This process, which is referred to as coupled folding and binding, is facilitated 
due to their flexibility and is involved in a number of processes such as 
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phosphorylation, transcription control and also disease development (Fukuchi et al., 
2011, Ota et al., 2013).  Bulky and aromatic amino acid residues are order-promoting 
due to their ability to form the hydrophobic core of folded globular proteins 
(Uversky, 2013). These order promoting groups appear to be limiting in the long 
unstructured regions of the Vaps. An inspection of the VapA structure (model) 
reveals that over 94 % of aromatic amino acids residues (e.g. trytophan, 
phenylalanine and tyrosine) are found in the ȕ-barrel core. However, there are twelve 
serines (which are predominantly clustered) in the long unstructured part of the 
model. Serine is a disorder-promoting residue (Uversky, 2013). Thus the low mean 
hydrophobicity favours the formation of the unstructured region of VapA (Uversky, 
2011). Though this feature appears to be least conserved among VapB, VapD and 
VapG, it could be an important element via which interaction with host cellular 
targets, other Vaps or other bacterial components are mediated to promote the 
virulence of Rhodococcus equi. 
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Figure 4.15 Electrostatic surface rendering of Vap models 
Positive and negative electrostatic potentials are shown in blue and red 
respectively.  The apparent ribbon tracing are shown in green.   
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 CHAPTER FIVE 
5 Interactions of virulence associated proteins 
5.1 Introduction 
Almost all biological processes are either direct or indirectly controlled by 
macromolecules, especially proteins. Association between proteins plays a central 
role in the structural assembly and functional regulation of biological systems (Freire 
et al, 1990; Ladbury and Chowdhry, 1996). Processes such as nastic responses, gene 
expression, polarisation/depolarisation of action potentials, hormone-receptor 
interactions and cell-ligand interactions, amongst others, are mediated by specific 
protein-protein interactions. These interactions involve dipole-dipole effects, 
covalent bond formation, hydrophobic interactions and the formation of salt bridges 
and are characterised by some thermodynamic variables like enthalpy, entropy, free 
energy and stoichiometry of the interacting species. 
Even though the precise role of the Vap proteins is yet to be elucidated, VapA has 
been reported to be a possible virulence determinant from gene knock-out studies.  
Jain et al. (2003) reported that an R. equi mutant lacking a 7.9 kb DNA region 
spanning five vap genes (vapA, -C, -D, -E and –F) was attenuated for virulence in 
mice as it was unable to replicate in vivo and was rapidly cleared by the immune 
system. In complementation analyses, expression of vapA alone restored full 
virulence, whereas expression of vapC, -D and -E did not. Similarly, an R. equi strain 
lacking only vapA was also attenuated for growth in vivo. Both of these mutant 
strains could attach to but were unable to grow in macrophages. Although these 
studies established the importance of VapA, others have demonstrated that the 
protein is not sufficient for the proliferation of R. equi in macrophages (Giguere et al, 
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1999; Coulson et al, 2010). A recombinant, virulence plasmid-cured strain that 
expressed vapA to wild-type levels did not grow in macrophages and was avirulent in 
experimental infections of both mice and foals (Giguere et al, 1999). Similarly, 
Coulson et al. (2010) constructed an avirulent PAI deletion mutant. When vapA was 
expressed from a constitutive promoter in this mutant, full virulence was not 
restored. 
It is clear that the PAI of the R. equi virulence plasmid is essential for intra-
macrophagic replication and that VapA plays a major role in this, but VapA alone is 
not sufficient to restore virulence indicating that additional virulence genes are 
located within the pathogenicity island. 
The production of VapA is coordinated with other Vaps.  Both VapA and VapD are 
induced in response to acid stress while the transcription of both vapA and vapG 
increases in the presence of hydrogen peroxide. Temperature and pH could also up-
regulate gene expression in a synergistic manner (Miranda-CasoLuengo et al, 2011).  
This data may suggest that VapA, VapD and VapG may act in concert to enable the 
survival of Rhodococcus equi in macrophages (Benoit et al, 2002). Though the 
interactions between the Vap proteins are not known, available evidence seem to 
suggest that they all may contribute to the virulence of the organism based on their 
homology, regulatory strategies and the presence of their genes on a single locus 
(Jacks et al, 2007; Letek et al, 2008). 
We hypothesised that the importance of VapA may reside in its ability to be retained 
at the cell surface by its unusual lipid modification and that other Vaps might interact 
with it to promote virulence as an assemblage.  Potential interactions of Vap proteins 
were explored and investigated through the use of experimental biochemical and 
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biophysical approaches. Specifically, a combination of electrophoresis in native gels, 
analytical ultracentrifugation (AUC) and surface plasmon resonance (SPR) were 
deployed to follow Vap interactions in vitro.  All of the data described in this chapter 
is derived from the use of C-terminal tagged Vaps. 
5.2 Self-association and the influence of metals 
VapA is recognised for its complex electrophoretic migration. The characteristic 
broadening of the VapA band might be related to its unusual lipidation or an ability 
to interact with other migrating species or with the polyacrylamide matrix itself even 
under the denaturing conditions of SDS-PAGE. This broad banding pattern was 
diminished but not completely abrogated in this study when an N-terminally 
truncated (lacking its signal sequence) vapA was expressed in a heterologous host. 
An unusual lipidation is less likely in this situation but the possibility of retarding 
interactions remains. One distinct possibility is that VapA might oligomerise. We 
considered the possibility that any potential self-interaction might be enhanced under 
native electrophoresis conditions. When VapA was tested, two distinct bands were 
observed that could most easily be reconciled as monomeric and dimeric forms of the 
protein (Figure 5.1). Evidence for self-association of VapG was not observed using 
this methodology. 
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Figure 5.1 Purified VapG and VapA subjected to Native-PAGE. 
 
When early data were emerging from the analysis of VapG diffraction data, the 
possibility that this protein might bind a metal, likely Ca2+ or K+ was envisaged; a 
property not associated with VapD (Pers. comm. A. Wilkinson); no data were 
available to us for other Vaps in this regard. In order to investigate whether this 
metal binding might impact upon the ability of VapG to associate with itself or other 
Vaps, the protein was incubated in the presence of each metal (1 – 10 mM) for 30 
mins and migration on native gels was analysed, no evidence was found for 
alteration of its electrophoretic migration in isolation (data not shown). Similar 
experiments with VapA revealed that its apparent dimerisation was not affected in 
the presence of these metals (data not shown). 
With reference to our working hypothesis that other Vaps might associate with 
VapA, mixtures of VapA and VapG were analysed in the presence and absence of 
these two metals. Again no evidence was seen for an association of these two Vaps 
in either scenario (data not shown). However, this methodology is crude and the 
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interactions explored were limited; any physiological association of VapA and VapG 
might be indirect and mediated by another agent. However, clear evidence for VapA 
dimerisation was observed so confirmation was sought via an alternative 
methodology. 
5.3 Analytical ultracentrifugation 
Analytical ultracentrifugation is an important technique used to characterise 
macromolecular associations (in terms of stoichiometry and strength) in solutions 
(Howlett et al, 2006). The following section describes the use of AUC to study the 
sedimentation properties of VapA and VapG and the effect of metals on self-
association of these Vaps. Experiments were carried out in The University of 
Birmingham Institute of Microbiology and Infection as a guest of Prof. Gurdyal 
Besra. 
In order to validate the possibility of self-association, each purified recombinant 
protein (VapA and VapG) were subjected to analytical ultracentrifugation at 40,000 
rpm in the presence and absence of metals (KCl, LiCl or CaCl2 at 1mM) using the 
sedimentation velocity mode. LiCl was included in the study at this stage as poor 
quality VapG crystals had formed in Li+-containing liquors. Since it was considered 
that the binding of a Group I metal might be a pre-requisite for crystallogenesis, 
crystal formation in Li+ might indicate a valid interaction. The absorbance data for 
the effect of the metals on the sedimentation behaviour of VapA is shown in figures 
5.2, while the data on the effect of the metals on VapG is shown in figures 5.3 and 
5.4 and summarised in Table 5.1. 
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Figure 5.2 Influence of metals on sedimentation of VapA in analytical 
ultracentrifugation 
Recombinant VapA was incubated with 1mM KCl or 1mM LiCl for 
several minutes prior to centrifugation. Both VapA and salts were 
dissolved in 0.02 M Tris.HCl pH7.9, 0.05 M NaCl. The upper panel 
describes the relationship between the absorbance signal (c(s)) and 
sedimentation coefficient (S) and the lower panel relates absorbance 
signal (c(M)) to the apparent molecular mass. 
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Figure 5.3 Influence of 1mM potassium on the sedimentation coefficient of 
VapG in analytical ultracentrifugation 
Both protein and salt were re-suspended in 0.02 M Tris.HCl (pH7.9 
containing 0.05 M NaCl) 
 
 
Figure 5.4 Influence of 1mM lithium on the sedimentation coefficient of VapG 
in analytical ultracentrifugation 
Both protein and salt were re-suspended in 0.02 M Tris.HCl (pH7.9 
containing 0.05 M NaCl) 
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Figure 5.5 Influence of 1mM calcium on the sedimentation coefficient of VapG 
in analytical ultracentrifugation 
Both protein and salt were re-suspended in 0.02 M Tris.HCl (pH7.9 
containing 0.05 M NaCl) 
 
 
Figure 5.6 Influence of 1mM metals on the apparent molecular mass of VapG 
in analytical ultracentrifugation 
Both protein and salts were re-suspended in 0.02 M Tris.HCl (pH7.9 
containing 0.05 M NaCl) 
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This data reveal that both VapA and VapG were predominantly monomeric but did 
not sediment in a manner expected of a globular protein of the calculated molecular 
mass of the recombinant molecule.  These masses were over-estimated in both cases 
by approximately 6 and 4.6 kDa for VapA and VapG respectively. Long unstructured 
(disordered) motifs of proteins have larger hydrodynamic dimensions than globular 
equivalents of the same molecular mass (Kozlowska et al, 2014).  VapG has a ȕ-
barrel structure and possesses a long unstructured region at the N-terminus (Chapter 
4). VapA shares significant homology with the structurally characterised VapB, 
which also shares this characteristic (Geerds et al., 2014).  Thus these unstructured 
regions of the proteins could be a major contributing factor to the difference between 
the apparent and the calculated molecular masses of the recombinant molecule on 
AUC. 
However with the increasing protein concentration associated with sedimentation, a 
second molecular weight became apparent which indicates the formation of a dimer.  
The observations reveal that both VapA and VapG could exist in a monomer-dimer 
equilibrium at high concentrations. These equilibria would require multiple AUC 
runs in sedimentation equilibrium mode to resolve. A superficial examination of 
these traces does reveal that the ratio of peak heights (monomer: dimer) for proteins 
in the absence of metal were 6.8 and 10.9 for VapA and VapG respectively. This is 
not a rigorous examination but it suggests that VapA has a greater predisposition for 
dimerisation than VapG, which is in agreement with the dimerisation seen on Native-
PAGE (Figure 5.1) for VapA only. 
The presence of metals in the medium did not change the sedimentation behaviour of 
VapA significantly as both signals for monomer and dimer were retained (Figure 
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5.2). However, the dimer signal (centred around 2.68 S, Figures 5.3-5.5) for VapG 
seem to have been lost with the metals in the medium. It appears that exposing VapG 
to the metals reduced the ability of protein to self associate (i.e. homodimerise) even 
with increasing protein concentration upon sedimentation. 
 
Table 5.1 Sedimentation properties of VapA and VapG 
  VapA (17.6 kDa)  VapG (16.8kDa) 
Metals *Monomer *Dimer  1 2 
Sedimentation 
Coefficient (S) 
Nil 1.8 2.9  1.6 2.7 
K+ 1.7 2.8  1.6 0 
Li+ 1.7 2.8  1.5 0 
Ca2+ N/A N/A  1.6 0 
       
Molecular 
Mass (kDa) 
Nil 23.6 46.9  21.4 48.5 
K+ 21.6 44.7  19.7 0 
Li+ 22.3 45.9  20.2 0 
Ca2+ N/A N/A  19.5 0 
All values are approximations based on data analysis fitting a single frictional coefficient. N/A, effect 
of Ca2+ on sedimentation behaviour of VapA was not performed. *These are apparent values from 
sedimentation velocity experiments. Values in brackets are the calculated molecular masses of the 
recombinant molecule using ExPASy Protparam. 
 
5.4 Surface plasmon resonance 
Although AUC could be used to carry out studies of Vap interactions, this was not 
convenient and uses high concentrations of protein samples. We chose to explore 
potential interactions between Vaps using surface plasmon resonance (SPR), a 
flexible label-free technique through which both affinity and binding constants can 
be obtained from binding responses over a range of concentrations (Besenicar et al, 
2006) in real time using relatively small amounts of analytes in a native or native-
like environment (Stahelin, 2013; Patching, 2014). This latter aspect was interesting 
as interactions between immobilised VapA and other Vaps could be measured at an 
interface, to an extent emulating the in vivo scenario. SPR was available locally and 
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experiments were carried out as a guest of Prof Jeremy Lakey at the University of 
Newcastle upon Tyne. 
5.4.1 Interaction of VapA with other Vaps 
In Rhodococcus equi, available evidence suggests VapA has an unusual lipidation 
and is tethered to the cell wall surface while other Vaps are mostly secreted and 
diffusible proteins (Byrne et al., 2008).  It is possible that other Vaps might associate 
with VapA to form an assemblage that might promote virulence. Based on this 
intrinsic property of VapA to adhere to the cell surface, it was chosen to be 
immobilised on the SPR sensor chip as the ligand; the experimental model involved 
the passage of other Vaps over the immobilised VapA to monitor interactions that 
might promote such assembly. 
VapA was adsorbed on a Biacore CM5 sensor chip (via amide coupling as described 
in section 2.8.16).  After 1 min of loading VapA (at 42 µg/mL) at 5 µl/min, a signal 
of 1483 RU was obtained which was stable after completion of the blocking protocol 
to prevent covalent capture of analytes by the activated carboxymethylated dextran 
matrix. 
For analytical runs, solutions of the other Vaps available to us VapD, E, G and H 
were passed over the VapA chip for 3 minutes in an association phase at one of two 
concentrations (50 µM and 100 µM in HBS buffer; 0.01 M HEPES, 0.15 M NaCl, 
0.003 M EDTA, 0.05 % P20).  The analysis was continued in a dissociation phase in 
which HBS buffer was passed over the chip. Data were adjusted by subtraction of the 
signal from the analyte passing simultaneously through the control flow-cell.  
Adjusted and compiled sensograms are shown in figure 5.7. 
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Figure 5.7 Interaction of Rhodococcus equi virulence associated proteins with 
immobilised VapA 
Individual Vaps were run as analytes on a VapA modified CM5 chip at 
50 µM and 100 µM using a Biacore X100.  1434 RU VapA was bound 
to the CM5 sensor chip. 
 
The experiments with VapD resulted in no measurable response indicating a very 
poor binding between VapA and VapD in this format. Experiments with VapE and 
VapH produced very similar responses, showing a gradual accumulation of signal 
over approximately 2 minutes, which continued for at a slower rate for the rest of the 
association phase in most cases, VapE at 100µM showed a minor loss of signal at 
this point. The magnitude of the apparent binding was broadly concentration 
dependent. VapG behaved differently with complex concentration dependence and a 
markedly more rapid association in the early part of the experiment.  On entering the 
dissociation phase of the experiment, the signal deteriorated in the order 
VapG>VapH>VapE. 
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As VapG produced the strongest signal at the concentrations considered, a broader 
range of VapG concentrations between 1 and 100µM was considered (figure 5.8). 
 
 
Figure 5.8 Interaction of Rhodococcus equi VapG with immobilised VapA 
VapG was run as an analyte on a VapA-modified CM5 chip at 
concentrations between 1µM and 100 µM using a Biacore X100.  1434 
RU VapA was bound to the CM5 sensor chip. 
 
Significant binding of VapG to VapA was observed at all concentrations thus the 
kinetics of binding (including binding of VapE to VapA) was measured using the 
‘wizard’ mode, which manages automatic runs with in-built technical replication. 
5.4.2 Binding kinetics 
The kinetics of binding of both VapG and VapE to immobilised VapA were 
considered using various concentrations between 1µM and 100 µM via the 
automated ‘wizard’ mode. Data were fitted using the 1:1 interaction model which 
assumes a simple reversible biomolecular interaction between the ligand i.e. VapA 
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and the analyte i.e. either VapG or VapE which can be represented by the following 
equation. 
 
Where the association rate constant and dissociation rate constant are represented by 
ka and kd respectively). Due to mass transport effects that were envisaged, ligand 
concentrations higher than 100 µM were not used since it could be rate limiting 
thereby reduce the reliability of the binding data (Rich and Myszka, 2000; Tudos and 
Schasfoort, 2008). 
 
Figure 5.9 Kinetic analysis of VapG with immobilised using surface plasmon 
resonance. 
Each concentration (1 µM, 10 µM, 25 µM, 50 µM and 100 µM) was 
run in duplicate using a Biacore X100.  Prior to fitting, values for the 
blank i.e. HBS running buffer were subtracted from real experimental 
values.  Fitted curves are superimposed in black. 
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Figure 5.10 Kinetic analysis of VapE with immobilised VapA using surface 
plasmon resonance 
Each concentration (1 µM, 10 µM, 25 µM, 50 µM and 100 µM) was 
run in duplicate using a Biacore X100.  Prior to fitting, values for the 
blank i.e. HBS running buffer were subtracted from real experimental 
values. Fitted curves are superimposed in black. 
 
After measuring the interactions via the wizard mode (i.e. VapG/E interaction with 
VapA), the data was fitted using a 1:1 interaction model using the Biacore X100 
evaluation software. In the case of VapG, the experimental data fitted the 1:1 binding 
model very well (Figure 5.9) with the calculated descriptive constants presented in 
Table 5.2. The fit for VapE was less convincing. However, a generally accepted 
indicator of quality of fit for SPR data is indicated by the ratio of Rmax and Chi
2 
generated by the Biacore X100 Evaluation Software. Generally, a Chi2 amounting to 
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less than 10% of Rmax is accepted for a fit (Yapeng et al., 2013). In this respect both 
data sets would be acceptably described by this 1:1 binding model. 
Table 5.2 Kinetic parameters for VapG/E interaction to VapA from a 1:1 
binding model 
Parameter VapG VapE 
Ka (1/Ms) 471.7 272.0 
Kd (1/s) 0.05895 0.001951 
KD (M) 1.25 x 10
-4 7.17 x 10-6 
Rmax (RU) 12.64 3.119 
Chi2 (RU2) 0.129 0.264 
 
VapG was found to interact with VapA with an equilibrium dissociation constant 
(KD) of 125 µM while the KD for the interaction of VapE to VapA was 7.17 µM 
(Table 4.3). This reveals a weak interaction between VapG and VapA i.e. KD > 100 
µM and a higher affinity interaction (Qin and Gronenborn, 2014) between VapE and 
VapA. Thus VapE is more readily recognised by VapA thus a VapAE complex is 
more stable than a VapAG complex. 
VapA was immobilised on the sensor chip via lysine residues and there are three 
lysines in the mature protein sequence. In the 3D-model of VapA, Lys 37 is part of 
the unstructured N-terminus, Lys 77 is in the ȕγ while Lys 108 is part of the α-helix. 
The side chain of Lys 108 is outside the core so Lys 37 and108 could be solvent-
exposed and available for reaction with the activated carboxymethylated dextran 
matrix. The side chain of Lys 77 is buried inside the core so may not be solvent 
exposed. Thus two modes of immobilisation could be reflected in these experiments. 
Steric effects could limit interactions in either case. It is likely that the unstructured 
N-terminus is involved in binding events; the immobilisation of VapA via Lys 37 
might severely restrict the mobility of this region and limit its participation in any 
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possible Vap-Vap interactions. Likewise immobilisation via Lys 108 might also 
restrict access of binding partners to important sites. Another mode of 
immobilisation could be attempted using the hexahistidine tags (either N-terminal or 
C-terminal) of the recombinant VapA proteins on Ni-NTA chips. In each case the 
orientation of the protein would be better understood and differential affinities that 
might arise for each Vap analyte might be rationalised. Here analyte proteins would 
need to be untagged.  Additionally, the individual contributions of the VapA core and 
its unstructured N-terminal region could be analysed separately by producing discrete 
truncated molecular constructs to be immobilised on Biacore chips. 
Another factor that should be explored is the ambient pH at which such interactions 
might occur. One factor that is particularly relevant is the up-regulation of vapA and 
vapD at acidic pH (Benoit et al., 2001); superior results might be achieved by 
conducting these binding experiments at a range of pH values. 
This preliminary study of Vap interactions is limited in its scope but has revealed 
some interesting avenues for further study.  It is clear that Vaps might associate with 
VapA to varying extents and with varying affinities. The value of this method should 
be evaluated further. 
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 CHAPTER SIX 
6 Lipidation of Envelope proteins and recombinant VapA 
6.1 Introduction 
At the outer margins of bacterial cells are located different molecules whose 
functions are quite indispensable to their survival and natural history (Navarre and 
Schneewind, 1999). The architecture of bacterial envelopes is varied but essentially 
they fall into two groups with reference to the number of hydrophobic permeability 
barriers they possess; monoderms and diderms. The former are exemplified by the 
Gram-positive Firmicutes. Diderms possess an outer permeability barrier; these are 
varied in their composition and fine architecture having evolved different solutions to 
common functional challenges across varied lineages (Desvaux et al., 2009). 
Following biosynthesis, proteins targeted to the cell envelope are translocated across 
the plasma membrane through a confined aqueous channel composed of sets of 
integral membrane proteins comprising the General secretory pathway (Sec) and the 
twin-arginine translocation pathway (TAT) (van Wely et al., 2001). Some proteins 
are destined for an absolute secretion in which they operate at a distance to the cell.  
Those that are required to function in the outer margins but in a stable and defined 
position are subject to one of a number of modifications during or after this first 
secretion process. Although its primary function is to provide a rigid exoskeleton for 
protection against both mechanical and osmotic lysis, the cell wall of Gram-positive 
bacteria also serves as an attachment site for proteins that perform diverse tasks, 
especially mediating interaction of bacteria with their external environment which 
are often secured covalently to the peptidoglycan matrix via sortase enzymes 
(Navarre and Schneewind, 1999; Marraffini et al., 2006). Due to the absence of a 
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retentive outer membrane, monoderms like the archetypal Gram-positive bacteria use 
N-terminal lipidation as another major mechanism by which proteins are retained in 
the periplasmic area; these lipoproteins can then be anchored via the modifying lipid 
to hydrophobic surfaces (Kovacs-Simon et al., 2011). 
Rhodococcus equi is a diderm; much research effort has been applied to its relative 
Mycobacterium tuberculosis, they share a highly conserved cell wall architecture. Its 
outer mycolate-rich lipid layer represents another potential anchoring point for 
lipoproteins that would allow their presentation at the cell surface (Kovacs-Simon et 
al., 2011).  
In addition to VapA being a secreted protein, it is also thought to be lipidated and 
surface-located (Tan et al., 1995; Meijer and Prescott, 2004) though the nature of 
that lipidation is poorly understood. The lipid moiety could either be a permanent co-
translational addition or a post-translational modification which may perform 
additional roles other than simple anchorage (Lavental et al., 2010). The lipid 
modification of VapA is recognised as being unusual, partly from the fact that the 
post-processing N-terminus is not the cysteinyl residue expected of a common 
lipoprotein. Recently, channel-forming porins of Corynebacterium glutamicum 
(another mycolylated relative of R. equi) have been shown to bear O-linked mycolate 
residues (Huc et al., 2010) and a mycolyltransferase (Cmt) has been identified to 
catalyse this transfer (Huc et al., 2013). Since lipoproteins and channel-forming 
porins are non-covalently attached to the wall, it is possible that a range of 
mycolylated proteins might be located at the outer membrane. Indeed, mycolylation 
might be an important intermediate step in the trafficking of a subset of secreted 
proteins to be retained at the outer surface of the mycolata. 
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Previous attempts to characterise the supposed lipidation of VapA via traditional 
methods have been unsuccessful. We sought to determine whether mycolylation of 
outer membrane proteins occurred in R. equi and then whether a molecular biology 
approach could address the hypothesis that VapA might bear a mycolyl residue. 
6.2 Investigation of envelope protein-bound lipids of Rhodococcus equi 
6.2.1 Phase separation of Rhodococcus equi membrane proteins 
Membrane proteins were extracted from washed R. equi cells in buffer containing the 
non-ionic detergent Triton X-114. The detergent replaces most of the lipid molecules 
in contact with the hydrophobic units of the proteins producing a protein-detergent 
mixed micelle (Bordier, 1981).  Hence via the amphiphilic nature of these proteins, 
they can be effectively separated from hydrophilic proteins which do not possess any 
hydrophobic moiety. Below 20°C, Triton X-114 molecules disperse in aqueous 
solutions into small micelles which form quite a homogenous solution but above 
22°C, these micelles coalesce, becoming large enough to produce a phase separation 
(Kittelberger et al., 1995; González de la Vara and Alfaro, 2009). Thus when Triton 
X-114 is used to extract membrane proteins and the temperature is raised above 
22°C, hydrophobic proteins concentrate in the lower detergent phase as an oily 
droplet while the hydrophilic proteins separate in the upper detergent-free phase thus 
separation of hydrophobic and hydrophilic proteins can be achieved in a single step 
(González de la Vara and Alfaro, 2009). 
As this aspect of the study is principally concerned with VapA, an experimental 
design that established the partitioning of this key protein during its fractionation was 
required. The VapA-specific monoclonal antibody Mab10G5 was ideal detection 
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reagent in this respect. After phase separation (as described in section 2.8.10), 
protein extracts from both aqueous and detergent phases were immobilised on a 
nitrocellulose membrane in a dot blot format and the presence of VapA was 
determined immunochemically using Mab10G5 as the primary antibody (Figure 6.1). 
 
Figure 6.1 Fractionation of VapA in Triton X-114 
Extracts of Rhodococcus equi 103+ membrane proteins were 
fractionated between Aqueous (AP) and Detergent (DP) phases.   
Samples were applied to nitrocellulose membrane in a dot blot format.  
The blot was probed with the VapA-specific monoclonal antibody 
Mab10G5 and visualised with an anti-mouse IgG (alkaline phosphatase 
conjugate): Samples: VapA (recombinant expressed in E. coli BL21 
(DE3); DP, 2 x detergent phase extracts; 2 x AP, aqueous phase extract 
after phase separation. Two independent extractions are shown here. 
 
A strong signal was seen for a recombinant VapA positive control confirming the 
validity of our stock antibody as a detection device.  In all samples tested, a positive 
signal was detected within the detergent phase of R. equi extracts, although this 
varied in strength.  This immunochemical reaction supported the detection of VapA 
in these cell wall-derived fractions. No signal was detected when analysing the 
aqueous phase in any experiment indicating a large partition coefficient 
(unmeasured) and lipophilicity for VapA.  In the absence of structural information, it 
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was assumed this indicated that VapA was both present in the analyte sample and 
was probably lipidated.  In order to formally identify VapA in this detergent phase, 
the proteins were trypsin-digested (in gel), separated by reverse-phase HPLC and 
subject to tandem mass spectrometry in which the fragment 
ASDTAGQEQQYDVHGDVISAVVYQR representing 13% coverage of the VapA 
amino acid sequence was detected (Figure 6.2). 
 
 
Figure 6.2  MS/MS fragmentation of ASDTAGQEQQYDVHGDVISAVVYQR 
The fragment represents 13 % coverage of the amino acid sequence of 
VapA. Peptide score via Mascot is 56 %. 
 
6.2.2 Lipid analysis 
Virulence-associated proteins such as VapA may be tethered to the rhodococcal cell 
envelope by a lipid modification. With the emergence of mycoloylation as a post-
translational modification of secreted proteins, it would be interesting to know if this 
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was also a feature in rhodococci. The site of mycolylation is known in only one case 
and as no region of strong homology exists with the other poorly-defined small 
mycolylated porin (Huc et al., 2010), no important sequence motifs can yet be 
considered. Rhodococcus equi also contains porin proteins. As lipoproteins and 
channel-forming proteins are all non-covalently attached to the envelope, several 
proteins of R. equi might be bound to the wall via a mycolyl linkage. The working 
hypothesis is that proteins destined to be surface-exposed are mycolylated during 
secretion and consequently targeted to the mycolate-based outer membrane.  
To perform an analysis of protein–bound lipid within the fractions produced by 
Triton X-114 phase separation, proteins were precipitated using trichloroacetic acid, 
lyophilised overnight, and re-suspended in a methanol:NaCl solution. 
A major concern was that the extract may include mycolic acid-containing 
glycolipids that could contaminate the protein preparations and lead to a false 
interpretation that mycolic acid methyl esters had been derived from proteins. The 
solution was first delipidated by phase partition by mixing with petroleum ether (as 
described in section 2.9.1.1) to remove free lipids including the mycolate-containing 
glycolipids like the predominant trehalose (mono-/di-) mycolate. In order to 
understand the complexity of the lipid mixture removed at this point, the upper phase 
containing the free lipids was analysed by TLC (figure 6.3.).  
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Figure 6.3 TLC Analysis of free lipids from R. equi subjected to Triton X-114 
phase partitioning on silica. 
AP, aqueous phase extracts; DP, detergent phase extracts.  Five 
microlitre samples from equivalent extracts were loaded, the TLC was 
developed using chloroform:methanol (2:1). Lipids were visualised by 
charring with 5% ethanolic phosphomolybdic acid.  
 
When the plate was stained with molybdophosphoric acid and visualised, major 
bands were detected migrating with Rf = 0.2 and 0.8 and there was no significant 
difference in band pattern observed between lipids in the detergent phase and the 
aqueous phase extracts (Figure 6.3). These materials have not been further 
characterised but are likely to be phospholipids and free fatty acids respectively.  
There appeared to be no significant population of glycolipids in this extract since no 
bands were observed when an identical plate was visualised after staining with the 
carbohydrate-reactive 1-Naphthol (Results not shown). 
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The lower methanolic phase containing extracted protein was lyophilised and treated 
with 5 % aqueous tetrabutylammonium hydroxide at 100°C to release protein-bound 
lipids, which were then converted to methyl esters (as described in section 2.9.1.3).  
A similar process was carried out for proteins precipitated from the original aqueous 
phase of the Triton X-114 partitioning. 
 
Figure 6.4 Analysis of acyl-methyl esters released from protein-bound lipids 
from  R. equi cells subjected to Triton X-114 phase partitioning 
AP, aqueous phase extracts; DP detergent phase extracts. MAMEs?, 
putative mycolic acid methyl esters. Five microlitre samples from 
equivalent extracts were loaded, the TLC was developed using 
petroleum ether: acetone (95:5). Lipids were visualised by charring 
with 5% ethanolic phosphomolybdic acid.  
 
TLC analysis of methyl esters (Figure 6.4) revealed significant quantities of a 
common material both in the aqueous phase and the delipidated detergent phase 
extracts (Rf = 0.66) (these varied markedly in relative intensity with each extract, see 
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Figure 6.6) but methyl esters migrating at Rf = 0.46 only appear in the detergent 
phase extract.  Because of their relative migration in this solvent system, these lipids 
at Rf = 0.46 were believed to be mycolic acid methyl esters (MAMEs?). This 
indicates that hydrophobic proteins tethered in the wall of R. equi could possess 
mycolyl residues and thus a mycolylation of VapA could be considered. Lipid 
samples were later subjected to MALDI-TOF MS to confirm the identity of the lipids 
derivatised as methyl esters (see section 2.9.4 and Figure 6.7). 
In order to increase confidence in our interpretation of this interesting finding, the 
protein-bound lipids (derivatised as methyl esters) of Rhodococcus equi ΔkasA were 
also investigated in the same way. Rhodococcus equi ΔkasA is modified via a 
deletion of the gene for ȕ-ketoacyl-(acyl carrier protein)-synthase A (KasA), the key 
fatty acyl chain elongation activity of the FAS-II system responsible for synthesis of 
the long-chain meromycolic acid component of the mycolic acids. Thus the strain 
produces mycolic acids that are about ten carbons shorter in chain length than those 
of the parental strain (Sydor et al., 2013, see figure 6.5) suggesting condensation of 
FAS-I products to form short chain mycolates only. 
The extraction of protein-bound lipids from R. equiΔkasA revealed a slow-migrating 
acyl methyl ester on TLC. This material migrated to a similar Rf to that of the 
putative MAMEs recovered from the parental strain but consistently migrated to a 
lower Rf (0.32) (Figure 6.6). This chromatographic behaviour is consistent with an 
increased polarity related to the loss of acyl chain length in the mutant extract and 
consequently greater interaction of the polar ȕ-hydroxy and residual terminal 
carboxy- moieties with the silica matrix. 
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Taken together, these findings are wholly consistent with the demonstration of 
protein mycolylation in the outer cell wall of R. equi. 
 
 
Figure 6.5 Mass spectrometry (with electrospray ionisation) (as m/s) of 
mycolic acids from chloroform:methanol extracts of R. equi 
(A) wild type, from (B) kasA mutant (from Sydor et al., 2013). Their 
profiles show that many mycolic acids found beyond m/z 551.6 in the 
wild type seem to be lost in the mutant (Adapted from Sydor et al., 
2013). 
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Figure 6.6 TLC of mycolic acid methyl esters of R. equi. 
Methyl esters were released from the protein-bound lipids of the wild 
type (WT) and ΔkasA mutant strains of Rhodococcus equi subjected to 
Triton X-114 phase partitioning. Five microlitre samples from 
equivalent extracts were loaded, the TLC was developed using 
petroleum ether: acetone (95:5). Lipids were visualised by charring 
with 5% ethanolic phosphomolybdic acid. 
 
6.2.3 Identification of acyl-methyl esters via MALDI-TOF MS 
The TLC profiles in figures 6.4 and 6.6 appear to show that some of the acyl methyl 
esters detected in this study could be putative mycolic acid methyl esters.  In order to 
confirm the identities of these lipids, the samples were subjected to MALDI-TOF 
MS.  
Following Triton X-114 phase partitioning, protein-bound lipids (from R. equi 103S 
and R. equi ΔKasA) were extracted from the detergent phase and derivatised as 
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methyl esters as described earlier. Using α-Cyano-4-hydroxycinnamic acid as the 
matrix, MALDI-TOF MS (Figure 6.7) mass profiles mirror those seen from the 
corresponding crude cell wall extracts of the parental and kasA mutant strains (see 
figure 6.5, Sydor et al., 2013).  Both strains produced similar MAMEs up to m/z 568. 
The maximum chain length of the protein-bound lipids from R.equi ΔkasA was 36 
carbons (m/z 568, C36:0Me) while the wild type strain produced significant amount of 
lipids beyond m/z 568 (figure 6.7, Table 6.1).  For the mutant, residual signals for 
these larger lipids seem to be close to background levels.  
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Figure 6.7 MALDI-TOF spectra of mycoloyl acid methyl esters released from 
protein-bound lipids from the R. equi 103S and ΔkasA strains 
 
Taken together the combined results of the survey of protein-bound lipids in the 
walls of R. equi and its isogenic mutant in kasA were wholly consistent with 
mycolylation of proteins in this species. Immunochemical and mass spectrometric 
techniques established that VapA was among the proteins present in these extracts, 
supporting the hypothesis that lipid modification of this key virulence determinant 
could be via mycolylation. 
However, in the light of structural information identifying the relatively apolar 
surface of the core structure of the VapA model (Figure 4.10), a retrospective 
analysis of the partitioning of recombinant VapA from E. coli, and therefore unlikely 
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to be lipid-modified, revealed that this molecule partitioned to the detergent phase in 
triton X-114. This might indicate that the ‘top’ of the protein structure has enough 
hydrophobic nature to maintain an association with the mycolate membrane 
independently of a lipid modification. 
Table 6.1 Protein-bound lipids predominant in R. equi WT revealed by 
MALDI-TOF MS 
 Modelled configuration of putative mycolic acids 
m/z Number of Carbons (+ Me*) Number of unsaturations 
581.4 37 0 
597.4 38 0 
625.5 40 0 
641.5 42 4 
669.5 44 4 
685.5 45 3 
713.6 47 3 
729.6 48 2 
757.8 50 2 
773.8 51 1 
*Species were derivatised as methyl esters by treatment with iodomethane 
 
6.3 Lipidation of Recombinant VapA in Corynebacterium glutamicum 
6.3.1 Cloning of vapA into the inducible E. coli-C. glutamicum shuttle vector 
pEKEx2 
At the outset of this project, a novel post-translational modification was recognised 
in C. glutamicum, when it was determined that two porins are O-mycoloylated (Huc 
et al., 2010). If such a function were to be conserved across the mycolata, this could 
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provide a potential explanation for the unusual lipidation of VapA and suggest a 
generic means for partitioning proteins specifically to the outer mycolic acid 
containing membranes of the mycolata. Due to the similar cell wall morphology 
shared by these two organisms, it was logical to determine whether expression of 
vapA in C. glutamicum would result in its mycoloylation. Furthermore, the 
subcellular localisation of VapA in this recombinant system might represent a useful 
means to develop an assay as a proxy for lipid modification. In this way a panel of 
site-directed mutants might be readily screened to suggest a site(s) for the lipidation. 
Sequences encoding full-length VapA (designated CgvapA for expression in C. 
glutamicum) and its hexa-histidine tagged variant (designated CgvapAhistag) were 
amplified via PCR using oligonucleotide primers compatible with cloning in the E. 
coli-C. glutamicum shuttle vector pEKEx2 and analysed via agarose gel 
electrophoresis (Figure 6.8). CgvapAHistag was designed in order to introduce a C-
terminal hexa-histidine tag in the protein product to facilitate (if need be) its 
purification via affinity chromatography or detection in immunoblots. As pEKEx2 
has no coding sequence for hexahistidine tag, pET23-vapAfull, which contains the 
entire vapA sequence, was used as the template for PCR to provide the code. 
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Figure 6.8 PCR amplification of CgvapA and CgvapAhistag 
Lane H, 10 kbp size standard 
 
The DNA band that migrated similarly to the 600 bp marker was consistent with 
expectation for vapA (570 bp). Similarly, the product destined for the histidine 
tagging migrated between between the 600 bp and 800 bp marker bands was 
consistent with the expected 727 bp vapAhistag amplicons (Figure 6.8). Samples that 
contained amplified products were pooled together and purified from agarose after 
electrophoresis.  Each was subjected to restriction digestion using the enzymes KpnI 
and EcoRI. The shuttle vector pEKEx2 was also digested using the same protocol 
and ligated to the digested PCR products. Recombinant plasmid DNA was later 
purified from transformants of E. coli Top 10.  Analysis of the recombinant plasmids 
via agarose gel electrophoresis after restriction digestion is shown in figure 6.9. 
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Figure 6.9 Restriction digestion of pEKEx2-vapA; and pEKEx2-vapAhistag 
with KpnI and EcoRI 
Lane H is 10 kbp size standard marker (hyperladder 1). 
 
The pattern of the visible bands was compatible with expectations strongly indicating 
that vapA and vapAhistag were effectively ligated to pEKEx2, this was validated by 
nucleotide sequence analysis. 
6.3.2  Expression and subcellular localisation of recombinant VapA in 
Corynebacterium glutamicum 
These pEKEx2-derived plasmids were used to transform electrocompetent 
Corynebacterium glutamicum ATCC 13032. Thereafter, antibiotic-resistant colonies 
were grown and subjected to IPTG induction of gene expression. Cells were 
harvested and protein isolated from both pellet and the spent culture supernatant. 
Initial analyses of subcellular location focussed on the non-particulate fractions, i.e. a 
clarified lysate and secreted proteins, for ease of processing. It was anticipated that a 
putative mycolylated VapA state might not be replicated in a heterologous host and 
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that a non-modified VapA might be secreted to the culture medium. Western blot 
analysis (probed with Mab10G5) revealed the presence of heavy bands migrating at 
 
Figure 6.10 Western blot analysis of C. glutamicum proteins 
(A) Clarified lysate from cell pellet (B) proteins from secreted protein 
fraction. Figure shows blot from native C. glutamicum (control); and C. 
glutamicum transformed with either pEKEx2-vapA or pEKEx2-
vapAhistag and harvested 4 hrs post induction; or 24 hrs post induction. 
 
a rate between those of the 14 kDa and 20 kDa standards in both the clarified lysate 
and broth secreted protein fractions which were consistent with the expected but 
unusual electrophoretic migration of native R. equi VapA, that was not well 
reproduced when vapA was expressed in E. coli. The diffuse band observed is in 
concord with the reported electrophoretic behaviour of VapA (which has been 
reported to span 18 – 22 kDa in some cases) (Tan et al., 1995). This diffuse band was 
not detected in fractions from the non-transformed C. glutamicum cells inferring that 
these immunochemical reactions indicated bona fide detection of recombinant VapA. 
It was clear however that this overproduced recombinant VapA was not exclusively 
located at the surface of the cell. Detection of VapA in the clarified lysate 
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(representing cytosolic and plasma membrane locations) could be anticipated through 
translation and secretory processing. Detection of significant quantities of 
recombinant protein in a cell-free fraction was anticipated as an indicator of poor 
lipid modification. This observation could indicate that either recombinant VapA was 
not modified and retained at the cell surface in C. glutamicum at all or that this 
process was not well regulated and secreted and modified populations of the 
recombinant protein might co-exist. 
In order to rigorously identify recombinant VapA in these fractions, they were 
subjected to SDS-PAGE, protein bands (already stained corresponding to the 
molecular size of interest) were excised and subjected to in-gel trypsin digestion and 
LC-tandem MS. Raw chromatographic files were processed into Mascot 
compatibility files and searches performed using the online Mascot MS/MS ions 
search function against the NCBI non-redundant protein database with taxonomy set 
at Actinomyces (Table 6.2). The search parameters applied were peptide mass 
tolerance of ± 0.5, fragmented mass tolerance of ± 0.5, peptide charge of 2+ and 3+ 
and semitryptic specificity allowing for up to two missed cleavages. Other 
parameters were fixed modifications at carboxymethyl (of cysteine) and variable 
modifications with deamidation at asparagine and glutamine. Details of the score, 
number of non-redundant peptides identified, and the amino acid coverage of VapA 
sequence (NCBI Reference Sequence: NP_858467.1) are shown in table 6.2. LC-
MS/MS showed that peptides for VapA amino acid sequence were effectively 
identified both in the clarified lysate (CLY) and the broth supernatant proteins (BSP) 
with significant scores. All the fragments identified exceeded Mascot’s significant 
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level (Mascot score > 40). Thus it could be concluded that VapA was effectively 
expressed in C. glutamicum to a significant degree.  
Table 6.2 Confirmation of recombinant VapA from various fractions of C. 
glutamicum expressing recombinant vapA via LC-MS/MS. 
CLY indicates samples derived from a clarified lysate; SP indicates samples derived from secreted 
proteins and Q indicates a deamidated glutamine residue.  Text in Grey indicates that cleaved signal 
peptide of VapA.  Highlighted text identifies detected peptides. 
 
A few glutamine residues on some of the redundant peptides are evidently 
deamidated. Non-enzymatic deamidation of glutamine and asparagine is a post-
Fractio
n 
Induction 
period 
Score  No of Matched 
peptides  
Protein 
coverage 
Non-redundant peptides 
C. glutamicum pEKEx2-vapA 
CLY 4 67 1 13 
ASDTAGQEQQYDVHGDVISAVVYQ
R 
CLY 24 75 1 13 
ASDTAGQEQQYDVHGDVISAVVYQ
R 
CLY 4 67 1 13 
ASDTAGQEQQYDVHGDVISAVVYQ
R 
SP 24 63 1 13 
ASDTAGQEQQYDVHGDVISAVVYQ
R 
C. glutamicum pEKEx2-vapAhistag 
CLY 4 138 4 17 
FHVFGPEGK 
ASDTAGQEQQYDVHGDVISAVVYQ
R 
ASDTAGQEQQYDVHGDVISAVVYQ
R 
ASDTAGQEQQYDVHGDVISAVVYQ
R 
 
CLY 24 120 2 17 
 
FHVFGPEGK 
ASDTAGQEQQYDVHGDVISAVVYQ
R 
 
SP 4 127 3 17 
 
FHVFGPEGK 
ASDTAGQEQQYDVHGDVISAVVYQ
R 
ASDTAGQEQQYDVHGDVISAVVYQ
R 
 
Position of detected fragments in native VapA sequence 
MKTLHKTVSKAIAATAVAAAAAMIPAGVANATVLDSGSSSAILNSGAGSGIVGSGSY
DSS 
TTSLNLQKDEPNGRASDTAGQEQQYDVHGDVISAVVYQRFHVFGPEGKVFDGDAG
GLTLP 
GAGAFWGTLFTNDLQRLYKDTVSFQYNAVGPYLNINFFDSSGSFLGHIQSGGVSTVV
GVG 
GGSGSWHNA 
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translational modification that accompanies in vitro purification, storage and 
handling of proteins initiated by acids and the presence of non-bulky amino acids 
near glutamine in the protein’s primary sequence (Volkin et al., 1997; Joshi et al., 
2005). Thus trichloroacetic acid (though a weak acid) used in protein precipitation 
maybe responsible for the deamidation of glutamine in the tryptic fragments of VapA 
in the broth supernatant proteins. Though several of the peptides have 
glycinyl/alaninyl residues neighbouring the deamidated residue, secondary structure 
effects appear a less likely cause (Joshi et al., 2005). 
6.4 Analysis for corynomycolate modification and compartmentalisation of 
recombinant VapA in C. glutamicum 
Protein extracts following vapA expression in C. glutamicum were delipidated and 
protein-bound lipids extracted and analysed by TLC as before (Figure 6.11). TLC 
analysis of the preparation containing acyl methyl esters shows a common band (Rf = 
0.5, labelled P) in the clarified lysate and the secreted protein fraction of the 
transformants and the native C. glutamicum (Figure 6.11). However, the abundance 
of another common band (which occurs at Rf = 0.3, indicated as CgMAMEs) is 
significantly increased in the cells transformed with pEKEx2-vapAhistag (harvested 
4 hrs and 24 hrs post induction) and pEKEx2-vapA harvested 24 hrs after IPTG 
induction (Figure 6.11A) in both the clarified lysate and more markedly in the 
secreted protein fraction (Figure 6.11 B). This indicates that there is a pronounced 
increase in this unusual protein lipidation in C. glutamicum coincident with the over 
expression of vapA. These are described as putative MAMEs due to the similarity of 
their migration to C. glutamicum MAMEs described elsewhere (Gande et al., 2004). 
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Extracts of C. glutamicum pEKEx2-vapA harvested 4 hrs after induction with IPTG 
seem to show no difference in lipid pattern when compared with native cells (lane 1). 
 
 
Figure 6.11 TLC analysis of protein-bound lipids of delipidated extracts 
(A) Clarified lysate (B) secreted protein fraction. Figure shows profile 
from native C. glutamicum (control); and C. glutamicum transformed 
with either pEKEx2-vapA or pEKEx2-vapAhistag and harvested 4 hrs 
post induction; or 24 hrs post induction. CgMAMEs?, putative 
corynomycolic acid methyl esters. SF, solvent front.  Five microlitre 
samples from equivalent extracts were loaded, the TLC was developed 
using petroleum ether: acetone (95:5).  Lipids were visualised by 
charring with 5% ethanolic phosphomolybdic acid. 
 
The consistency of abundance in ‘P’ in these extracts validates the equivalent loading 
of the TLC samples. This apparent poor yield of MAMEs may indicate that the 
degree of post translational lipidation may occur more slowly with this construct as 
these bands became significantly pronounced in samples harvested 24 hrs post 
induction (figure 6.11).  It is possible that this lipidation profile might be secondary 
to a limiting polypeptide yield at this time point (not established). 
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The accumulation of protein-bound mycolic acids in the spent medium was not 
expected as accumulation of modified VapA in the outer membrane was envisaged. 
It is possible that accumulation of the protein at this site may have led to the 
formation of protein-bearing outer membrane vesicles. These are spherical, bilayered 
proteolipids with an average diameter of 20–200 nm that encapsulate various 
compounds such as lipopolysaccharide, lipids, soluble or membrane-associated 
proteins, genetic materials, and other factors associated with virulence in both Gram-
positive and Gram-negative bacteria. They perform various functions such as the 
transfer of proteins, cell-to-cell signalling, the elimination of competing organisms, 
and the delivery of toxins to host cells and are conserved across Gram-negative 
bacteria though they have also been reported in Gram-positive organisms such as 
Staphylococcus aureus (Lee et al., 2009; Berleman and Auer, 2013). They are 
discrete, closed outer membrane blebs produced by growing cells and not products of 
cell lysis or cell death which can often be deposited from a cell-free supernatant 
(Kuehn and Kesty, 2005).  In C. glutamicum, the shedding of significant amount of 
membrane vesicles and/or membrane fragments to the external culture medium is 
reported to be dependent on a highly perturbed cell wall which may occur as a result 
of deficiency in cell wall synthesis (Raad et al., 2010).  In this case, accumulation of 
recombinant VapA might be envisaged to cause disruption to the structure of the 
outer membrane. However when the culture supernatant was centrifuged at 100,000 
x g, no discernible pellet was formed, thus there was no visible evidence that outer 
membrane vesicles were shed. Performing the experiment at a larger scale (to 
increase the likelihood of detection) also showed a similar pattern thus the 
accumulation of VapA in the membrane may not cause significant disruption to the 
integrity of the cell wall. However, it is also possible that the density of such blebs 
Chapter Six Lipidation of VapA 
149 
 
might have caused them to be buoyant and that a thin layer of lipid material could 
have been overlooked at the surface. 
The next issue addressed was whether recombinant VapA was retained in the 
corynebacterial cell wall. Transformants (with pEKEx2-vapA) were grown and 
subjected to IPTG induction overnight. Proteins were extracted from both a plasma 
membrane fraction and the debris after clarification of the extract (which contains 
deposited wall materials) with SDS-Tris buffer and Urea-Tris buffer (as described in 
sections 2.8.13). Protein extracts were later analysed by Western blot using 
Mab10G5 as the primary antibody. These immunoblots show that VapA was 
detected in proteins from both the debris and the plasma membrane using both 
extraction systems (Figure 6.12). The retention in the cellular debris might suggest 
appropriate mycoloylation and location in the outer membrane of the heterologous 
host. 
The detection of a strong signal for VapA in the plasma membrane might indicate 
two populations of recombinant protein retained via different means. Firstly, some of 
the recombinant VapA might be associated with this fraction transiently, having been 
partially secreted at the point of extraction. Another explanation is that there is a 
contribution from mycoloylated protein retained here as an artefact of over 
expression and inappropriate/incomplete partitioning to the mycoloyl layer. Neither 
scenario has been rigorously investigated. 
 
 
 
Chapter Six Lipidation of VapA 
150 
 
 
 
Figure 6.12 Retention of recombinant VapA in cell wall material. 
Proteins were extracted using either SDS-Tris buffer or Urea-Tris 
buffer plasma membrane or wall-rich debris fractions. Proteins were 
separated using SDS-PAGE and immobilised on nitrocellulose 
membrane. VapA was visualised using Mab10G5 as a primary 
antibody. 
 
This preliminary result seemed to show that recombinant VapA could be bound to 
the cell wall of C. glutamicum in addition to being secreted. In order to improve our 
understanding of the subcellular distribution of VapA, the experiments were refined; 
the cell debris was washed and then subjected to density gradient centrifugation after 
re-suspension in 60 % Percoll. The final buoyant cell wall layer was washed free of 
Percoll in PBS. The clarified lysate was also subjected to ultracentrifugation to 
deposit the plasma membrane fraction as described in section 2.8.14. After 
standardising the total protein content of each, these plasma membrane and cell wall 
fractions as well as a secreted protein fraction (the cell-free culture supernatant) were 
analysed by Western blotting using MAb10G5 (Figure 6.13). 
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Figure 6.13 Refined fractionation of Recombinant VapA expressed in C. 
glutamicum. 
Proteins were extracted from the plasma membrane and purified cell 
wall fractions using SDS. Protein content-standardised samples of these 
fractions were electrophoresed alongside a secreted protein fraction 
from the same culture and immobilised on nitrocellulose membrane. 
VapA was visualised using Mab10G5 as a primary antibody. 
 
This enhanced protocol for following the subcellular compartmentation of VapA 
showed that the virulence-associated protein is primarily retained in the cell wall 
fraction of C. glutamicum, is considerably represented in the plasma membrane and 
is also secreted (Figure 6.13).  Thus, the processing of VapA could be similar in both 
R. equi and C. glutamicum. 
6.5 Site-directed mutagenesis 
Having established that protein extracts that include VapA from R. equi contain 
apparently covalently-linked mycolic acids, and that the over expression of 
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recombinant vapA in C. glutamicum causes an apparent marked mislocalisation of 
significant quantities of corynomycolic acids, and the protein is retained in purified 
cell wall material, we were encouraged to develop an alanine-scanning mutagenesis 
study to identify a lipidation sites using cell wall retention as a measure of lipidation. 
Mature VapA does not possess the terminal acylated N-terminal cysteine motif 
characteristic of membrane-anchored lipoproteins (Tan et al., 1995); in fact 
preproVapA does not even contain a cysteine residue. However, analysis of 
preproVapA via SignalP predicted its likely cleavage by signal peptidase between 
Ala31 and Thr32 (see Appendix E). A simply-drawn hypothesis is that this 
N-terminal threonine residue might be the site of an O-linked mycolylation. 
Countering this hypothesis is the evidence that N-terminal sequencing of mature 
native VapA has been achieved identifying Thr32 as the first product of the Edman 
degradation process (IC Sutcliffe, unpublished results). Likewise, if it is expected 
that VapA and VapB are similarly processed, Thr32 is not conserved. 
However, a Thr32Ala mutation was sought in the pEKEx2-vapA construct to test the 
hypothesis. Threonine has a hydroxyl side chain which could participate in O-linked 
modifications thus could provide a means of post-translational modifications of 
proteins (Mukherjee et al., 2007). Hence the substitution of threonine with alanine 
removes that possibility because of the lack of a hydroxyl group in alanine.  
Oligonucleotide primers were first designed for the amplification of pEKEx2-vapA 
in order to introduce a point mutation in vapA.  The aim was to substitute Thr32 to 
Ala by changing the codon ACC to GCC (using the primers shown in table 2.5). The 
plasmid pEKEx2-vapA was used as the template and amplified via PCR. After PCR, 
the mixture was subjected to restriction digestion using DpnI in order to digest dam 
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methylated parental DNA originally obtained from the dam positive E. coli Top10.  
Figure 6.14 shows an agarose gel electrophoresis image of the amplified plasmid 
before and after DpnI treatment. 
 
Figure 6.14 Gel image after amplification of pEKEx2-vapAmutant 
Figure shows products before and after DpnI treatment. Treatment of 
the product following PCR is designed to eliminate parental DNA 
(template DNA). 
 
The recombinant plasmid (PCR synthesised DNA) was used to transform competent 
E. coli Top10 cells and plasmid DNA was extracted after overnight culture of 
antibiotic-resistant colonies. In order to ensure that vapAThr32A was present, the 
plasmid was subjected to restriction digestion analysis using the enzymes EcoRI and 
KpnI.  
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The fluorescing bands pattern (data not shown) confirms the migration of pEKEx2 
(about 8161 bp) and vapAThr32Ala (570 bp) thus indicating the presence of the 
insert DNA in the plasmid.  The identity and integrity of the insert and mutation was 
confirmed by nucleotide sequence analysis. Corynebacterium glutamicum was later 
transformed with the plasmid to study the impact of the mutation on the subcelluar 
compartmentation of VapAmutant in that organism. 
6.6 Subcellular compartmentation of VapAmutant in Corynebacterium 
glutamicum 
Investigation of the behaviour of the Thr32Ala mutant in C. glutamicum revealed 
that the protein was still retained in the membrane and attached to the cell wall 
indicating that the mutation may not have a significant effect on the localisation of 
the protein (Figure 6.15) and perhaps lipidation.  This may indicate that Thr32 is not 
the site for VapA lipidation or that this single point mutation did not ablate 
functional lipidation, i.e. multiple sites might be lipidated. 
Since substitution of Thr32 to Ala seemed not to affect the subcellular localisation of 
VapA in Corynebacterium glutamicum, other mutants were sought since VapA 
possesses many other potential sites for O-acylation (Figure 6.16). In order to rapidly 
screen the entire Ser/Thr population in VapA, a strategy was developed that took 
advantage of clusters of these residues. These clusters were mutated as blocks in 
which all residues in that locale were mutated simultaeously. Should a profound 
change to subcellular location be evident, single mutations would be explored in each 
case to improve the resolution of the strategy to the single residue level. 
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Figure 6.15 The Thr32Ala mutation does not perturb recombinant VapA 
localisation in C. glutamicum 
Fractions of C. glutamicum pEKEX2-vapAThr32Ala were 
electrophoresed and immobilised on nitrocellulose membrane. VapA 
was detected using Mab10 G5 as primary antibody.  Fractions: Mem, 
plasma mebrane; Wall, purfied cell wall; BSP, secreted protein; Cyto, 
cytosol . Standardised loading of 5 µg protein were used throughout. 
 
 
 
Figure 6.16 Potential O-acylation sites of VapA 
Each coloured block was considered separately in the design of primers 
for site-directed mutagenesis (as shown in table 6.3). 
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Table 6.3 Targets for Alanine-scanning mutagenesis of VapA O-acylation 
sites 
Block ID 
(Mutant designation) 
Amino acyl sequence changes 
Native Mutant 
Block 2 
(S36A) 
VLDSGSSSAI VLDAGSSSAI 
Block 3 
(38SSS-AAA40) 
LDSGSSSAIL LDSGAAAAIL 
Block 4 
(45SGAGS-AGAGA49) 
LNSGAGSGIV LNAGAGAGIV 
Block 5 
(54SGS-AAA56) 
IVGSGSYDSS IVGAGAYDSS 
Block 6 
(59SSTTS-A(5)63) 
YDSSTTSLNL YDAAAAALNL 
Block 7 
(76SDT-ADA78) 
NGRASDTAGQ NGRAADAAGQ 
Block 8 
(S93A) 
GDVISAVVYQ GDVIAAVVYQ 
Block 9 
(T118A) 
AGGLTLPGAG AGGLALPGAG 
Block 10 
(128TLTF-ALFA131) 
FWGTLFTNDL FWGALFANDL 
Block 11 
(141TVS-AVA143) 
YKDTVSFQYN YKDAVAFQYN 
Block 12 
(160SSGS-AAGA163) 
FFDSSGSFLG FFDAAGAFLG 
Block 13 
(S170A) 
GHIQSGGVST GHIQAGGVST 
Block 14 
(174ST-AA175) 
GGVSTVVGVG GGVAAVVGVG 
Block 15 
(183SGS-AGA185) 
GGGSGSWHNA* GGGAGAWHNA* 
 
In all cases, targets were successfullly mutated to encode alanines using mutagenic 
primers described in table 2.5. Corynebacterium glutamicum was transformed with 
the pEKEx2-vapA mutants and the subcellular localisation of the mutant protein was 
investigated in each case.  The results revealed no significant change in the 
distribution of VapA (Appendix H). Logical analysis of this outcome did not exclude 
a covalent lipid/mycolic acid modification of VapA.  That no changes in 
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compartmentalisation were seen in any of the mutants might indicate that a mycolic 
acid modification is not absolutely critical with regard to the retention of VapA in 
wall material within this heterologous system. An alternate explanantion is that a 
unique mycolylation is sufficient for retention but does not represent the biological 
norm, i.e. multiple sites are lipidated.  However, with the significant circumstantial 
evidence suggesting a co-purification of protein–bound mycolates and VapA in C. 
glutamicum and R. equi, an in vitro assay was sought that might provide a superior 
analysis. 
6.7 Analysis of mycoloyl transferase activity in VapA acylation 
Recently, a study of porin mycoloylation activity across a panel of C. glutamicum 
mutants demonstrated that mutation of Cg0413, which encodes the 
mycolyltransferase Cmt1, was the cause of a loss-of-function in this respect (Rath et 
al., 2013). Two approaches were taken with the aim of confirming the circumstantial 
evident for VapA mycoloylation via an in vitro enzyme assay. Firstly, it was 
considered that the activity of Cmt1 might be explored with VapA as a terminal 
acceptor of mycolic acids derived from extractable glycolipid fractions of 
representative mycolata. Secondly, a bioinformatics approach could be taken to seek 
a Cmt1 orthologue(s) in R. equi. 
6.7.1 Extraction of Corybacterium glutamicum genomic DNA 
In order to amplify Cg0413, a high quality DNA preparation was required to serve as 
a template for polymerase chain reaction. The extraction of genomic DNA from C. 
glutamicum ATCC 13032 was performed as described in section 2.7.1.  The result 
was DNA of high quality (> 10,000 bp) which migrated as a single band on agarose 
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gel electrophoresis (Figure 6.17). The DNA was not fragmented and there was no 
low molecular weight contaminating nucleic acid. The DNA was considered 
appropriate to be used as a template for PCR. 
 
Figure 6.17 Analysis of Corynebacterium glutamicum genomic DNA 
H represents hyperladder I. 
 
6.7.2 Amplification of Cg0413 
The open reading frame encoding corymycoloyltransferase 1 (designated Cg0413) 
was amplified without the signal peptide region for cloning into pET23a and pET28a 
for production with a C-terminal or N-terminal hexahistidine tag respectively. 
Electrophoresis revealed that the reaction generated a DNA band migrating 
consistently with the expected 1008 bp product (Figure 6.18). The product was 
purified from agarose and subjected to restriction digestion for cloning into vectors. 
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Figure 6.18 PCR amplification of Cg0413 
PCR reaction was performed as described in sections 2.7.3 with 
oligonucleotide primers in table 2.1. H represents Hyperladder I. 
 
6.7.3 Cloning of Cg0413 into vectors 
The amplified Cg0413 was purified, digested with the restriction endonucleases NotI 
and NdeI and purified from agarose.  Thereafter the digested products were ligated to 
pET23a and pET28a (also digested with NotI and NdeI) as described in the methods 
section. The ligation mixture was used to transform competent E. coli Top 10. 
Plasmid DNA was recovered from antibiotic resistant transformants and screened for 
the release of Cg0413 (migrating consistent with ~1000 bp fragment) after digestion 
with NdeI and NotI and subsequent electrophoresis (Figure 6.19). The sequence of 
the selected clones was confirmed by nucleotide sequencing. 
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Figure 6.19 Restriction digestion analysis of recombinant plasmids pET23-
Cg0413 and pET28-Cg0413 
The bands clearly reveal the successful cloning of the cmt  gene into 
the plasmids. 
 
6.7.4 Expression and purification of Cmt1 corynomycoloyl transferase 
Sequencing results were in the affirmative since the gene was in frame with no 
mutation thus recombinant plasmid was used to transform E. coli BL 21 (DE3) cells. 
A single colony was grown in 10 mL LB broth (with antibiotic) as a starter culture 
overnight at 37°C with shaking at 200 rpm. This was used to inoculate 1 litre of 
terrific broth (with appropriate antibiotic) and grown at 37°C to OD600 of about 0.8. 
Isopropyl ȕ-D-1-thiogalactopyranoside (IPTG) was added to a final concentration of 
1 mM and incubated overnight at 20°C. After overnight incubation, cells were 
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harvested, re-suspended in lysis buffer, sonicated and clarified as described in section 
2.8.5. Protein was purified in a single step via immobilised metal affinity 
chromatography as described in section 2.8.7.1. For both variants, there was 
significant gene expression. SDS-PAGE profile of peak fractions after IMAC for N-
terminal hexa-histidine tagged protein is shown in figure 6.20. 
 
Figure 6.20 Peak fractions of Cmt1 subjected to SDS-PAGE following IMAC 
‘M’ size  markers; 20 kDa (Trypsin Inhibitor from soybean), 29 kDa 
(carbonic anhydrase from bovine erythrocytes), 36 kDa 
(glyceraldehyde-3-phosphate dehydrogenase from rabbit muscle), 45 
kDa (ovalbumin from chicken egg). 
 
6.7.5 Extraction of cell wall associated lipids 
Extractable cell wall associated lipids were considered as suitable substrates for 
studying protein mycoloylation. Lipids that are non-covalently associated with the 
rhodococcal cell envelope include TDMs and TMMs. TMM has been used as a lipid 
donor in mycoloylation reactions catalysed (addition of mycoloyl residue from TMM 
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to another TMM molecule in the synthesis of TDM) by the Mycobacterium 
tuberculosis Ag85A which is an homologue of Cmt1 (Kremer et al., 2002; Elamin et 
al., 2009; Huc et al., 2013). Thus the surface lipids of both Rhodococcus equi and 
Corynebacterium glutamicum were considered as potential sources of mycolates for 
the lipidation of VapA in an in vitro model.  Hence crude preparations of the surface 
attached lipids were made from C. glutamicum and R. equi. The composition of the 
extracts from each microorganism varied markedly. The extract from R. equi showed 
the majority to be in the form of TDM, while in the extract of C. glutamicum, TMM 
dominated (Figure 6.21). 
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Figure 6.21 Compositonal analysis of envelope glycolipids of R. equi and C. 
glutamicum 
Lipids extracted with chloroform:methanol and loaded on silica.  TLC 
was developed with chloroform:methanol:water (60:16:2). Lipids were 
visualised by staining with 5 % ethanolic phosphomolybdic acid and 
charred. TDM (trehalose dimycolate) and TMM (trehalose 
monomycolate) were identified by comparison to similar profiles 
(Brand et al., 2003) 
 
6.7.6 Mycoloyltransferase assay 
Cell wall associated lipids (dried) were re-suspended in buffer as detailed in section 
2.10.1. In the complete reaction, the lipid suspension was mixed with VapA (1 
mg/mL) and the reaction was initiated by the addition of Cmt1 (1 mg/mL) and 
incubated for 45 min as described in section 2.10.1. Enzymes tagged at both termini 
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were used with identical outcomes. Additionally, both variants of hexahistidine 
tagged mature VapA were used, again with identical outcomes. A series of controls 
excluding individual components were conducted simultaneously. Aliquots of the 
various reactions were subject to Urea PAGE which has been used to demonstrate 
various acyl:protein adducts (Brown et al., 2005). 
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Figure 6.22 Urea-PAGE profile of Cmt assay using lipids from C. glutamicum 
as donors and VapA as an acceptor substrate 
Volumes are 10 µL of Cmt (1 mg/mL) and VapA (1 mg/mL), 5 µL of 
lipid solution.   
 
When the mycolyltransferase was incubated with VapA and lipids from C. 
glutamicum, no shift in the mobility of VapA or Cmt1 was evident (Figure 6.22).  
However comparison of the banding profiles generated by Cmt1 alone and the 
protein incubated with lipids revealed a faint but reproducible band (arrowed) 
migrating more quickly than the recombinant enzyme. This banding pattern could 
indicate the limited formation of an acyl enzyme intermediate at an active site serine 
residue consistent with the recognised mode of action of mycobacterial 
mycolyltransferases (Belisle et al., 1997) and other esterases. Its presence in the 
complete assay would likely have been masked by the VapA component. 
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When similar reactions were carried out using R. equi lipids, a similar shift in 
migration was evident but this putative acyl enzyme intermediate (arrowed) appeared 
far more abundant in this instance when using heterologous lipids (figure 6.23), 
although there is a recognised overlap in acyl chain length (Sydor et al., 2013).  
Again no shifts in the migration of VapA were noted. 
 
 
Figure 6.23 Urea-PAGE profile of Cmt assay using lipids from R. equi and 
VapA as substrates 
Volumes are 10 µL of Cmt (1 mg/mL) and VapA (1 mg/mL), 5 µL of 
lipid solution 
 
Encouraged by the possibility of the formation of an acyl:enzyme intermediate, 
efforts were made to refine this assay approach.  The enzyme was incubated with the 
lipids from both sources in different proportions and was analysed by Urea-PAGE as 
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before. It was hoped that optimising lipid loading to the enzyme might enable 
detection of lipid transfer to VapA in the final stage of the complete reaction. 
 
Figure 6.24 Optimisation of adduct formation between Cmt and cell wall 
associated lipids from C. glutamicum. 
Crude lipids were solubilised in Tris-DTT and incubated with Cmt (1 
mg/mL) as indicated.  
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Figure 6.25 Urea-PAGE profile of optimisation of adduct formation between 
Cmt and cell wall associated lipids from R. equi. 
Crude lipids were solubilised in Tris-DTT and incubated with Cmt (1 
mg/mL) as indicated 
 
Figures 6.24 and 6.25 show that the lipids from both systems appeared to form 
apparent adducts with the enzyme. This was dependent on the volume of lipid 
suspension applied and thus appeared concentration dependent. Reducing the volume 
of the enzyme (5 µL) also reflected on the adduct formation. In both cases, optimum 
conditions were found when 10 microlitres of protein (1 mg/mL) were mixed with 15 
microlitres of lipids. It is interesting to note that the banding profile of Cmt1 on 
Urea-PAGE is complex, especially in the absence of lipid. Here multiple slowly 
migrating forms are evident relative to the modal state. Titration with lipids refined 
the profile with the less abundant forms appearing to unify into the putative adduct 
band with a relatively smaller impact on the abundant form of the enzyme.  Attempts 
to extract lipids from the recovered adduct as methyl esters (as with all other 
extractions of potentially acylated proteins from polyacrylamide in this study) 
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yielded no detectable MAME on MALDI-TOF analysis. This could be interpreted as 
indicating a lack of lipid in this material, its induced novel migration being the result 
of a lipid-driven denaturation of the enzyme, or simple poor recovery of bona fide 
acyl adducts from gels. 
The complete mycoloyltransferase assays were carried out with optimised 
enzyme:lipid composition being combined with VapA as a terminal acceptor for the 
lipids. In the first instance, all the components i.e. VapA, lipids, and Cmt were added 
at the same time while in the other case, Cmt and the lipids were incubated for 30 
min before addition of VapA and incubation for a further 30 min. Analysis on Urea-
PAGE revealed that no modification to the migration of VapA was seen with either 
methodology (Figures 6.26 and 6.27). 
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Figure 6.26 Urea-PAGE profile of Cmt assay using lipids from C. glutamicum 
and VapA as substrates 
Volumes are 10 µL of Cmt (1 mg/mL) and VapA (1 mg/mL), 10 µL of 
lipid solution. The asterisk indicates that Cmt and lipids were incubated 
for 30 min before adding VapA 
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Figure 6.27 Urea-PAGE profile of Cmt assay using lipids from R. equi and 
VapA as substrates 
Volumes are 10 µL of Cmt (1 mg/mL) and VapA (1 mg/mL), 10 µL of 
lipid solution. The asterisk indicates that Cmt and lipids were incubated 
for 30 min before adding VapA 
 
Several possible explanations for the apparent lack of transfer of lipids to VapA 
exist. Firstly, the hypothesis that Cmt1 can mycolyolate VapA in vivo might be 
rejected, the body of circumstantial evidence being rejected as artefact. However, 
explanations that conserve the hypothesis remain. It is possible that (i) the 
recombinant Cmt1 preparation is inactive and the various putative mycoloyl adducts 
are artefactual, (ii) the Cmt1 preparation is active and the various putative mycoloyl 
adducts are real but VapA is presented in a non-accepting configuration and (iii) the 
composition of the urea gel is appropriate for revealing formation of an acyl:Cmt1 
intermediate but not for the resolution of a VapA adduct. 
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In order to explore these possibilities via a more sensitive and discriminating assay, 
14C radiolabelled lipids from Mycobacterium bovis BCG (a gift from Prof G. Besra) 
were used in the similar mycoloylation assays. 
 
 
Figure 6.28 Autoradiogram Urea-PAGE profile of Cmt assay using 
radiolabelled lipids from Mycobacterium bovis BCG and VapA as 
substrates 
Volumes are 10 µL of Cmt (1 mg/mL) and VapA (1 mg/mL), 10 µL of 
lipid solution. The asterisk indicates that Cmt and lipids were incubated 
for 30 min before adding VapA 
 
Autoradiography (Figure 6.28) of a Urea-PAGE gel indicated the presence of a 
single radio-labelled species with a similar rate of migration to the apparent adduct 
seen with lipids from other sources. This is interpretted as indicating a significant 
stable association of M. bovis lipids with the mycolyltransferase and essentially 
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rejects (i) above. This would also indicate that Cmt1 might have a very relaxed 
specificity for mycoloyl substrate chain-length. However, as this experiment did not 
generate any other bands associated with expected VapA migration, it revealed no 
evidence for any lipid transfer to VapA, rejecting (iii) above. 
It remains possible that the conformation of the accepting protein is critical for 
activity. When one considers that lipoprotein processing is simultaneous with plasma 
membrane secretion (Sutcliffe and Harrington, 2002) then a folded purified (and 
artificially tagged) protein might not readily interact with an active Cmt1 
preparation. It is notable that an in vitro demonstration of Cmt1 modification of its 
only experimentally-validated substrate (PorA) was not a feature of its recent 
characterisation (Rath et al., 2013).  Exploration of small peptide fragments of VapA 
and PorA as acceptor substrates that might emulate less-structured forms of those 
proteins would be warranted. 
6.7.7 Identification of putative mycoloyltransferase of Rhodococcus equi 103S 
During the conduct of this study the product of C. glutamicum cmt1 (Cg0413), an 
already recognised mycolyltransferase (Brand et al., 2003) was demonstrated to 
carry a protein mycolyltranferase activity (Huc et al., 2013). Furthermore, 
orthologues were identified from Mycobacterium and Rhodococcus erythropolis RP4 
through their ability to complement an in-frame cmt1 deletion mutation evidenced by 
the restoration of mycolylation of the porin substrate proteins CgPorAB.  In order to 
establish the identity of any Rhodococcus equi orthologue and study its 
mycolyltransferase activity with respect to VapA modification, Cmt1 was used as a 
query in BLASTP (Altschul et al., 1990)  searching the R. equi 103S proteome.  Four 
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sequences were recognised with alignment scores =>200 and E values < 4x10-63 
(Table 6.4).   
It is likely that the mycolylation of proteins is a critical component process that 
contributes to the population of the mycolate membrane with proteins. The molecular 
basis of protein trafficking and insertion is inherently interesting given the unusual 
composition of these membranes. Study of the three genera Rhodococcus, 
Mycobacterium and Corynebacterium offers opportunities for comparisons of 
physical properties and recognition of any attendant biological modifications that 
may greatly extend our current understanding of the function of this key biological 
structure. All three genera include significant pathogens. It is well recognised that 
surface structures are critical to key aspects of infection including adherence, nutrient 
acquisition, cellular and tissue invasion, and immune modulation. Experimental 
definition of substrate protein recognition motifs might help establish a surface-
exposed target for anti-infective discovery. In order to achieve this, a biochemical 
characterisation of protein mycolylation is required. In order to facilitate this study in 
R. equi, a strategy was required to identify candidate genes for cloning and product 
characterisation. 
A feature of all of the mycolata is their apparent redundancy in mycolyltransferase 
activity. Before its association with protein acceptors of mycolic acids, Cmt1 was 
shown to participate in the synthesis of the trehalose dicorynomycolate 
glycoconjugate. Given this apparent redundancy and the promiscuity exhibited by 
individual enzymes in terms of acceptor specificity, it is important to carefully 
consider sequence data before defining characterisation studies.  In order to establish 
strong candidacy for orthology, in terms of its protein mycolyltransferase activity, it 
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is important to establish that homologues generated in this initial BLASTP screen 
identify Cmt1 as best match when used as a query. The protein sequence for each of 
the R. equi 10γS ‘hits’ was then used as a query in a BLASTP search of the C. 
glutamicum ATCC 13032 proteome. Interestingly, these reciprocal analyses revealed 
that each of the 4 candidate R. equi mycolyltransferase sequences shared strongest 
homology with C. glutamicum Cmt1 (NP_599594.1), which given the most trivial 
interpretation, might suggest significant redundancy in provision for protein 
mycolyltransferase activity in R. equi.  
The amino acid sequence of R. erythropolis PR4 RER_15370 (Genbank PID 
YP_002764984.1), which restored protein mycolyltransferase activity in the C. 
glutamicum Δcmt1 mutant, was used as a query in a BLASTP search limited to R. 
equi 103S.  This search generated nine hits with alignment scores =>200 and e scores 
< 5x10-77 (Table 6.5). 
The existing annotations associated with these hits were of two types: esterase or 
secreted esterase. It is well established that mycolyltransferase activity is associated 
with the pseudoperiplasm and this had been recognised for Cmt1 through its 
possession of a signal peptide leader sequence.  Two of these interesting hits, namely 
REQ_32810 and REQ_02570 (ranked 1 and 4 respectively, Table 2) were annotated 
as esterases. Individual scrutiny of both of these archived predicted protein 
sequences using SignalP4.1 (Peterson et al., 2011) failed to identify a canonical 
signal peptide for REQ_32810 but did recognise REQ_02570 as a putative secreted 
protein.  It is noteworthy that SignalP3.0, which was current at the time of annotation 
predicted a non-secreted protein. 
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Table 6.4  Identification of Rhodococcus equi protein mycolyltransferase 
candidates based on Cmt1 homology.  
R. equi 103S BLASTP hit E value Reciprocal C. glutamicum 
BLASTP hit 
E value 
1 
YP_004007959.1 
REQ_32180 
1x10-85 
1 NP_599594.1 4 x10-87 
2 YP_225214.1 6 x10-64 
3 NP_600254.1 3 x10-49 
4 YP_227116.1 2 x10-48 
2 
YP_004008131.1 
REQ_34590 
7 x10-78 
1 NP_599594.1 6 x10-83 
2 YP_225214.1 6 x10-61 
3 YP_227116.1 2 x10-48 
4 NP_600254.1 4 x10-47 
3 
YP_004005782.1 
REQ_09940 
9 x10-70 
1 NP_599594.1 8 x10-70 
2 YP_225214.1 2 x10-54 
3 NP_600254.1 3 x10-45 
4 NP_602067.1 8 x10-42 
4 
YP_004005093.1 
REQ_02570 
7 x10-67 
1 NP_599594.1 7 x10-67 
2 YP_227116.1 3 x10-60 
3 NP_600254.1 2 x10-57 
4 NP_601385.1 9 x10-42 
The amino acid sequence of the experimentally-validated protein mycolyltransferase C. glutamicum 
Cmt1 was used as a BLASTP search limited to R. equi 103S. Candidates with strong alignment scores 
(+>200) (identified by Genbank PID) were used as BLASTP queries of C. glutamicum ATCC 13032. 
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Table 6.5  Identification of Rhodococcus equi protein mycolyltransferase 
candidates based on RER_15370 homology. 
Rank Description Total 
score 
Query 
cover 
E value Identity Accession 
1 esterase 486 89% 8x10
-172 72% YP_004007959.1 
REQ_32810 
2 secreted esterase 401 81% 1x10-139 69% YP_004008131.1  
REQ_34590 
3 secreted esterase 382 99% 1x10-131 55% YP_004005782.1  
REQ_09940 
4 esterase 286 96% 2x10-94 44% YP_004005093.1  
REQ_02570 
5 secreted esterase 285 97% 4x10-94 46% YP_004008589.1  
REQ_39250 
6 secreted esterase 280 84% 3x10-92 48% YP_004008523.1  
REQ_38570 
7 secreted esterase 249 80% 7x10-80 44% YP_004006071.1  
REQ_12940 
8 secreted esterase 248 86% 4x10-79 41% YP_004009020.1  
REQ_43790 
9 secreted esterase 242 85% 5x10-77 42% YP_004006331.1  
REQ_15690 
The amino acid sequence of the experimentally-validated protein mycolyltransferase Rhodococcus 
erythropolis PR4 RER_15370 was used as a BLASTP search limited to R. equi 103S.  Statistics 
describing candidates with strong alignment scores (+>200) are tabulated. 
 
 
However, analysis of sequence alignments (AlignX) revealed that REQ_32810 was 
predicted to carry a significant N-terminal extension of between 47 to 60 amino acids 
relative to Cmt1 and R. equi homologues (Figure 6.29).  Five other potential start 
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codons (A/G-TGV/M) could be considered for REQ_32810, two coincide with 
positions in the alignment that correspond to predicted N-termini of REQ_02570 and 
Cmt1 respectively, while one coincides with that for both REQ_09940 and 
REQ_34590. 
 
 
Figure 6.29  Alignment of predicted gene products representing closest R. equi 
homologues of C. glutamicum Cmt1 used to explore alternate N-
terminus for REQ_32810.  
Alignments were generated using the AlignX within Vector NTI 
(Invitrogen) 
 
Analysis of predicted REQ_32810 gene products initiated at each of the alternate 
initiation codons using SignalP4.1 revealed a likely signal peptide if the N-terminus 
occupied position 61 by the current numbering, which would be coincident with the 
N-termini of both REQ_09940 and REQ_34590. On the basis of a likely 
misinterpretation of the site of translation initiation and its strongest homology with 
Cmt1 of R. equi gene products, REQ_32810 was retained in the set of candidate 
protein mycoloyltransferases; in subsequent sequence alignments, residue M61 was 
assumed the N-terminus of the nascent REQ_32810 protein. 
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When the amino acid sequences of each of the 9 RER_15370 homologues were used 
as a BLASTP query of C. glutamicum ATCC 13032, those ranked 1-6 (Table 6.5) all 
showed greatest homology with Cmt1. The difference in the extent of amino acid 
identity between those ranked 2 (69%) and 3 (55%) is marked and might indicate 
some resolution in biochemical role and substrate selectivity.  Those ranked 1 and 2, 
REQ_32810 and REQ_34590 respectively share 72% and 69% sequence identity 
with respectively RER_15370 and 66% with each other.  Both might be considered 
strong candidates, efforts to clone these enzymes toward the end of this study were 
unsuccessful. 
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 CHAPTER SEVEN 
7 General discussion 
Despite research into Rhodococcus equi pathogenesis, rhodococcosis remains a 
major cause of wastage in the equine industry. Though foals are able to develop 
protective immunity against infection, there are still no registered vaccines against 
rhodococcosis (Lohmann et al., 2013). This lack of vaccines could be primarily 
attributed to the complexity of the immunity to R. equi; the disease affects foals 
under six months of age, thus a vaccine must provide protection against R. equi 
infection early in life (Bordin et al., 2013). 
Because of the intracellular nature of the organism, the range of antibiotics that could 
be effective in the treatment of R. equi infections is limited. Treatments involving 
combinations of rifampin (or doxycycline) with other antibiotics such as 
azithromycin, clarithromycin has been recommended but have produced mixed 
results (Giguere et al., 2012; Venner et al., 2013). However, the emergence of 
antibiotic-resistant strains which tolerate macrolides and rifampin has led to concern 
around the definition of an effective treatment strategy (Yamshchikov et al., 2010; 
Burton et al., 2013). 
The ability of Rhodococcus equi to survive in the harsh macrophage environment is, 
in part, defined by its complex cell envelope. The wall’s configuration offers some 
resistance to antibiotics.  Mycolic acids present a formidable permeability barrier and 
channel-forming porins control access through their selectivity. The biosynthesis and 
assembly of its dominant components such as mycolic acids and arabinogalactan 
could represent useful drug targets (Prescott, 1991; Sutcliffe et al., 2010). 
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More broadly, both chromosomal and plasmid-encoded factors have been identified 
as potential drug targets for Rhodococcus equi infections. Important chromosomal-
encoded factors include the enzymes of aromatic acid biosynthesis (Letek et al. 
2010,), enzymes of steroid catabolism (van der Geize et al., 2011), nitrate reductase 
(Letek et al., 2010) and rhequichelin (Miranda-CasoLuengo et al., 2012). The 
plasmid encoded factors are mainly proteins (which are secretory in nature) 
expressed by genes of the vap cluster of the pathogenicity island (Meijer and 
Prescott, 2004). 
Secretory proteins especially of intracellular pathogens are often in direct contact 
with host tissues and thus are of utmost importance in the investigation of bacterial 
pathogenesis. Rhodococcus equi expresses a group of Virulence associated proteins 
(Vaps) that are encoded by the vap locus of the plasmid-borne pathogenicity island 
which contributes significantly to pathogenesis. Almost all Vaps are secreted, 
diffusible and immunogenic and thus are primary targets for vaccine development, 
but VapA (a surface-located protein) been shown to induce the strongest immune 
response in both foals and adult horses (Kaufmann and Hess, 1999; Byrne et al., 
2008; Dawson et al., 2010). 
VapA has been shown to be a major virulence determinant since mutants that lack its 
gene were attenuated to the same degree as a mutant that lacks the majority of the 
vap locus. Nevertheless VapA alone is not sufficient to support the ability to 
replicate in the macrophage (Jain et al. 2003, Vazquez-Boland et al., 2013); that may 
require interplay of various factors. Despite many years of study, the mechanism by 
which Vaps exert their effects remains unclear. One avenue for research was to 
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address the lack of understanding of the structural basis for virulence; this was the 
main focus of chapter four. 
The apparently dominant role of VapA in virulence, despite its limited mobility in 
comparison to other closely-related Vaps, remains interesting. The tethering of this 
protein at the cellular surface was considered as an interesting rationale for its 
ascendency. Disruption of this tethering may limit virulence and extend knowledge 
regarding its mode of action.  In this regard, identifying the nature and the site of the 
lipid modification evidenced elsewhere by radiolabelling with 3H-palmitate (Tan et 
al, 1995) was a major goal (Chapter six). 
 It was also considered that the Vaps might act in a concerted fashion, their similarity 
might promote assembly of a cell surface structure tethered by VapA to the mycolic 
acid layer of the outer wall. In order to explore this hypothesis, a biophysical 
approach to monitoring Vap interactions was taken in Chapter five. 
7.1 Production, purification and structural characterisation of Vaps 
Apart from VapC, all of the Vaps of Rhodococcus equi 103S were produced in E. 
coli and purified using a combination of metal chelate affinity chromatography 
followed by anion exchange chromatography. Given the overall similarity of this 
family of proteins, the lack of success in achieving reasonable yields of VapC is 
puzzling. In order to make progress, VapC was omitted from further studies but it 
would be valuable to explore the reasons for the poor yield in future. Modifications 
to replace any uncommon E. coli codons or to remove secondary structures in 
mRNA that might inhibit translation (Usha et al., 2006) could be considered.  
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Although all of the C-terminally hexahistidine-tagged Vap proteins tested 
concentrated well, only VapG crystallised.  Several crystal forms were achieved but 
one diffracted well to 1.8 Å.  At this time we became aware that VapD had also been 
crystallised, its structure was resolved first (Whittingham et al., 2014) via the 
addition of extra methionine residues wherever those were found in other Vap 
proteins. This led to resolution of phase via analysis of selenomethionine containing 
crystal. This success accelerated solving of VapG by molecular replacement based 
on the new VapD structure. Both structures revealed a core structure of an 8-stranded 
closed ȕ-barrel representing the C-terminal part of the molecule. The N-terminal 
sequences in both cases appeared to be missing but given that the crystallisation of 
intact pure protein was rapid, they appear likely to be unstructured, rather than 
having been lost via degradative processes in each case. While solving the crystal 
structure, we also became aware that crystal structure of VapB had also been solved. 
All three proteins possessed a similar ȕ-barrel topology, which has not been found in 
any other protein from other organisms. Although many outer membrane proteins 
from Gram-negative bacteria are ȕ-barrel shaped (Mizianty and Kurgan, 2011), these 
barrels are typically embedded in the bacterial outer membrane having a hydrophobic 
exterior face and a more polar internal aspect and represent water-filled channels 
(Rigel and Silhavy, 2012). The uniqueness of the Vap structure could be an 
important feature for this group of proteins. 
VapG differed from VapD in that two molecules were present in the asymmetric unit 
of the crystal. The barrel of that designated as molecule 1 exhibited a bound metal 
ion, which appears to be potassium, the corresponding site of molecule 2 was 
unoccupied. Whether the potassium ion is of physiological relevance is not known 
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since the mother liquor contained potassium chloride. Most of the co-coordinating 
groups were related to main chain atoms and a water molecule but mutation of  
residue Asn 107 and Asn 114, which had side chain ligands, combined with 
biochemical techniques such as isothermal titration microcalorimtery would allow 
investigation of specificity and affinity. 
Homology modelling of the other Vap proteins revealed that they conformed well to 
this topology. Although no functional insight can be immediately drawn from these 
structures, the bipartite organisation into an unstructured N-terminal region and a 
highly conserved closed ȕ-barrel core appears to be a common feature of these 
proteins. The flexibility that this N-terminus exhibits might allow it to interact freely 
with other proteins, either host-derived or bacterial, including other Vaps. It seems 
less likely to represent an anchoring device to the mycolate membrane as it is not 
restricted to VapA and VapB. Now that the boundaries of these domains are 
understood, these can be dissected through molecular approaches to define individual 
functions and synergies using both infection based and biochemical investigations.  
In terms of the structured core domain, we now possess a valuable blue-print for 
structure: function studies. 
Chapter five also reported the effect of metals on the hydrodynamic behaviour of 
VapA and VapG using analytical ultracentrifugation. While both proteins (at 1 
mg/mL) exist in a monomer-dimer equilibrium, K+, Ca+, Li+ seem to reduce the 
tendency of VapG to dimerise. In both cases, the apparent molecular masses were 
found to be higher than the calculated molecular masses of each recombinant 
molecule which could be ascribed to the possession of a disordered N-terminus.  The 
self-association of VapA might be attributed partly to the intrinsic ability of the 
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protein to dimerise (since the protein exists as a monomer and a dimer) while the 
self-association of VapG was caused by the forces of sedimentation. This might have 
led to the effect of the metals on the hydrodynamic traits of the proteins. 
7.2 Interaction of Vaps in free solution with immobilised VapA  
Since VapA alone could not confer on the organism the ability to proliferate in 
macrophages, and expression vapA and other Vap genes is under the control of the 
VirR operon (Wang et al., 2014), functional interaction between VapA and other Vap 
proteins was possible. In chapter five, the study sought to determine whether Vaps in 
free solution could interact with an immobilised VapA. It was demonstrated via 
surface plasmon resonance that VapA could interact with all the other Vap proteins 
(except VapD). Vap G associated and dissociated rapidly while VapE and VapH 
associated and dissociated at a slower rate. The low micromolar equilibrium 
dissociation constant is consistent with a transient interaction. These observations are 
very preliminary; the study will be extended to address several considerations. The 
immobilisation of VapA could have occurred via two lysine residues, one in the 
unstructured N-terminus and the other in the ȕ-barrel core. Alternative 
immobilisation strategies could utilise N- and C-terminal hexahistidine-tagged ligand 
via these tags on NTA-chips to explore the consequences of immobilisation mode.  
As VapA is induced at acidic culture pH, the effect of pH on these interactions 
should also be explored. Likewise, the impact of possible binding of K+ by VapG 
could be explored by incorporating the metal in the buffers. Additionally, it is also 
possible that multi-Vap assemblages could form and that associations might be 
stabilised by subsequent binding of other partners.  All of these scenarios can be 
explored using the SPR methodology. 
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7.3 Lipidation of VapA and other envelope proteins 
Chapter six focussed on the lipidation of envelope proteins of Rhodococcus equi.  
Available evidence suggests that VapA is lipidated as it incorporates radiolabelled  
3H-palmitate (Tan et al., 1995), but it seems to be an unusual protein since its 
lipidation may be independent of lipoprotein diacylglycerol transferase (Lgt), which 
is a key enzyme in lipoprotein processing (Meijer and Prescott, 2004). 
Some lipoproteins are non-covalently associated with the mycoloyl layer of the cell 
wall and, in the case of C. glutamicum porins, the proteins are covalently linked to 
mycolates.  In the latter case, it has been reported that such mycoloylation is critical 
for those proteins to function (Huc et al., 2010). In fact many porins discovered in 
mycolic acid containing bacteria are integral membrane proteins thus could be 
lipidated (Siroy et al., 2008; Rath et al., 2011). Membrane proteins were extracted 
from Rhodococcus equi and VapA was confirmed to be among them. Further 
chemical analysis revealed that collectively, these proteins possess mycoloyl 
residues. When vapA was over expressed in C. glutamicum an increase in lipidation 
was seen.  Although the study demonstrated protein mycolylation in Rhodococcus, a 
formal link to Vap was not achieved. Attempts to analyse lipids released from 
proteins recovered from polyacrylamide gels were unsuccessful. 
Although the evidence suggested that mycolylation of VapA was a distinct 
possibility, a bioinformatic approach to identify a likely lipidation site was not 
possible.  Although C. glutamicum PorA/H are lipidated via a mycolyl residue (Rath 
et al., 2013) they do not share any obvious sequence motif with the VapA/B.  
Initially Thr31 was identified as the putative lipidated residue in VapA as it occupied 
the position immediately after the predicted signal peptidase cleavage point 
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analogous to the cysteine residue usually modified in typical lipoproteins. As the link 
between lipid modification and membrane retention was anticipated to be critical, 
analysis of subcellular localisation was considered as a means to relate structure to 
function. Mutating Thr31 to Ala did not affect the subcellular localisation of the 
protein in C. glutamicum. All other threonines and serines were mutated and equally 
this did not change the subcellular localisation of VapA in C. glutamicum.  In the 
light of structural data, the hydrophobic ‘top’ of the Vap molecules emerged as an 
alternate means of associating with the mycolate membrane. Alternatively, multiple 
mycolylation sites might be deployed and loss of one if the protein were in a dimeric 
form, might not equate to a loss of membrane association. 
Recently a different strategy was used to investigate site of mycoloylation of PorH in 
Corynebacterium glutamicum. This involved a combination of 2D and 3D NMR 
through 1H and 15N protein assignment and partial 13C assignment of protein residues 
and mycolic acid protons and carbons combined with MALDI-TOF MS (Rath et al., 
2013). A similar strategy could be adopted to investigate the site for mycoloylation 
of VapA. Though lipidations on threonine and serine have been widely reported for 
membrane anchored lipoproteins, tyrosine is also a possible residue (Rath et al., 
2013). 
In the structured barrel core of the VapA model, the side chains of Tyr 66, Thr 97, 
Ser 132, Ser 152 and Ser 154 (which occur in sheet motifs) are exposed (though Ser 
152 and 154 are at the C-terminus) (Figure 7.1). The rest are either embedded inside 
the core (thus may not be solvent-exposed) or occur in the inter strand regions.  This 
non-uniform distribution of these unique polar residues could be critical in designing 
an experimental strategy for mutagenesis. 
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Since mycoloylation of small proteins in Corybacterium glutamicum (e.g PorA ) is 
catalysed by a mycoloylation transferase (Huc et al., 2010), it was envisaged that 
VapA could also be lipidated via a similar mechanism since lipoproteins and channel 
forming porins are non-covalently attached to the wall (Sutcliff et al., 2010). 
However, corynemycoloyl transferase did not catalyse the lipidation of VapA using 
extractable lipids from Rhodococcus equi, Corynebacterium glutamicum and 
Mycobacterium bovis BCG. In addition to catalysing the mycoloylation of small 
proteins (e.g. PorA), it has been discovered that Cmt also catalyses the lipidation of 
polypeptides in corynebacteria (Huc et al., 2013). Hence the failure of VapA to act as 
the final acyl acceptor in the in vitro model could be related to the fact that the 
protein was in a fully folded form and thus the mycoloylation site may not be 
available. This could be true if the protein is lipidated before export or translocation 
via the Sec machinery is complete. 
 
 
 
 
 
 
 
 
 
Chapter Seven General Discussion 
189 
 
 
 
Figure 7.1  Electrostatic surface rendering of VapA model 
Side chains of Ser, Thr, Tyr that are exposed are shown in fat bonds. 
The ribbon tracings (in green) show the orientation of the surfaces. The 
model was created using CCP4mg (McNicholas et al., 2011) 
 
In summary, mycoloylation of proteins in R. equi is now established and the 
structural definition of the Vaps generated in this study and others (Whittingham et 
al., 2014, Geerds et al., 2014) provides a strong blue print for further study of Vap 
modification and function. 
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Appendix A 
MEDIA RECIPES 
Luria-Bertani (LB) Broth  
10.0 g Tryptone (Oxoid) 
5.0 g Yeast extract (Oxoid) 
10.0 g NaCl (Sigma) 
Dissolve in 1 litre distilled water and autoclave 
 
Brain Heart Infusion (BHI) Broth 
47 g BHI broth powder (Oxoid) 
Dissolve in 1 litre distilled water and autoclave 
 
Brain Heart Infusion containing sorbitol (BHIS) 
BHI supplemented with 2 % sorbitol (Fisher) 
 
Terrific Broth 
12 g Bacto Tryptone 
24 g Bacto Yeast Extract 
900 mL Milli-Q water and autoclave. Cool to about 60°C 
Add 100 mL of 0.17 M KH2PO4, 0.72 M K2HPO4 solution (separately autoclaved). 
 
Solid media 
Solid media used were LB agar and BHI agar.  
For LB agar, the initial broth was supplemented with 2 % Agar (Bacteriological No. 
1) and autoclaved.  
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For BHI agar, 4.72 g of BHI agar powder (Oxoid) was dissolved in 100 mL of 
distilled water and autoclaved. 
For both media, the autoclaved medium was cooled to about 50°C and aseptically 
poured into Petri dishes and allowed to set at room temperature.  
 
Special Medium (for growing electro-competent cells) 
1 g Tryptone 
0.5 g Yeast Extract 
1 g NaCl (Sigma) 
Dissolve in 80 mL distilled water and autoclave (LB base) 
20 mL of distilled water (containing glycine (10 % w/v), Tween-80 (0.5 % v/v)) to 
LB base (cooled to ~ 60°C) through a 0.22 µm filter. 
 
Selective media 
Dissolve recipes for liquid and solid media in water (as above). After autoclaving, 
each medium was allowed to cool to about 55°C and filter-sterilised antibiotic stock 
solution was added to the desired concentration and gently shaken. Antibiotics used 
include ampicillin (100 µg/mL final concentration), and kanamycin (25 µg/mL final 
concentration) 
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Appendix B 
 
Table IIA Relevant features of plasmid vectors 
Plasmid Size Relevant features 
pET 23a 3666 bp AmpR, T7 tag, T7 term, pRB 322 ori 
pET 28a 5369 bp KanR, T7 tag, T7 lac, pRB 322 ori 
pEKEx2 8161 bp KanR, Ptac, lacI
q, pBL1 oriVCg, pUC18 oriVEc 
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Appendix C 
 
 
 
 
Figure C1: Standard curve for protein quantitation via the 
Bradford method 
Bovine serum albumin was used as the standard 
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Appendix D 
List of buffers and solutions 
GTE-RNase buffer (for C. glutamicum genomic DNA extraction) 
200 µL RNase A 
20 mL GTE buffer (50 mM glucose, 25 mM Tris pH 8, 10 mM EDTA pH 8) 
 
DNA Loading buffer (6x)  
0.025 g Bromophenol blue 
0.025 g Xylene cyanol FF 
3 mL glycerol 
7 mL deionised water. 
 
50 x Gel buffer or Tris-Acetic acid-EDTA buffer (TAE) 
242 g Tris.HCl, pH 8 
57.1 mL Glacial acetic acid 
100 mL of 0.5 M EDTA 
Made to 1 L with deionised water 
 
SDS-PAGE 4x Resolving gel buffer  
45.41 g of Tris-HCl pH 8.8 
1 g Sodium dodecyl sulphate (SDS) 
 Made to 250 mL with deionised water  
 
SDS-PAGE 4x Stacking gel buffer  
6.06 g of Tris.HCl, pH 6.8 
0.4 g SDS  
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Made to 100 mL with deionised water 
 
SDS-PAGE Sample loading buffer (5x) 
0.757 g Tris.HCl, pH 6.8 
 2 g SDS 
10 mL glycerol, 
0.15 g Dithiothreitol 
0.025 g Bromophenol blue 
Made to 100 mL with deionised water  
 
SDS-PAGE running buffer (1x) 
3.03 g of Tris base 
1 g SDS 
14.4 g Glycine 
Made to 1 L with deionised water 
 
Native-PAGE 4x Resolving gel buffer  
45.41 g of Tris-HCl pH 8.8 
Made to 250 mL with deionised water  
 
Native-PAGE 4x Stacking gel buffer  
6.06 g of Tris.HCl, pH 6.8 
Made to 100 mL with deionised water 
 
Native-PAGE Sample loading buffer (5x) 
0.757 g Tris.HCl, pH 6.8 
10 mL glycerol, 
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0.025 g Bromophenol blue 
Made to 100 mL with deionised water  
 
Urea-PAGE Sample loading buffer 
2.42 g Tris.HCl, pH 6.8 
75 mL glycerol 
3 g Bromophenol blue 
Made to 100 mL with deionised water 
 
Native-PAGE running buffer (1x) 
3.03 g of Tris base 
14.4 g Glycine 
Made to 1 L with deionised water 
 
 
Coomassie blue stain 
0.25 g of Coomassie brilliant blue R-250 
45% mL methanol 
45% mL Distilled H2O 
10 mL Acetic acid 
 
Destain 
100 mL Methanol 
100 mL Acetic acid 
800 mL Distilled water. 
 
10 x Phosphate buffered saline (PBS) 
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80 g NaCl 
2 g KCl 
14.4 g Na2HPO4 
2.4 g KH2PO4 
pH 7.4 using NaOH, made to 1 L using deionised water and autoclaved.  
PBS was diluted 1 in 10 times before use.   
 
Phosphate buffered saline containing Tween-20 (PBST):  
500 mL PBS (1x) 
250 µL Tween-20 
 
Transfer buffer: 
3.03 g of Tris 
14.4 g Glycine 
200 mL Absolute Methanol  
Made to 1 litre with deionised water 
 
Blocking solution: This is PBST containing 2 % of dried skimmed milk. 
 
Tris buffered saline (TBS buffer)  
0.61 g of Tris.HCl, pH 7.4 
4.39 g NaCl 
Made to 500 mL with deionised water and autoclaved 
 
IMAC equilibration buffer  
2.42 g Tris.HCl pH 7.4 
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2.04 g Imidazole  
Made to 1 Litre with deionised water. 
 
 
IMAC elution buffer (0.02 M Na2HPO4, 0.5 M Imidazole):  
2.42 g Tris.HCl pH 7.4 
34.04 g or 68.08 g Imidazole  
Made to 1 Litre with deionised water. 
 
Anion exchange equilibration buffer  
 2.42 g of Tris. HCl, pH 8.02 
Made to 1 Litre with deionised water 
 
Anion exchange elution buffer  
2.42 g of Tris.HCl, pH 8.02 
58.4 g NaCl 
Made to 1 Litre with deionised water 
 
Electroporation buffers (Tris.Glycerol Buffer) 
0.12 g Tris.HCl, pH 7.5 
100 mL glycerol 
Made to 1 Litre with distilled water and autoclaved 
 
Molecular weight markers for SDS-PAGE 
-Lactalbumin from bovine milk       14.2 kDa 
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Trypsin Inhibitor from soybean       20 kDa 
Carbonic Anhydrase from bovine erythrocytes                   29 kDa 
Glyceraldehyde-3-phosphate Dehydrogenase from rabbit muscle  36 kDa 
Ovalbumin from chicken egg       45 kDa 
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Appendix E 
 
 
OLIGO DESIGN AND SIGNALP OF R. EQUI VAPS 
 
 
VapA 
 
Figure E1 Prediction of signal peptidase cleavage position of VapA using the 
SignaP 4.0 server. 
Figure shows maximum cleavage probability between Alanine (31) and 
Threonine (32) 
 
VapA 
MKTLHKTVSKAIAATAVAAAAAMIPAGCANATVLDSGSSSAILNSGAGSGIVGSGSYDSSTT
SLNLQKDEPNGRASDTAGQEQQYDVHGDVISAVVYQRFHVFGPEGKVFDGDAGGLTLPGAGA
FWGTLFTNDLQRLYKDTVSFQYNAVGPYLNINFFDSSGSFLGHIQSGGVSTVVGVGGGSGSW
HNA 
 “T” is the predicted N-terminal amino acid of the fully 
processed protein 
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VapA 
ATGAAGACTCTTCACAAGACGGTTTCTAAGGCGATCGCAGCCACAGCCGTAGCTGCGGCTGC
GGCTATGATTCCCGCCGGCTGCGCTAATGCGACCGTTCTTGATTCCGGTAGCAGCAGTGCG
ATTCTCAATAGTGGGGCAGGCAGTGGCATTGTCGGTTCTGGGAGCTATGACAGCTCGACGAC
TTCGTTAAACCTTCAGAAAGACGAACCGAACGGTCGAGCAAGCGATACCGCCGGGCAAGAGC
AGCAGTACGACGTTCACGGAGACGTCATCAGCGCGGTCGTCTACCAGAGGTTTCACGTATTC
GGGCCAGAAGGAAAGGTCTTCGATGGCGATGCAGGGGGACTCACGCTTCCTGGGGCCGGCGC
GTTCTGGGGGACTCTCTTCACAAATGACCTTCAGCGTCTCTACAAAGACACCGTCTCGTTCC
AGTACAACGCCGTGGGGCCATACCTGAACATCAACTTCTTCGATAGCTCAGGTAGCTTCCTC
GGCCATATCCAGTCCGGTGGAGTTAGTACTGTGGTGGGCGTCGGCGGCGGCTCTGGTAGCTG
GCACAACGCCTAG 
 
“ACC” is the codon for threonine at the predicted N-terminal 
amino acid of the fully processed protein 
 
 
 
VapA without the signal sequence gene 
 
ACCGTTCTTGATTCCGGTAGCAGCAGTGCGATTCTCAATAGTGGGGCAGGCAGTGGCATTGT
CGGTTCTGGGAGCTATGACAGCTCGACGACTTCGTTAAACCTTCAGAAAGACGAACCGAACG
GTCGAGCAAGCGATACCGCCGGGCAAGAGCAGCAGTACGACGTTCACGGAGACGTCATCAGC
GCGGTCGTCTACCAGAGGTTTCACGTATTCGGGCCAGAAGGAAAGGTCTTCGATGGCGATGC
AGGGGGACTCACGCTTCCTGGGGCCGGCGCGTTCTGGGGGACTCTCTTCACAAATGACCTTC
AGCGTCTCTACAAAGACACCGTCTCGTTCCAGTACAACGCCGTGGGGCCATACCTGAACATC
AACTTCTTCGATAGCTCAGGTAGCTTCCTCGGCCATATCCAGTCCGGTGGAGTTAGTACTGT
GGTGGGCGTCGGCGGCGGCTCTGGTAGCTGGCACAACGCCTAG 
 
 
      pET23vapA up   GATCGATCCATATGACCGTTCTTGATTCCGGTAGCAGCAGTGCG 
      pET23vapA lo TATAAATAGCGGCCGCGGCGTTGTGCCAGCTACCAGAGCCG 
 
Nde1…. CATATG 
Not1…. GCGGCCGC 
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VapC 
 
Figure E2 Prediction of signal peptidase cleavage position of VapC using the 
SignaP 4.0 server. 
Figure shows maximum cleavage probability between Alanine (29) and 
Asparagine (30) 
 
 
 
 
VapC 
MFRVGRPSKSIAVVASVLCFLALGGTARANVVAPSAWGGAQSAADKEGEGVTLGGVGVLRPH
NKDADEQYTVHGVVVSALFYNHLRISVDGGMTFDGDGGGLSTPGGGALWGTLTTSDLQQLYD
ETASFECNAVGPYLNINFYDSYGRILASVQAGGVSTMIGIGGGNGRWHLV 
 “N” (30) is the predicted N-terminal amino acid of the fully 
processed protein 
 
 
VapC 
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ATGTTCCGCGTGGGTCGTCCATCCAAATCGATAGCCGTTGTGGCGAGTGTCCTATGCTTCTT
GGCCTTGGGAGGCACTGCACGGGCCAATGTAGTCGCTCCGTCGGCGTGGGGAGGGGCGCAA
TCCGCTGCTGACAAAGAGGGCGAAGGGGTCACGCTTGGTGGCGTCGGAGTTCTACGGCCGCA
CAATAAAGATGCCGACGAACAGTATACGGTTCATGGGGTAGTTGTCAGTGCGTTGTTTTATA
ATCATCTGCGGATCTCTGTCGATGGGGGAATGACCTTCGATGGAGACGGAGGTGGGCTATCC
ACTCCGGGAGGAGGTGCGCTCTGGGGAACTCTTACAACTAGCGATCTTCAGCAACTATACGA
CGAAACTGCGTCCTTCGAATGTAATGCGGTTGGCCCGTATTTGAACATCAACTTTTACGACA
GTTACGGTCGCATTCTTGCGAGTGTTCAGGCGGGCGGTGTCAGCACAATGATTGGTATAGGC
GGTGGGAATGGGCGATGGCATTTGGTGTGA 
 
“AAT” is the codon for asparagine at the predicted N-terminal 
amino acid of the fully processed protein 
 
 
VapC without signal sequence gene 
AATGTAGTCGCTCCGTCGGCGTGGGGAGGGGCGCAATCCGCTGCTGACAAAGAGGGCGAAGG
GGTCACGCTTGGTGGCGTCGGAGTTCTACGGCCGCACAATAAAGATGCCGACGAACAGTATA
CGGTTCATGGGGTAGTTGTCAGTGCGTTGTTTTATAATCATCTGCGGATCTCTGTCGATGGG
GGAATGACCTTCGATGGAGACGGAGGTGGGCTATCCACTCCGGGAGGAGGTGCGCTCTGGGG
AACTCTTACAACTAGCGATCTTCAGCAACTATACGACGAAACTGCGTCCTTCGAATGTAATG
CGGTTGGCCCGTATTTGAACATCAACTTTTACGACAGTTACGGTCGCATTCTTGCGAGTGTT
CAGGCGGGCGGTGTCAGCACAATGATTGGTATAGGCGGTGGGAATGGGCGATGGCATTTGGT
GTGA 
 
For cloning into pET23 
Forward primer 5’-GATCGATCCATATGAATGTAGTCGCTCCGTCGGCGTGG -3’ 
Reverse primer 5’-AATTTATAGCGGCCGCCACCAAATGCCATCGCCCATTCC -3’ 
 
Nde1…. CATATG 
Not1…. GCGGCCGC 
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VapD 
 
Figure E3 Prediction of signal peptidase cleavage position of VapD using the 
SignaP 4.0 server. 
Figure shows maximum cleavage probability between Alanine (30) and 
Glutamine (31) 
 
 
VapD 
MVRARAFGRLFTFLLAVAVIATVSMGGANAQELAGTKTSDAALLSGNKAAIPEDKEYDVSGR
VVSALVYQYFIVTVDDAEDKKGKTFQGDAGGVTIPGVDFFWGTLHTPDLEKLYSDTVSFQYN
AAATFLNINFFDSKGERLGYVLAGAAGTVSGIGGGTGGWE 
 “Q” (31) is the predicted N-terminal amino acid of the fully 
processed protein 
 
VapD 
ATGGTCCGTGCACGAGCCTTTGGGCGTTTATTCACTTTCTTGCTCGCGGTGGCTGTGATCGC
AACGGTCTCAATGGGAGGGGCCAACGCTCAGGAGCTAGCTGGCACCAAGACGTCGGATGCG
GCACTTCTCTCCGGAAACAAGGCTGCCATTCCTGAAGATAAAGAGTATGACGTATCGGGTAG
GGTTGTCAGTGCTCTAGTCTACCAATATTTCATTGTAACCGTCGATGATGCTGAGGATAAGA
AGGGCAAGACGTTCCAGGGGGACGCTGGGGGTGTGACCATTCCGGGAGTCGACTTCTTCTGG
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GGTACTTTGCACACGCCGGACCTTGAAAAGCTGTATTCCGATACAGTGTCGTTTCAATACAA
TGCGGCCGCAACATTCTTGAATATCAACTTTTTCGACAGCAAGGGCGAACGACTTGGTTACG
TTCTTGCTGGTGCTGCTGGGACAGTATCGGGGATCGGTGGTGGCACTGGCGGGTGGGAGTAG 
“CAG” is the codon for glutamine at the predicted N-terminal 
amino acid of the fully processed protein 
 
VapD without signal sequence 
CAGGAGCTAGCTGGCACCAAGACGTCGGATGCGGCACTTCTCTCCGGAAACAAGGCTGCCAT
TCCTGAAGATAAAGAGTATGACGTATCGGGTAGGGTTGTCAGTGCTCTAGTCTACCAATATT
TCATTGTAACCGTCGATGATGCTGAGGATAAGAAGGGCAAGACGTTCCAGGGGGACGCTGGG
GGTGTGACCATTCCGGGAGTCGACTTCTTCTGGGGTACTTTGCACACGCCGGACCTTGAAAA
GCTGTATTCCGATACAGTGTCGTTTCAATACAATGCGGCCGCAACATTCTTGAATATCAACT
TTTTCGACAGCAAGGGCGAACGACTTGGTTACGTTCTTGCTGGTGCTGCTGGGACAGTATCG
GGGATCGGTGGTGGCACTGGCGGGTGGGAGTAG 
 
For cloning into pET28 
Forward Primer 5’-GTAGGAACCATATGCAGGAGCTAGCTGGCACCAAGAC-3’ 
Reverse primer 5’-GTAGGAACGAATTCCTACTCCCACCCGCCAGTG-3’ 
CATATG……NdeI site 
GAATTC……EcoRI site 
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VapE 
 
Figure E4 Prediction of signal peptidase cleavage position of VapE using the 
SignaP 4.0 server. 
Figure shows maximum cleavage probability between Alanine (46) and 
Arginine (47) 
 
VapE 
MTTVHKKASKAIAFTVALRLPFAGTAVALVLIALTIVAAPTGIAGAREIGAQAWPASQLES
GLAVSGNPVGVHDVRMAVHDDSTHTREFKEDDSEKQYPVHGFASSFIFYQTVSIIIDDDGRG
GPGKTFEGEAGGITTPGAAGYAGVLFTSDLERLYRETVSFEYNAVGPYLNINLFAGDGGLLG
HVQSGAISSLVGIGGGTGAWR 
 “R” (47) is the predicted N-terminal amino acid of the fully 
processed protein 
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VapE 
ATGACGACCGTTCACAAGAAAGCCTCTAAGGCAATCGCCTTCACAGTCGCATTGCGGCTCCC
TTTCGCGGGAACCGCAGTAGCATTGGTTCTAATCGCACTGACTATAGTAGCTGCTCCTACAG
GCATAGCCGGCGCGCGGGAAATTGGCGCCCAGGCCTGGCCAGCTTCGCAATTGGAAAGCGG
CCTTGCTGTGTCGGGAAATCCTGTGGGCGTACATGACGTCCGTATGGCGGTGCATGACGATT
CCACGCACACGCGGGAGTTTAAGGAAGATGACTCAGAGAAGCAGTATCCGGTACATGGCTTT
GCTTCGAGCTTTATCTTCTATCAAACCGTATCAATAATAATTGATGACGACGGGCGCGGAGG
GCCGGGTAAGACGTTCGAAGGAGAAGCTGGCGGTATTACCACGCCCGGCGCCGCTGGTTACG
CCGGTGTTCTATTCACGAGCGATCTCGAGCGGCTCTACCGCGAGACGGTTTCGTTTGAGTAC
AACGCTGTCGGTCCGTACTTGAACATCAATCTTTTCGCCGGAGACGGAGGTTTGCTGGGGCA
CGTCCAATCTGGCGCTATCAGTAGTTTGGTGGGCATCGGAGGAGGCACTGGCGCCTGGCGAT
AG 
 
“CGG” is the codon for arginine at the predicted N-terminal 
amino acid of the fully processed protein 
 
VapE without signal sequence 
CGGGAAATTGGCGCCCAGGCCTGGCCAGCTTCGCAATTGGAAAGCGGCCTTGCTGTGTCGGG
AAATCCTGTGGGCGTACATGACGTCCGTATGGCGGTGCATGACGATTCCACGCACACGCGGG
AGTTTAAGGAAGATGACTCAGAGAAGCAGTATCCGGTACATGGCTTTGCTTCGAGCTTTATC
TTCTATCAAACCGTATCAATAATAATTGATGACGACGGGCGCGGAGGGCCGGGTAAGACGTT
CGAAGGAGAAGCTGGCGGTATTACCACGCCCGGCGCCGCTGGTTACGCCGGTGTTCTATTCA
CGAGCGATCTCGAGCGGCTCTACCGCGAGACGGTTTCGTTTGAGTACAACGCTGTCGGTCCG
TACTTGAACATCAATCTTTTCGCCGGAGACGGAGGTTTGCTGGGGCACGTCCAATCTGGCGC
TATCAGTAGTTTGGTGGGCATCGGAGGAGGCACTGGCGCCTGGCGATAG 
For cloning into pET28 
 
Forward primer 5’-GTACGATCCATATGCGGGAAATTGGCGCCCAG-3’ 
Reverse primer 5’-GTACGATCGAATTCCTATCGCCAGGCGCCAGTG-3’ 
Nde1…. CATATG 
EcoR1… GAATTC 
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VapG 
 
Figure E5: Prediction of signal peptidase cleavage position of VapG using the 
SignaP 4.0 server. 
Figure shows maximum cleavage probability between Alanine (26) and 
glutamic acid (27) 
 
VapG 
MSVRTLLAATLVAGISVLAPAGIANAETSMVSTTAASSVEHAANTYDFAEAKSGSSIPAKVA
AEQANSYSVHGLVTSLAVYQHFSLTVEGGGKTFTGDSGGISIPGVAVLEGTLFTEDLQHLYS
DTVSFEYNAVGPYLNINFFDSHGTLLGHVQSGSIGTVSGIGGGTGGWQ 
 
 “E” (27) is the predicted N-terminal amino acid of the fully 
processed protein 
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VapG 
GTGAGTGTTCGGACCCTTTTGGCGGCAACGCTCGTTGCTGGAATATCAGTCTTGGCACCGGC
CGGCATTGCGAACGCGGAAACTTCAATGGTATCCACTACAGCAGCATCGAGTGTCGAGCAC
GCTGCAAACACCTACGACTTTGCAGAGGCGAAGAGCGGGAGCTCTATCCCCGCCAAAGTAGC
CGCAGAGCAGGCAAACAGCTATTCGGTCCACGGGCTTGTCACCAGCCTCGCCGTATACCAGC
ACTTTTCACTGACCGTTGAAGGCGGCGGAAAGACGTTTACTGGTGATTCTGGCGGGATTTCG
ATTCCCGGGGTTGCAGTGCTGGAGGGAACCCTATTCACCGAGGATCTGCAGCATTTGTACAG
CGACACCGTCTCGTTCGAGTACAACGCCGTAGGCCCGTACCTGAACATCAACTTTTTTGACA
GCCATGGCACTCTCCTAGGCCACGTGCAGTCTGGATCCATCGGGACCGTCTCCGGCATCGGT
GGCGGAACCGGAGGGTGGCAATAG 
 
“GAA” is the codon for glutamic acid at the predicted N-
terminal amino acid of the fully processed protein 
 
VapG without signal sequence 
GAAACTTCAATGGTATCCACTACAGCAGCATCGAGTGTCGAGCACGCTGCAAACACCTACGA
CTTTGCAGAGGCGAAGAGCGGGAGCTCTATCCCCGCCAAAGTAGCCGCAGAGCAGGCAAACA
GCTATTCGGTCCACGGGCTTGTCACCAGCCTCGCCGTATACCAGCACTTTTCACTGACCGTT
GAAGGCGGCGGAAAGACGTTTACTGGTGATTCTGGCGGGATTTCGATTCCCGGGGTTGCAGT
GCTGGAGGGAACCCTATTCACCGAGGATCTGCAGCATTTGTACAGCGACACCGTCTCGTTCG
AGTACAACGCCGTAGGCCCGTACCTGAACATCAACTTTTTTGACAGCCATGGCACTCTCCTA
GGCCACGTGCAGTCTGGATCCATCGGGACCGTCTCCGGCATCGGTGGCGGAACCGGAGGGTG
GCAATAG 
 
For cloning into pET28 
Forward primer 5’-
GACGATCCATATGGAAACTTCAATGGTATCCACTACAGCAGCATCG-3’ 
Reverse primer 5’-GACGATCGAATTCCTATTGCCACCCTCCGGTTCC-3’ 
 
Nde1…. CATATG 
EcoR1… GAATTC 
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VapH 
 
Figure E6 Prediction of signal peptidase cleavage position of VapG using the 
SignaP 4.0 server. 
Figure shows maximum cleavage probability between alanines 31 and 32 
 
 
VapH 
MNLSKTTRKFLSRTAVPATFVMALTVPWGCAAPPPLPDGPTHDLPTWREEGANYSDGTMLV
RASSNFLEPSTHSDSGQQQWTVQGVLASALVYQRLKLNVEGGETFEGYAGGLSFPGGAMVWG
TLFTDNIQRLYDRTESFEFNAVGPYLNVNFFDGHSAILGHAQLGGVSSVIGIGGGTGTWIGD
VA 
 “A” (32) is the predicted N-terminal amino acid of the fully 
processed protein 
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VapH 
ATGAATCTATCAAAAACAACTCGAAAGTTCCTATCAAGGACAGCTGTGCCTGCAACATTCGT
AATGGCGCTCACTGTCCCGTGGGGATGCGCGGCCCCGCCACCATTACCAGATGGTCCCACA
CACGACCTGCCTACTTGGCGCGAAGAAGGGGCAAACTATAGCGACGGTACGATGCTTGTACG
CGCTTCATCCAATTTTCTCGAGCCATCGACTCACAGTGACAGTGGGCAGCAGCAGTGGACAG
TGCAAGGAGTACTGGCCAGCGCGTTGGTGTACCAACGGCTGAAGCTCAATGTTGAGGGAGGC
GAGACGTTTGAGGGTTATGCAGGTGGATTGTCATTTCCCGGCGGGGCGATGGTCTGGGGCAC
GCTTTTCACCGACAACATACAGCGACTATACGATCGGACGGAATCGTTTGAGTTCAACGCGG
TCGGACCCTATCTAAATGTCAACTTCTTCGACGGTCACAGCGCCATACTCGGCCATGCACAA
TTAGGAGGGGTGAGCTCCGTAATCGGTATTGGCGGAGGTACGGGAACCTGGATAGGCGATGT
AGCGTAG 
“GCC” is the codon for alanine at the predicted N-terminal 
amino acid of the fully processed protein 
 
 
 
VapH without signal sequence 
GCCCCGCCACCATTACCAGATGGTCCCACACACGACCTGCCTACTTGGCGCGAAGAAGGGGC
AAACTATAGCGACGGTACGATGCTTGTACGCGCTTCATCCAATTTTCTCGAGCCATCGACTC
ACAGTGACAGTGGGCAGCAGCAGTGGACAGTGCAAGGAGTACTGGCCAGCGCGTTGGTGTAC
CAACGGCTGAAGCTCAATGTTGAGGGAGGCGAGACGTTTGAGGGTTATGCAGGTGGATTGTC
ATTTCCCGGCGGGGCGATGGTCTGGGGCACGCTTTTCACCGACAACATACAGCGACTATACG
ATCGGACGGAATCGTTTGAGTTCAACGCGGTCGGACCCTATCTAAATGTCAACTTCTTCGAC
GGTCACAGCGCCATACTCGGCCATGCACAATTAGGAGGGGTGAGCTCCGTAATCGGTATTGG
CGGAGGTACGGGAACCTGGATAGGCGATGTAGCGTAG 
 
 
Forward primer 5’-GACGATCCATATGGCCCCGCCACCATTACCAGATG-3’ 
Reverse primer 5’-
GACGATCGAATTCCTACGCTACATCGCCTATCCAGGTTCCCGTAC-3’ 
 
Nde1…. CATATG 
EcoR1… GAATTC 
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Appendix F 
 
 
Figure F1 SDS-PAGE of recombinant VapD, VapE and VapH (expressed 
in E. coli) following anion exchange chromatography 
Peak fractions (marked) were concentrated and used for further 
analysis. ‘M’ indicates molecular weight markers (14.β kDa, α-
Lactalbumin from bovine milk; 20.1 kDa, Trypsin Inhibitor from 
soybean). 
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Appendix G 
 
 
 
Figure G1: Model quality plots of VapA and VapC showing Z-scores of -4.4 
and -4.35 respectively. 
 
 
Figure G2: Model quality plots of VapE and VapH showing Z-scores of -4.88 
and -3.35 respectively 
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Appendix H 
 
Figure H1 Site-directed mutagenesis did not perturb recombinant VapA 
localisation in C. glutamicum 
Fractions were subjected to Western Blot using Mab 10G5 as the 
primary antibody. Site-directed mutagenesis was performed in 
blocks as described. Shown are blocks 2 – 7. Fractions are M, 
plasma membrane; Wall, purified cell wall; BSP, secreted protein; 
and cyto, cytosol. Standardised loading of 5 µg total protein was 
used throughout. 
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Figure H2 Site-directed mutagenesis did not perturb recombinant VapA 
localisation in C. glutamicum 
Fractions were subjected to Western Blot using Mab 10G5 as the 
primary antibody. Site-directed mutagenesis was performed in 
blocks as described. Shown are blocks 8 – 13. Fractions are M, 
plasma membrane; Wall, purified cell wall; BSP, secreted protein; 
and cyto, cytosol. Standardised loading of 5 µg total protein was 
used throughout. 
 
 
 
 
 Appendices 
 
237 
 
 
 
Figure H3 Site-directed mutagenesis did not perturb recombinant VapA 
localisation in C. glutamicum 
Fractions were subjected to Western Blot using Mab 10G5 as the 
primary antibody. Site-directed mutagenesis was performed in 
blocks as described. Shown are blocks 14 – 15. Fractions are M, 
plasma membrane; Wall, purified cell wall; BSP, secreted protein; 
and cyto, cytosol. Standardised loading of 5 µg total protein was 
used throughout. 
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Appendix I 
Plasmid maps 
 
Figure I1: Map of pET23a-vapA 
Gene (vapA) was cloned into the NotI/NdeI cloning sites of pET23a 
as shown. Map created using PlasMapper (Dong et al., 2004). 
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Figure I2: Map of pET28a-vapA. 
Gene (vapA) was cloned into the NotI/NdeI cloning sites of 
pET28a as shown. Map created using PlasMapper (Dong et al., 
2004). 
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Figure I3: Map of pET23a-vapC. 
Gene (vapC) was cloned into the NotI/NdeI cloning sites of pET23a 
as shown. Map created using PlasMapper (Dong et al., 2004). 
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Figure I4: Map of pET28a-vapC. 
Gene (vapC) was cloned into the NotI/NdeI cloning sites of 
pET28a as shown. Map created using PlasMapper (Dong et al., 
2004). 
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Figure I5: Map of pET23a-vapD 
Gene (vapD) was cloned into the EcoRI/NdeI cloning sites of pET23a as 
shown. Map created using PlasMapper (Dong et al., 2004).  
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Figure I6: Map of pET28a-vapD. 
Gene (vapD) was cloned into the EcoRI/NdeI cloning sites of 
pET28a as shown. Map created using PlasMapper (Dong et al., 
2004).  
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Figure I7: Map of pET23a-vapE. 
Gene (vapE) was cloned into the EcoRI/NdeI cloning sites of pET23a 
as shown. Map created using PlasMapper (Dong et al., 2004).  
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Figure I8: Map of pET28a-vapE. 
Gene (vapE) was cloned into the EcoRI/NdeI cloning sites of 
pET28a as shown. Map created using PlasMapper (Dong et al., 
2004).  
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Figure I9: Map of pET23a-vapG 
Gene (vapG) was cloned into the EcoRI/NdeI cloning sites of 
pET23a as shown. Map created using PlasMapper (Dong et al., 
2004). 
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Figure I10: Map of pET28a-vapG. 
Gene (vapG) was cloned into the EcoRI/NdeI cloning sites of pET28a as 
shown. Map created using PlasMapper (Dong et al., 2004). 
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Figure I11 Map of pET23a-vapH 
Gene (vapH) was cloned into the EcoRI/NdeI cloning sites of pET23a 
as shown. Map created using PlasMapper (Dong et al., 2004). 
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Figure I12: Map of pET28a-vapH. 
Gene (vapH) was cloned into the EcoRI/NdeI cloning sites of 
pET28a as shown. Map created using PlasMapper (Dong et al., 
2004). 
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Appendix J 
Crystallisation Liquors 
Table J1: PEG/ION screen components 
Tube 
No. 
Salt Precipitant 
1 0.2 M Sodium fluoride  20% w/v PEG 3,350 
2 0.2 M Potassium fluoride   20% w/v PEG 3,350 
3 0.2 M Ammonium fluoride   20% w/v PEG 3,350 
4 0.2 M Lithium chloride  20% w/v PEG 3,350 
5 0.2 M Magnesium chloride 
hexahydrate 
20% w/v PEG 3,350 
6 0.2 M Sodium chloride 20% w/v PEG 3,350 
7 0.2 M Calcium chloride 
dehydrate 
20% w/v PEG 3,350 
8 0.2 M Potassium chloride  20% w/v PEG 3,350 
9 0.2 M Ammonium chloride   20% w/v PEG 3,350 
10 0.2 M Sodium iodide   20% w/v PEG 3,350 
11 0.2 M Potassium iodide 
  
20% w/v PEG 3,350 
12 0.2 M Ammonium iodide   20% w/v PEG 3,350 
13 0.2 M Sodium thiocyanate 
  
20% w/v PEG 3,350 
14 0.2 M Potassium thiocyanate  20% w/v PEG 3,350 
15 0.2 M Lithium nitrate   20% w/v PEG 3,350 
16 0.2 M Magnesium nitrate 
hexahydrate 
20% w/v PEG 3,350 
17 0.2 M Sodium nitrate   20% w/v PEG 3,350 
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18 0.2 M Potassium nitrate  20% w/v PEG 3,350 
19 0.2 M Ammonium nitrate  20% w/v PEG 3,350 
20 0.2 M Magnesium formate 
dihydrate 
20% w/v PEG 3,350 
21 0.2 M Sodium formate 20% w/v PEG 3,350 
22 0.2 M Potassium formate  20% w/v PEG 3,350 
23 0.2 M Ammonium formate  20% w/v PEG 3,350 
24 0.2 M Lithium acetate dihydrate 20% w/v PEG 3,350 
25 0.2 M Magnesium acetate 
tetrahydrate 
20% w/v PEG 3,350 
26 0.2 M Zinc acetate dihydrate  20% w/v PEG 3,350 
27 0.2 M Sodium acetate trihydrate 20% w/v PEG 3,350 
28 0.2 M Calcium acetate hydrate 20% w/v PEG 3,350 
29 0.2 M Potassium acetate  20% w/v PEG 3,350 
30 0.2 M Ammonium acetate  20% w/v PEG 3,350 
31 0.2 M Lithium sulfate 
monohydrate 
20% w/v PEG 3,350 
32 0.2 M Magnesium sulfate 
heptahydrate 
20% w/v PEG 3,350 
33 0.2 M Sodium sulfate 
decahydrate 
20% w/v PEG 3,350 
34 0.2 M Potassium sulfate  20% w/v PEG 3,350 
35 0.2 M Ammonium sulfate 20% w/v PEG 3,350 
36 0.2 M Sodium tartrate dibasic 
dihydrate 
20% w/v PEG 3,350 
37 0.2 M Potassium sodium tartrate 
tetrahydrate  
20% w/v PEG 3,350 
38 0.2 M Ammonium tartrate dibasic 20% w/v PEG 3,350 
39 0.2 M Sodium phosphate 20% w/v PEG 3,350 
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monobasic monohydrate 
40 0.2 M Sodium phosphate dibasic 
dihydrate  
20% w/v PEG 3,350 
41 0.2 M Potassium phosphate 
monobasic 
20% w/v PEG 3,350 
42 0.2 M Potassium phosphate 
dibasic   
20% w/v PEG 3,350 
43 0.2 M Ammonium phosphate 
monobasic   
20% w/v PEG 3,350 
44 0.2 M Ammonium phosphate 
dibasic   
20% w/v PEG 3,350 
45 0.2 M Lithium citrate tribasic 
tetrahydrate   
20% w/v PEG 3,350 
46 0.2 M Sodium citrate tribasic 
dihydrate 
20% w/v PEG 3,350 
47 0.2 M Potassium citrate tribasic 
monohydrate 
20% w/v PEG 3,350 
48 0.2 M Ammonium citrate dibasic 20% w/v PEG 3,350 
 
Table J2 Hampton Crystal Screen I components 
Tube 
No 
Salt Buffer Precipitant 
1  0.02 M 
Calcium 
chloride 
dihydrate 
 0.1 M Sodium 
acetate trihydrate 
pH 4.6 
 30% (v/v) 2-Methyl-2,4-
pentanediol 
2 None None 0.4 M Potassium sodium 
tartrate tetrahydrate 
3 None None 0.4 M Ammonium phosphate 
monobasic 
4 None 0.1 M TRIS 
hydrochloride pH 
2.0 M Ammonium sulfate 
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8.5 
5 0.2 M 
Sodium 
citrate 
tribasic 
dihydrate 
0.1 M HEPES 
sodium pH 7.5 
30% (v/v) 2-Methyl-2,4-
pentanediol 
6 0.2 M 
Magnesium 
chloride 
hexahydrate 
0.1 M TRIS 
hydrochloride pH 
8.5 
30% (w/v) Polyethylene glycol 
4,000 
7 None 0.1 M Sodium 
cacodylate 
trihydrate pH 6.5 
1.4 M Sodium acetate 
trihydrate 
8 0.2 M 
Sodium 
citrate 
tribasic 
dihydrate 
0.1 M Sodium 
cacodylate 
trihydrate pH 6.5 
30% (v/v) 2-Propanol 
9 0.2 M 
Ammonium 
acetate 
0.1 M Sodium 
citrate tribasic 
dihydrate pH 5.6 
30% (w/v) Polyethylene glycol 
4,000 
10 0.2 M 
Ammonium 
acetate 
0.1 M Sodium 
acetate trihydrate 
pH 4.6 
30% (w/v) Polyethylene glycol 
4,000 
11 None 0.1 M Sodium 
citrate tribasic 
dihydrate pH 5.6 
1.0 M Ammonium phosphate 
monobasic 
12 0.2 M 
Magnesium 
chloride 
hexahydrate 
0.1 M HEPES 
sodium pH 7.5 
30% (v/v) 2-Propanol 
13 0.2 M 
Sodium 
citrate 
tribasic 
dihydrate 
0.1 M TRIS 
hydrochloride pH 
8.5 
30% (v/v) Polyethylene glycol 
400 
14 0.2 M 
Calcium 
0.1 M HEPES 
sodium pH 7.5 
28% (v/v) Polyethylene glycol 
400 
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chloride 
dihydrate 
15 0.2 M 
Ammonium 
sulfate 
0.1 M Sodium 
cacodylate 
trihydrate pH 6.5 
30% (w/v) Polyethylene glycol 
8,000 
16 None 0.1 M HEPES 
sodium pH 7.5 
1.5 M Lithium sulfate 
monohydrate 
17 0.2 M 
Lithium 
sulfate 
monohydrate 
0.1 M TRIS 
hydrochloride pH 
8.5 
30% (w/v) Polyethylene glycol 
4,000 
18 0.2 M 
Magnesium 
acetate 
tetrahydrate 
0.1 M Sodium 
cacodylate 
trihydrate pH 6.5 
20% (w/v) Polyethylene glycol 
8,000 
19 0.2 M 
Ammonium 
acetate 
0.1 M TRIS 
hydrochloride pH 
8.5 
30% (v/v) 2-Propanol 
20 0.2 M 
Ammonium 
sulfate 
0.1 M Sodium 
acetate trihydrate 
pH 4.6 
25% (w/v) Polyethylene glycol 
4,000 
21 0.2 M 
Magnesium 
acetate 
tetrahydrate 
0.1 M Sodium 
cacodylate 
trihydrate pH 6.5 
30% (v/v) 2-Methyl-2,4-
pentanediol 
22 0.2 M 
Sodium 
acetate 
trihydrate 
0.1 M TRIS 
hydrochloride pH 
8.5 
30% (w/v) Polyethylene glycol 
4,000 
23 0.2 M 
Magnesium 
chloride 
hexahydrate 
0.1 M HEPES 
sodium pH 7.5 
30% (v/v) Polyethylene glycol 
400 
24 0.2 M 
Calcium 
chloride 
dihydrate 
0.1 M Sodium 
acetate trihydrate 
pH 4.6 
20% (v/v) 2-Propanol 
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25 None 0.1 M Imidazole pH 
6.5 
1.0 M Sodium acetate 
trihydrate 
26 0.2 M 
Ammonium 
acetate 
0.1 M Sodium 
citrate tribasic 
dihydrate pH 5.6 
30% (v/v) 2-Methyl-2,4-
pentanediol 
27 0.2 M 
Sodium 
citrate 
tribasic 
dihydrate 
0.1 M HEPES 
sodium pH 7.5 
20% (v/v) 2-Propanol 
28 0.2 M 
Sodium 
acetate 
trihydrate 
0.1 M Sodium 
cacodylate 
trihydrate pH 6.5 
30% (w/v) Polyethylene glycol 
8,000 
29 None 0.1 M HEPES 
sodium pH 7.5 
0.8 M Potassium sodium 
tartrate tetrahydrate 
30 0.2 M 
Ammonium 
sulfate 
None 30% (w/v) Polyethylene glycol 
8,000 
31 0.2 M 
Ammonium 
sulfate 
None 30% (w/v) Polyethylene glycol 
4,000 
32 None None 2.0 M Ammonium sulphate 
33 None None 4.0 M Sodium formate 
34 None 0.1 M Sodium 
acetate trihydrate 
pH 4.6 
2.0 M Sodium formate 
35 None 0.1 M HEPES 
sodium pH 7.5 
0.8 M Sodium phosphate 
monobasic monohydrate,  
0.8 MPotassium phosphate 
monobasic 
36 None 0.1 M TRIS 
hydrochloride pH 
8.5 
8% (w/v) Polyethylene glycol 
8,000 
37 None 0.1 M Sodium 
acetate trihydrate 
8% (w/v) Polyethylene glycol 
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pH 4.6 8,000 
38 None 0.1 M HEPES 
sodium pH 7.5 
1.4 M Sodium citrate tribasic 
dihydrate 
39 None 0.1 M HEPES 
sodium pH 7.5 
2% (v/v) Polyethylene glycol 
400, 2.0 M Ammonium sulfate 
40 None 0.1 M Sodium 
citrate tribasic 
dihydrate pH 5.6 
20% (v/v) 2-Propanol,  
20% (w/v) Polyethylene glycol 
4,000 
41 None 0.1 M HEPES 
sodium pH 7.5 
10% (v/v) 2-Propanol,  
20% (w/v) Polyethylene glycol 
4,000 
42 0.05 M 
Potassium 
phosphate 
monobasic 
None  20% (w/v) Polyethylene 
glycol 8,000 
43 None None 30% (w/v) Polyethylene glycol 
1,500 
44 None None 0.2 M Magnesium formate 
dihydrate 
45 0.2 M Zinc 
acetate 
dihydrate 
0.1 M Sodium 
cacodylate 
trihydrate pH 6.5 
18% (w/v) Polyethylene glycol 
8,000 
46 0.2 M 
Calcium 
acetate 
hydrate 
0.1 M Sodium 
cacodylate 
trihydrate pH 6.5 
 18% (w/v) Polyethylene 
glycol 8,000 
47 None 0.1 M Sodium 
acetate trihydrate 
pH 4.6 
2.0 M Ammonium sulfate 
48 None 0.1 M TRIS 
hydrochloride pH 
8.5 
2.0 M Ammonium phosphate 
monobasic 
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Table J3 Hampton Crystal Screen II components 
Tube 
No 
Salt Buffer Precipitant 
1 2.0 M 
Sodium 
chloride 
None 10% (w/v) Polyethylene glycol 
6,000 
2 0.5 M 
Sodium 
chloride, 0.01 
M 
Magnesium 
chloride 
hexahydrate 
None 0.01M 
Hexadecyltrimethylammonium 
bromide 
3 None None 25% (v/v) Ethylene glycol 
4 None None 35% (v/v) 1,4-Dioxane 
5 2.0 M 
Ammonium 
sulfate 
None 5% (v/v) 2-Propanol 
6 None None 1.0 M Imidazole pH 7.0 
7 None None 10% (w/v) Polyethylene glycol 
1,000,  
10% (w/v) Polyethylene glycol 
8,000 
8 1.5 M 
Sodium 
chloride 
None 10% (v/v) Ethanol 
9 None 0.1 M Sodium 
acetate 
trihydrate pH 
4.6 
2.0 M Sodium chloride 
10 0.2 M 
Sodium 
chloride 
0.1 M Sodium 
acetate 
trihydrate pH 
4.6 
30% (v/v) 2-Methyl-2,4-
pentanediol 
11 0.01 M 
Cobalt(II) 
chloride 
hexahydrate 
0.1 M Sodium 
acetate 
trihydrate pH 
4.6 
1.0 M 1,6-Hexanediol 
12 0.1 M 
Cadmium 
chloride 
hydrate 
0.1 M Sodium 
acetate 
trihydrate pH 
4.6 
30% (v/v) Polyethylene glycol 
400 
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13 0.2 M 
Ammonium 
sulfate 
0.1 M Sodium 
acetate 
trihydrate pH 
4.6 
30% (w/v) Polyethylene glycol 
monomethyl ether 2,000 
14 0.2 M 
Potassium 
sodium 
tartrate 
tetrahydrate 
0.1 M Sodium 
citrate tribasic 
dihydrate pH 
5.6 
2.0 M Ammonium sulfate 
15 0.5 M 
Ammonium 
sulfate 
0.1 M Sodium 
citrate tribasic 
dihydrate pH 
5.6 
1.0 M Lithium sulfate 
monohydrate 
16 0.5 M 
Sodium 
chloride 
0.1 M Sodium 
citrate tribasic 
dihydrate pH 
5.6 
2% (v/v) Ethylene imine 
polymer 
17 None 0.1 M Sodium 
citrate tribasic 
dihydrate pH 
5.6 
35% (v/v) tert-Butanol 
18 0.01 M 
Iron(III) 
chloride 
hexahydrate 
0.1 M Sodium 
citrate tribasic 
dihydrate pH 
5.6 
10% (v/v) Jeffamine M-600 
19 None 0.1 M Sodium 
citrate tribasic 
dihydrate pH 
5.6 
2.5 M 1,6-Hexanediol 
20 None 0.1 M MES 
monohydrate 
pH 6.5 
1.6 M Magnesium sulfate 
heptahydrate 
21 0.1 M 
Sodium 
phosphate 
monobasic 
monohydrate, 
0.1 M 
Potassium 
phosphate 
monobasic 
0.1 M MES 
monohydrate 
pH 6.5 
2.0 M Sodium chloride 
22 None 0.1 M MES 
monohydrate 
pH 6.5 
12% (w/v) Polyethylene glycol 
20,000 
23 1.6 M 
Ammonium 
0.1 M MES 
monohydrate 
10% (v/v) 1,4-Dioxane 
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sulfate pH 6.5 
24 0.05 M 
Cesium 
chloride 
0.1 M MES 
monohydrate 
pH 6.5 
30% (v/v) Jeffamine M-600 
25 0.01 M 
Cobalt(II) 
chloride 
hexahydrate 
0.1 M MES 
monohydrate 
pH 6.5 
1.8 M Ammonium sulfate 
26 0.2 M 
Ammonium 
sulfate 
0.1 M MES 
monohydrate 
pH 6.5 
30% (w/v) Polyethylene glycol 
monomethyl ether 5,000 
27 0.01 M Zinc 
sulfate 
heptahydrate 
0.1 M MES 
monohydrate 
pH 6.5 
25% (v/v) Polyethylene glycol 
monomethyl ether 550 
28 None None 1.6 M Sodium citrate tribasic 
dihydrate pH 6.5 
29 0.5 M 
Ammonium 
sulfate 
0.1 M HEPES 
pH 7.5 
30% (v/v) 2-Methyl-2,4-
pentanediol 
30 None 0.1 M HEPES 
pH 7.5 
10% (w/v) Polyethylene glycol 
6,000, 5% (v/v) 2-Methyl-2,4-
pentanediol 
31 None 0.1 M HEPES 
pH 7.5 
20% (v/v) Jeffamine M-600 
32 0.1 M 
Sodium 
chloride 
0.1 M HEPES 
pH 7.5 
1.6 M Ammonium sulfate 
33 None 0.1 M HEPES 
pH 7.5 
2.0 M Ammonium formate 
34 0.05 M 
Cadmium 
sulfate 
hydrate 
0.1 M HEPES 
pH 7.5 
1.0 M Sodium acetate 
trihydrate 
35 None 0.1 M HEPES 
pH 7.5 
70% (v/v) 2-Methyl-2,4-
pentanediol 
36 None 0.1 M HEPES 
pH 7.5 
4.3 M Sodium chloride 
37 None 0.1 M HEPES 
pH 7.5 
10% (w/v) Polyethylene glycol 
8,000,  
8% (v/v) Ethylene glycol 
38 None 0.1 M HEPES 
pH 7.5 
20% (w/v) Polyethylene glycol 
10,000 
39 0.2 M 
Magnesium 
chloride 
0.1 M Tris pH 
8.5 
3.4 M 1,6-Hexanediol 
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hexahydrate 
40 None 0.1 M Tris pH 
8.5 
25% (v/v) tert-Butanol 
41 0.01 M 
Nickel(II) 
chloride 
hexahydrate 
0.1 M Tris pH 
8.5 
1.0 M Lithium sulfate 
monohydrate 
42 1.5 M 
Ammonium 
sulfate 
0.1 M Tris pH 
8.5 
12% (v/v) Glycerol 
43 0.2 M 
Ammonium 
phosphate 
monobasic 
0.1 M Tris pH 
8.5 
50% (v/v) 2-Methyl-2,4-
pentanediol 
44 None 0.1 M Tris pH 
8.5 
20% (v/v) Ethanol 
45 0.01 M 
Nickel(II) 
chloride 
hexahydrate  
0.1 M Tris pH 
8.5 
20% (w/v) Polyethylene glycol 
monomethyl ether 2,000 
46 0.1 M 
Sodium 
chloride 
0.1 M BICINE 
pH 9.0 
20% (v/v) Polyethylene glycol 
monomethyl ether 550 
47 None 0.1 M BICINE 
pH 9.0 
2.0 M Magnesium chloride 
hexahydrate 
48 None 0.1 M BICINE 
pH 9.0  
2% (v/v) 1,4-Dioxane, 
10% (w/v) Polyethylene glycol 
20,000 
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Table J4 Hampton SaltRx Screen components 
Tube 
No 
Salt Buffer 
1 1.8 M Sodium acetate 
pH 7.0 
0.1 M Bis-Tris propane pH 7.0 
2 2.8 M Sodium acetate 
pH 7.0 
0.1 M Bis-Tris propane pH 7.0 
3 1.5 M Ammonium 
chloride 
0.1 M Sodium acetate pH 4.6 
4 1.5 M Ammonium 
chloride 
0.1 M Bis-Tris propane pH 7.0 
5 1.5 M Ammonium 
chloride 
0.1 M Tris pH 8.5 
6 3.5 M Ammonium 
chloride 
0.1 M Sodium acetate pH 4.6 
7 3.5 M Ammonium 
chloride 
0.1 M Bis-Tris propane pH 7.0 
8 3.5 M Ammonium 
chloride 
0.1 M Tris pH 8.5 
9 2.2 M Sodium 
chloride 
0.1 M Sodium acetate pH 4.6 
10 2.2 M Sodium 
chloride 
0.1 M BIS-TRIS propane pH 7.0 
11 2.2 M Sodium 
chloride 
0.1 M Tris pH 8.5 
12 3.2 M Sodium 
chloride 
0.1 M Sodium acetate trihydrate pH 4.6 
13 3.2 M Sodium 
chloride 
M BIS-TRIS propane pH 7.0 
14 3.2 M Sodium 
chloride 
0.1 M Tris pH 8.5 
15 1.0 M Ammonium 
citrate dibasic 
0.1 M Sodium acetate trihydrate pH 4.6 
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16 1.8 M Ammonium 
citrate dibasic 
0.1 M Sodium acetate trihydrate pH 4.6 
17 1.0 M Ammonium 
citrate tribasic pH 7.0 
0.1 M BIS-TRIS propane pH 7.0 
18 2.0 M Ammonium 
citrate tribasic pH 7.0 
0.1 M BIS-TRIS propane pH 7.0 
19 0.7 M Sodium citrate 
tribasic dihydrate 
0.1 M BIS-TRIS propane pH 7.0 
20 0.7 M Sodium citrate 
tribasic dihydrate 
0.1 M Tris pH 8.5 
21 1.2 M Sodium citrate 
tribasic dihydrate 
0.1 M BIS-TRIS propane pH 7.0 
22 1.2 M Sodium citrate 
tribasic dihydrate 
0.1 M Tris pH 8.5 
23 0.4 M Magnesium 
formate dihydrate 
0.1 M Sodium acetate trihydrate pH 4.6 
24 0.4 M Magnesium 
formate dihydrate 
0.1 M BIS-TRIS propane pH 7.0 
25 0.4 M Magnesium 
formate dihydrate 
0.1 M Tris pH 8.5 
26 0.7 M Magnesium 
formate dihydrate 
0.1 M BIS-TRIS propane pH 7.0 
27 2.0 M Sodium formate 0.1 M Sodium acetate trihydrate pH 4.6 
28 2.0 M Sodium formate 0.1 M BIS-TRIS propane pH 7.0 
29 2.0 M Sodium formate 0.1 M Tris pH 8.5 
30 3.5 M Sodium formate 0.1 M Sodium acetate trihydrate pH 4.6 
31 3.5 M Sodium formate 0.1 M BIS-TRIS propane pH 7.0 
32 3.5 M Sodium formate 0.1 M Tris pH 8.5 
33 1.2 M DL-Malic acid 
pH 7.0 
0.1 M BIS-TRIS propane pH 7.0 
34 2.2 M DL-Malic acid 0.1 M BIS-TRIS propane pH 7.0 
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pH 7.0 
35 1.4 M Sodium 
malonate pH 7.0 
0.1 M BIS-TRIS propane pH 7.0 
36 2.4 M Sodium 
malonate pH 7.0 
0.1 M BIS-TRIS propane pH 7.0 
37 2.5 M Ammonium 
nitrate 
0.1 M Sodium acetate trihydrate pH 4.6 
38 2.5 M Ammonium 
nitrate 
0.1 M BIS-TRIS propane pH 7.0 
39 2.5 M Ammonium 
nitrate 
0.1 M Tris pH 8.5 
40 6.0 M Ammonium 
nitrate 
0.1 M Sodium acetate trihydrate pH 4.6 
41 6.0 M Ammonium 
nitrate 
0.1 M BIS-TRIS propane pH 7.0 
42 6.0 M Ammonium 
nitrate 
0.1 M Tris pH 8.5 
43 1.5 M Sodium nitrate 0.1 M Sodium acetate trihydrate pH 4.6 
44 1.5 M Sodium nitrate 0.1 M BIS-TRIS propane pH 7.0 
45 1.5 M Sodium nitrate 0.1 M Tris pH 8.5 
46 4.0 M Sodium nitrate 0.1 M Sodium acetate trihydrate pH 4.6 
47 4.0 M Sodium nitrate 0.1 M BIS-TRIS propane pH 7.0 
48 4.0 M Sodium nitrate 0.1 M Tris pH 8.5 
49 1.0 M Ammonium 
phosphate monobasic 
0.1 M Sodium acetate trihydrate pH 4.6 
50 1.8 M Ammonium 
phosphate monobasic 
0.1 M Sodium acetate trihydrate pH 4.6 
51 1.5 M Ammonium 
phosphate dibasic 
0.1 M Tris pH 8.5 
52 2.4 M Ammonium 
phosphate dibasic 
0.1 M Tris pH 8.5 
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53 1.0 M Sodium 
phosphate monobasic 
monohydrate, 
Potassium phosphate 
dibasic / pH 5.0 
None 
54 1.0 M Sodium 
phosphate monobasic 
monohydrate, 
Potassium phosphate 
dibasic / pH 6.9 
None 
55 1.0 M Sodium 
phosphate monobasic 
monohydrate, 
Potassium phosphate 
dibasic / pH 8.2 
None 
56 1.8 M Sodium 
phosphate monobasic 
monohydrate, 
Potassium phosphate 
dibasic / pH 5.0 
None 
57 1.8 M Sodium 
phosphate monobasic 
monohydrate, 
Potassium phosphate 
dibasic / pH 6.9 
None 
58 1.8 M Sodium 
phosphate monobasic 
monohydrate, 
Potassium phosphate 
dibasic / pH 8.2 
None 
59 0.5 M Succinic acid 
pH 7.0 
0.1 M BIS-TRIS propane pH 7.0 
60 1.0 M Succinic acid 
pH 7.0 
0.1 M BIS-TRIS propane pH 7.0 
61 1.5 M Ammonium 
sulfate 
0.1 M Sodium acetate trihydrate pH 4.6 
62 1.5 M Ammonium 
sulfate 
0.1 M BIS-TRIS propane pH 7.0 
63 1.5 M Ammonium 
sulfate 
0.1 M Tris pH 8.5 
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64 2.5 M Ammonium 
sulfate 
0.1 M Sodium acetate trihydrate pH 4.6 
65 2.5 M Ammonium 
sulfate 
0.1 M BIS-TRIS propane pH 7.0 
66 2.5 M Ammonium 
sulfate 
0.1 M Tris pH 8.5 
67 0.8 M Lithium sulfate 
monohydrate 
0.1 M Sodium acetate trihydrate pH 4.6 
68 0.8 M Lithium sulfate 
monohydrate 
0.1 M BIS-TRIS propane pH 7.0 
69 0.8 M Lithium sulfate 
monohydrate 
0.1 M Tris pH 8.5 
70 1.5 M Lithium sulfate 
monohydrate 
0.1 M Sodium acetate trihydrate pH 4.6 
71 1.5 M Lithium sulfate 
monohydrate 
0.1 M BIS-TRIS propane pH 7.0 
72 1.5 M Lithium sulfate 
monohydrate 
0.1 M Tris pH 8.5 
73 1.0 M Magnesium 
sulfate hydrate 
0.1 M Sodium acetate trihydrate pH 4.6 
74 1.0 M Magnesium 
sulfate hydrate 
0.1 M BIS-TRIS propane pH 7.0 
75 1.0 M Magnesium 
sulfate hydrate 
0.1 M Tris pH 8.5 
76 1.8 M Magnesium 
sulfate hydrate 
0.1 M Sodium acetate trihydrate pH 4.6 
77 1.8 M Magnesium 
sulfate hydrate 
0.1 M BIS-TRIS propane pH 7.0 
78 1.8 M Magnesium 
sulfate hydrate 
0.1 M Tris pH 8.5 
79 0.7 M Ammonium 
tartrate dibasic 
0.1 M Sodium acetate trihydrate pH 4.6 
80 0.7 M Ammonium 
tartrate dibasic 
0.1 M BIS-TRIS propane pH 7.0 
81 0.7 M Ammonium 
tartrate dibasic 
0.1 M Tris pH 8.5 
82 1.0 M Ammonium 
tartrate dibasic 
0.1 M Sodium acetate trihydrate pH 4.6 
83 1.3 M Ammonium 
tartrate dibasic 
0.1 M BIS-TRIS propane pH 7.0 
84 1.4 M Ammonium 
tartrate dibasic 
0.1 M Tris pH 8.5 
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85 0.6 M Potassium 
sodium tartrate 
tetrahydrate 
0.1 M BIS-TRIS propane pH 7.0 
86 1.2 M Potassium 
sodium tartrate 
tetrahydrate 
0.1 M BIS-TRIS propane pH 7.0 
87 0.6 M Potassium 
sodium tartrate 
tetrahydrate 
0.1 M Tris pH 8.5 
88 1.2 M Potassium 
sodium tartrate 
tetrahydrate 
0.1 M Tris pH 8.5 
89 0.5 M Potassium 
thiocyanate 
0.1 M Sodium acetate trihydrate pH 4.6 
90 0.5 M Potassium 
thiocyanate 
0.1 M BIS-TRIS propane pH 7.0 
91 0.5 M Potassium 
thiocyanate 
0.1 M Tris pH 8.5 
92 4.0 M Ammonium 
acetate 
0.1 M Sodium acetate trihydrate pH 4.6 
93 4.0 M Ammonium 
acetate 
0.1 M BIS-TRIS propane pH 7.0 
94 4.0 M Ammonium 
acetate 
0.1 M Tris pH 8.5 
95 35% v/v Tacsimate 
pH 7.0 
0.1 M BIS-TRIS propane pH 7.0 
96 60% v/v Tacsimate 
pH 7.0 
0.1 M BIS-TRIS propane pH 7.0 
 
Table J5: Molecular Dimensions Clear Strategy Screen I 
Tube 
No 
Salt Precipitant 
1 0.3 M Sodium acetate 
trihydrate  
25 % PEG 2000 monomethyl ether 
2 0.2 M Lithium 
sulphate 
25 % PEG 2000 monomethyl ether 
3 0.2 M Magnesium 
chloride 
25 % PEG 2000 monomethyl ether 
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4 0.2 M Potassium 
bromide 
25 % PEG 2000 monomethyl ether 
5 0.2 M Potassium 
thiocyanate 
25 % PEG 2000 monomethyl ether 
6 0.8 M Sodium formate 25 % PEG 2000 monomethyl ether 
7 0.3 M Sodium acetate 15 % PEG 4000 
8 0.2 M Lithium 
sulphate 
15 % PEG 4000 
9 0.2 M Magnesium 
chloride 
15 % PEG 4000 
10 0.2 M Potassium 
bromide 
15 % PEG 4000 
11 0.2 M Potassium 
thiocyanate 
15 % PEG 4000 
12 0.8 M Sodium formate 15 % PEG 4000 
13 0.3 M Sodium acetate 
trihydrate  
10 % PEG 1000 
14 0.2 M Lithium 
sulphate 
10 % PEG 1000 
15 0.2 M Magnesium 
chloride 
10 % PEG 1000 
16 0.2 M Potassium 
bromide 
10 % PEG 1000 
17 0.2 M Potassium 
thiocyanate 
10 % PEG 1000 
18 0.8 M Sodium formate 10 % PEG 1000 
19 0.3 M Sodium acetate 
trihydrate  
8 % PEG 20000 + 8 % PEG 500 
monomethyl ether 
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20 0.2 M Lithium 
sulphate 
8 % PEG 20000 + 8 % PEG 500 
monomethyl ether 
21 0.2 M Magnesium 
chloride 
8 % PEG 20000 + 8 % PEG 500 
monomethyl ether 
22 0.2 M Potassium 
bromide 
8 % PEG 20000 + 8 % PEG 500 
monomethyl ether 
23 0.2 M Potassium 
thiocyanate 
8 % PEG 20000 + 8 % PEG 500 
monomethyl ether 
24 0.8 M Sodium formate 8 % PEG 20000 + 8 % PEG 500 
monomethyl ether 
 
Table J6: Molecular Dimensions Clear Strategy Screen II 
Tube 
No 
Salt Precipitant 
1 1.5 M Ammonium 
sulphate 
None 
2 0.8 M Lithium 
sulphate 
None 
3 2 M Sodium formate None 
4 0.5 M Potassium 
phosphate monobasic 
None 
5 0.2 M Calcium acetate 25 % PEG 2000 monomethyl ether 
6 0.2 M Calcium acetate 15 % PEG 4000 
7 2.7 M Ammonium 
sulphate 
None 
8 1.8 M Lithium 
sulphate 
None 
9 4 M Sodium formate None 
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10 1.0 M Potassium 
phosphate monobasic 
None 
11 0.2 M Calcium acetate 10 % PEG 8000 + 10 % PEG 1000 
12 0.2 M Calcium acetate 8 % PEG 20000 + 8 % PEG 500 
monomethyl ether 
13 None 40 % 2-methyl-2,4-pentanediol 
14 None 40 % 1,4-butanediol 
15 5 mM Cadmium 
chloride 
20 % PEG 4000 
16 0.15 M Potassium 
thiocyanate 
20 % PEG 500 monomethyl ether 
17 0.15 M Potassium 
thiocyanate 
20 % PEG 600 
18 0.15 M Potassium 
thiocyanate 
20% PEG 1500 
19 None 35 % v/v propanol 
20 None 30 % v/v Jeffamine 
21 5 mM Nickel chloride 20 % PEG 4000 
22 0.15 M Potassium 
thiocyanate 
18 % PEG 3350 
23 0.15 M Potassium 
thiocyanate 
18 % PEG 5000 monomethyl ether 
24 0.15 M Potassium 
thiocyanate 
15 % PEG 6000 
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Appendix K 
Sequencing Results 
 
GENE ID: 1238265 vapA | virulence associated protein VapA [Rhodococcus equi] 
(10 or fewer PubMed links) 
 
 Score =   283 bits (724),  Expect = 1e-98, Method: Compositional matrix 
adjust. 
 Identities = 158/161 (98%), Positives = 160/161 (99%), Gaps = 0/161 (0%) 
 Frame = +2 
 
Query  104  SHMTVLDSGSSSAILNSGAGSGIVGSGSYDSSTTSLNLQKDEPNGRASDTAGQEQQYDVH  
283 
            ++ TVLDSGSSSAILNSGAGSGIVGSGSYDSSTTSLNLQKDEPNGRASDTAGQEQQYDVH 
Sbjct  29   ANATVLDSGSSSAILNSGAGSGIVGSGSYDSSTTSLNLQKDEPNGRASDTAGQEQQYDVH  88 
 
Query  284  GDVISAVVYQRFHVFGPEGKVFDGDAGGLTLPGAGAFWGTLFTNDLQRLYKDTVSFQYNA  
463 
            GDVISAVVYQRFHVFGPEGKVFDGDAGGLTLPGAGAFWGTLFTNDLQRLYKDTVSFQYNA 
Sbjct  89   GDVISAVVYQRFHVFGPEGKVFDGDAGGLTLPGAGAFWGTLFTNDLQRLYKDTVSFQYNA  
148 
 
Query  464  VGPYLNINFFDSSGSFLGHIQSGGVSTVVGVGGGSGSWHNA  586 
            VGPYLNINFFDSSGSFLGHIQSGGVSTVVGVGGGSGSWHNA 
Sbjct  149  VGPYLNINFFDSSGSFLGHIQSGGVSTVVGVGGGSGSWHNA  189 
 
 
GENE ID: 1238267 vapC | virulence associated protein VapC [Rhodococcus equi] 
(10 or fewer PubMed links) 
 
 Score =   295 bits (755),  Expect = 8e-104, Method: Compositional matrix 
adjust. 
 Identities = 145/148 (98%), Positives = 146/148 (99%), Gaps = 0/148 (0%) 
 Frame = +2 
 
Query  110  SHMNVVAPSAWGGAQSAADKEGEGVTLGGVGVLRPHNKDADEQYTVHGVVVSALFYNHLR  
289 
            +  NVVAPSAWGGAQSAADKEGEGVTLGGVGVLRPHNKDADEQYTVHGVVVSALFYNHLR 
Sbjct  27   ARANVVAPSAWGGAQSAADKEGEGVTLGGVGVLRPHNKDADEQYTVHGVVVSALFYNHLR  86 
 
Query  290  ISVDGGMTFDGDGGGLSTPGGGALWGTLTTSDLQQLYDETASFECNAVGPYLNINFYDSY  
469 
            ISVDGGMTFDGDGGGLSTPGGGALWGTLTTSDLQQLYDETASFECNAVGPYLNINFYDSY 
Sbjct  87   ISVDGGMTFDGDGGGLSTPGGGALWGTLTTSDLQQLYDETASFECNAVGPYLNINFYDSY  
146 
 
Query  470  GRILASVQAGGVSTMIGIGGGNGRWHLV  553 
            GRILASVQAGGVSTMIGIGGGNGRWHLV 
Sbjct  147  GRILASVQAGGVSTMIGIGGGNGRWHLV  174 
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GENE ID: 1238269 vapE | virulence associated protein VapE [Rhodococcus equi] 
(10 or fewer PubMed links) 
 
 Score =  328 bits (841),  Expect = 3e-113, Method: Compositional matrix 
adjust. 
 Identities = 160/160 (100%), Positives = 160/160 (100%), Gaps = 0/160 (0%) 
 Frame = +1 
 
Query  118  REIGAQAWPASQLESGLAVSGNPVGVHDVRMAVHDDSTHTREFKEDDSEKQYPVHGFASS  
297 
            REIGAQAWPASQLESGLAVSGNPVGVHDVRMAVHDDSTHTREFKEDDSEKQYPVHGFASS 
Sbjct  47   REIGAQAWPASQLESGLAVSGNPVGVHDVRMAVHDDSTHTREFKEDDSEKQYPVHGFASS  
106 
 
Query  298  FIFYQTVSIIIDDDGRGGPGKTFEGEAGGITTPGAAGYAGVLFTSDLERLYRETVSFEYN  
477 
            FIFYQTVSIIIDDDGRGGPGKTFEGEAGGITTPGAAGYAGVLFTSDLERLYRETVSFEYN 
Sbjct  107  FIFYQTVSIIIDDDGRGGPGKTFEGEAGGITTPGAAGYAGVLFTSDLERLYRETVSFEYN  
166 
 
Query  478  AVGPYLNINLFAGDGGLLGHVQSGAISSLVGIGGGTGAWR  597 
            AVGPYLNINLFAGDGGLLGHVQSGAISSLVGIGGGTGAWR 
Sbjct  167  AVGPYLNINLFAGDGGLLGHVQSGAISSLVGIGGGTGAWR  206 
GENE ID: 1238341 VapG | virulence associated protein VapG [Rhodococcus equi] 
  
Query  88   SGLVPRG-SHMETSMVSTTAASSVEHAANTYDFAEAKSGSSIPAKVAAEQANSYSVHGLV  
264 
            S L P G ++ ETSMVSTTAASSVEHAANTYDFAEAKSGSSIPAKVAAEQANSYSVHGLV 
Sbjct  16   SVLAPAGIANAETSMVSTTAASSVEHAANTYDFAEAKSGSSIPAKVAAEQANSYSVHGLV  75 
 
Query  265  TSLAVYQHFSLTVEGGGKTFTGDSGGISIPGVAVLEGTLFTEDLQHLYSDTVSFEYNAVG  
444 
            TSLAVYQHFSLTVEGGGKTFTGDSGGISIPGVAVLEGTLFTEDLQHLYSDTVSFEYNAVG 
Sbjct  76   TSLAVYQHFSLTVEGGGKTFTGDSGGISIPGVAVLEGTLFTEDLQHLYSDTVSFEYNAVG  
135 
 
Query  445  PYLNINFFDSHGTLLGHVQSGSIGTVSGIGGGTGGWQ  555 
            PYLNINFFDSHGTLLGHVQSGSIGTVSGIGGGTGGWQ 
Sbjct  136  PYLNINFFDSHGTLLGHVQSGSIGTVSGIGGGTGGWQ  172 
 
 
 
 
GENE ID: 1238264 vapH | virulence associated protein VapH [Rhodococcus equi] 
(10 or fewer PubMed links) 
 
 Score =  320 bits (820),  Expect = 2e-113, Method: Compositional matrix 
adjust. 
 Identities = 159/163 (98%), Positives = 159/163 (98%), Gaps = 1/163 (1%) 
 Frame = +2 
 
Query  95   VPRGSHMAPPPLPDGPTHDLPTWREEGANYSDGTMLVRASSNFLEPSTHSDSGQQQWTVQ  
274 
            VP G   APPPLPDGPTHDLPTWREEGANYSDGTMLVRASSNFLEPSTHSDSGQQQWTVQ 
Sbjct  26   VPWGC-AAPPPLPDGPTHDLPTWREEGANYSDGTMLVRASSNFLEPSTHSDSGQQQWTVQ  84 
 
Query  275  GVLASALVYQRLKLNVEGGETFEGYAGGLSFPGGAMVWGTLFTDNIQRLYDRTESFEFNA  
454 
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            GVLASALVYQRLKLNVEGGETFEGYAGGLSFPGGAMVWGTLFTDNIQRLYDRTESFEFNA 
Sbjct  85   GVLASALVYQRLKLNVEGGETFEGYAGGLSFPGGAMVWGTLFTDNIQRLYDRTESFEFNA  
144 
 
Query  455  VGPYLNVNFFDGHSAILGHAQLGGVSSVIGIGGGTGTWIGDVA  583 
            VGPYLNVNFFDGHSAILGHAQLGGVSSVIGIGGGTGTWIGDVA 
Sbjct  145  VGPYLNVNFFDGHSAILGHAQLGGVSSVIGIGGGTGTWIGDVA  187 
 
pET23-cmt 
esterase [Corynebacterium glutamicum ATCC 13032]  
Sequence ID: gi|19551592|ref|NP_599594.1|Length: 365Number of Matches: 1 
Gene-associated gene details 
Identical Proteins-Proteins identical to the subject 
Range 1: 30 to 365GenPeptGraphics Next Match Previous Match First Match  
Alignment statistics for match #1 
Score Expect Method Identities Positives Gaps Frame 
660 
bits(1702) 
0.0() 
Compositional 
matrix adjust. 
324/336(96%) 324/336(96%) 0/336(0%) +2 
 
Query  56    AEVTPADVAGDTALSTISDSAPADEASAPRWRAHVNAADERVKEMWAYSPSMDRNVPLVV  
235 
             AEVTPADVAGDTALSTISDSAPADEASAPRWRAHVNAADERVKEMWAYSPSMDRNVPLVV 
Sbjct  30    AEVTPADVAGDTALSTISDSAPADEASAPRWRAHVNAADERVKEMWAYSPSMDRNVPLVV  
89 
 
Query  236   ITADESAGPRPVIYLLNGGDGGEGAANWVMQTDVLDFYLEKNVNVVIPMEGKFSYYTDWV  
415 
             ITADESAGPRPVIYLLNGGDGGEGAANWVMQTDVLDFYLEKNVNVVIPMEGKFSYYTDWV 
Sbjct  90    ITADESAGPRPVIYLLNGGDGGEGAANWVMQTDVLDFYLEKNVNVVIPMEGKFSYYTDWV  
149 
 
Query  416   EENASLGGKQMWETFLVKELPGPLEEKLNTDGQRAIAGMSMSATTSLLFPQHFPGFYDAA  
595 
             EENASLGGKQMWETFLVKELPGPLEEKLNTDGQRAIAGMSMSATTSLLFPQHFPGFYDAA 
Sbjct  150   EENASLGGKQMWETFLVKELPGPLEEKLNTDGQRAIAGMSMSATTSLLFPQHFPGFYDAA  
209 
 
Query  596   ASFSGCAATSSLLPWEYLKLTLDRGNATPEQMWGPRGGEYNIYNDALINSDKLRGTELYV  
775 
             ASFSGCAATSSLLPWEYLKLTLDRGNATPEQMWGPRGGEYNIYNDALINSDKLRGTELYV 
Sbjct  210   ASFSGCAATSSLLPWEYLKLTLDRGNATPEQMWGPRGGEYNIYNDALINSDKLRGTELYV  
269 
 
Query  776   SNASGLAGEWESVDSPRFEGLNQQVQSIAMAETVVTGGIIEAATNKCTHDLKAKLDSAGI  
955 
             SNASGLAGEWESVDSPRFEGLNQQVQSIAMAETVVTGGIIEAATNKCTHDLKAKLDSAGI 
Sbjct  270   SNASGLAGEWESVDSPRFEGLNQQVQSIAMAETVVTGGIIEAATNKCTHDLKAKLDSAGI  
329 
 
Query  956   PADWKPPPNRHPLMGLVADDLRGSWTTFARAFELEA  1063 
             PADW   P      G   DDLRGSWTTFARAFELEA 
Sbjct  330   PADWNLRPTGTHSWGWWQDDLRGSWTTFARAFELEA  365 
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Rev 
Range 1: 30 to 365GenPeptGraphics Next Match Previous Match First Match  
Alignment statistics for match #1 
Score Expect Method Identities Positives Gaps Frame 
588 
bits(1515) 
0.0() 
Compositional 
matrix adjust. 
296/347(85%) 301/347(86%) 21/347(6%) +3 
Features:  
Query  210   AEVTPADVAGDTALIHHLR*CSCR*SLCTRWR-RTRQRSRRARQ---------RNVGILP  
359 
             AEVTPADVAGDTAL           +   RWR        R ++         RNV ++  
Sbjct  30    AEVTPADVAGDTALSTISDSAPADEASAPRWRAHVNAADERVKEMWAYSPSMDRNVPLVV  
89 
 
Query  360   FHGTAMCHW*L*TADESAGPRPVIYLLNGGDGGEGAANWVMQTDVLDFYLEKNVNVVIPM  
539 
                         TADESAGPRPVIYLLNGGDGGEGAANWVMQTDVLDFYLEKNVNVVIPM 
Sbjct  90    I-----------TADESAGPRPVIYLLNGGDGGEGAANWVMQTDVLDFYLEKNVNVVIPM  
138 
 
Query  540   EGKFSYYTDWVEENASLGGKQMWETFLVKELPGPLEEKLNTDGQRAIAGMSMSATTSLLF  
719 
             EGKFSYYTDWVEENASLGGKQMWETFLVKELPGPLEEKLNTDGQRAIAGMSMSATTSLLF 
Sbjct  139   EGKFSYYTDWVEENASLGGKQMWETFLVKELPGPLEEKLNTDGQRAIAGMSMSATTSLLF  
198 
 
Query  720   PQHFPGFYDAAASFSGCAATSSLLPWEYLKLTLDRGNATPEQMWGPRGGEYNIYNDALIN  
899 
             PQHFPGFYDAAASFSGCAATSSLLPWEYLKLTLDRGNATPEQMWGPRGGEYNIYNDALIN 
Sbjct  199   PQHFPGFYDAAASFSGCAATSSLLPWEYLKLTLDRGNATPEQMWGPRGGEYNIYNDALIN  
258 
 
Query  900   SDKLRGTELYVSNASGLAGEWESVDSPRFEGLNQQVQSIAMAETVVTGGIIEAATNKCTH  
1079 
             SDKLRGTELYVSNASGLAGEWESVDSPRFEGLNQQVQSIAMAETVVTGGIIEAATNKCTH 
Sbjct  259   SDKLRGTELYVSNASGLAGEWESVDSPRFEGLNQQVQSIAMAETVVTGGIIEAATNKCTH  
318 
 
Query  1080  DLKAKLDSAGIPADWNLRPTGTHSWGWWQDDLRGSWTTFARAFELEA  1220 
             DLKAKLDSAGIPADWNLRPTGTHSWGWWQDDLRGSWTTFARAFELEA 
Sbjct  319   DLKAKLDSAGIPADWNLRPTGTHSWGWWQDDLRGSWTTFARAFELEA  365 
pET28-cmt 
For 
Related Information  
Identical Proteins-Proteins identical to the subject 
Range 1: 1 to 243GenPeptGraphics Next Match Previous Match First Match  
Alignment statistics for match #1 
Score Expect Method Identities Positives Gaps Frame 
443 
bits(1139) 
4e-
170(2) 
Compositional matrix 
adjust. 
219/243(90%) 224/243(92%) 0/243(0%) +2 
Features:  
Query  35   LTLRRRYTMGSSHHHHHHSSGLVPRGSHMAEVTPADVAGDTALSTISDSAPADEASAPRW  
214 
            + L RR    +       S+ + P  +  AEVTPADVAGDTALSTISDSAPADEASAPRW 
Sbjct  1    MKLLRRIAAPAIALGIAMSTIVTPSTAGAAEVTPADVAGDTALSTISDSAPADEASAPRW  60 
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Query  215  RAHVNAADERVKEMWAYSPSMDRNVPLVVITADESAGPRPVIYLLNGGDGGEGAANWVMQ  
394 
            RAHVNAADERVKEMWAYSPSMDRNVPLVVITADESAGPRPVIYLLNGGDGGEGAANWVMQ 
Sbjct  61   RAHVNAADERVKEMWAYSPSMDRNVPLVVITADESAGPRPVIYLLNGGDGGEGAANWVMQ  
120 
 
Query  395  TDVLDFYLEKNVNVVIPMEGKFSYYTDWVEENASLGGKQMWETFLVKELPGPLEEKLNTD  
574 
            TDVLDFYLEKNVNVVIPMEGKFSYYTDWVEENASLGGKQMWETFLVKELPGPLEEKLNTD 
Sbjct  121  TDVLDFYLEKNVNVVIPMEGKFSYYTDWVEENASLGGKQMWETFLVKELPGPLEEKLNTD  
180 
 
Query  575  GQRAIAGMSMSATTSLLFPQHFPGFYDAAASFSGCAATSSLLPWEYLKLTLDRGNATPEQ  
754 
            GQRAIAGMSMSATTSLLFPQHFPGFYDAAASFSGCAATSSLLPWEYLKLTLDRGNATPEQ 
Sbjct  181  GQRAIAGMSMSATTSLLFPQHFPGFYDAAASFSGCAATSSLLPWEYLKLTLDRGNATPEQ  
240 
 
Query  755  MWG  763 
            MWG 
Sbjct  241  MWG  243 
 
 
Rev 
Range 1: 30 to 365GenPeptGraphics Next Match Previous Match First Match  
Alignment statistics for match #1 
Score Expect Method Identities Positives Gaps Frame 
609 bits(1570) 0.0() Compositional matrix adjust. 299/337(89%) 303/337(89%) 1/337(0%) +3 
Features:  
Query  189   AEVTPADVAGDNCTIHHLRIVLLQMKPLHSLARHTSTQQTSASKKCGHTPLSMDRNVPLV  
368 
             AEVTPADVAGD                      H +       +   ++P SMDRNVPLV 
Sbjct  30    AEVTPADVAGDTALSTISDSAPADEASAPRWRAHVNAADERVKEMWAYSP-SMDRNVPLV  
88 
 
Query  369   VITADESAGPRPVIYLLNGGDGGEGAANWVMQTDVLDFYLEKNVNVVIPMEGKFSYYTDW  
548 
             VITADESAGPRPVIYLLNGGDGGEGAANWVMQTDVLDFYLEKNVNVVIPMEGKFSYYTDW 
Sbjct  89    VITADESAGPRPVIYLLNGGDGGEGAANWVMQTDVLDFYLEKNVNVVIPMEGKFSYYTDW  
148 
 
Query  549   VEENASLGGKQMWETFLVKELPGPLEEKLNTDGQRAIAGMSMSATTSLLFPQHFPGFYDA  
728 
             VEENASLGGKQMWETFLVKELPGPLEEKLNTDGQRAIAGMSMSATTSLLFPQHFPGFYDA 
Sbjct  149   VEENASLGGKQMWETFLVKELPGPLEEKLNTDGQRAIAGMSMSATTSLLFPQHFPGFYDA  
208 
 
Query  729   AASFSGCAATSSLLPWEYLKLTLDRGNATPEQMWGPRGGEYNIYNDALINSDKLRGTELY  
908 
             AASFSGCAATSSLLPWEYLKLTLDRGNATPEQMWGPRGGEYNIYNDALINSDKLRGTELY 
Sbjct  209   AASFSGCAATSSLLPWEYLKLTLDRGNATPEQMWGPRGGEYNIYNDALINSDKLRGTELY  
268 
 
Query  909   VSNASGLAGEWESVDSPRFEGLNQQVQSIAMAETVVTGGIIEAATNKCTHDLKAKLDSAG  
1088 
             VSNASGLAGEWESVDSPRFEGLNQQVQSIAMAETVVTGGIIEAATNKCTHDLKAKLDSAG 
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Sbjct  269   VSNASGLAGEWESVDSPRFEGLNQQVQSIAMAETVVTGGIIEAATNKCTHDLKAKLDSAG  
328 
 
Query  1089  IPADWNLRPTGTHSWGWWQDDLRGSWTTFARAFELEA  1199 
             IPADWNLRPTGTHSWGWWQDDLRGSWTTFARAFELEA 
Sbjct  329   IPADWNLRPTGTHSWGWWQDDLRGSWTTFARAFELEA  365 
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Figure L1 Sequence trace of VapE optimised for expression in E. coli BL21 (DE3) 
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Figure L2 Sequence trace of VapH optimised for expression in E. coli BL21 (DE3) 
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Figure L3 Sequence trace of VapG optimised for expression in E. coli BL21 (DE3) 
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